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ABSTRACT  
Porcine reproductive and respiratory syndrome (PRRS) is one of the most important 
pig diseases worldwide. The causative PRRS virus (PRRSV) is rapidly evolving and 
there is an urgent need for the development of safer and more efficacious vaccines to 
improve PRRS control. Immunity to PRRSV is not well understood but there are 
data suggesting that virus-specific T cell IFN-γ responses play an important role. 
Therefore, this project focussed on characterising the T cell response PRRSV and 
applied this knowledge to develop a novel vaccine strategy. The first part of the 
project aimed to identify the antigenic targets of the T cell response to PRRSV by 
utilising a proteome-wide synthetic peptide library and a cohort of PRRSV immune 
animals. The T cell IFN-γ response was directed at a range of viral proteins but the 
M and NSP5 proteins stood out as major antigens. Further experiments confirmed M 
and NSP5 as well conserved targets of in many instances dominant T cell responses. 
Characterisation of the responding T cell populations showed NSP5-specific 
responders to be CD8 T cells with a predominant CD44highCD62LlowCD27lowCD25- 
phenotype. The majority of cells were polyfunctional as assessed by co-expression of 
TNF-α and mobilisation of the cytotoxic degranulation marker CD107a. Both CD8 
and CD4 T cells responded to M with a comparable phenotype to that observed for 
NSP-specific T cells. In addition, conserved antigenic regions of each protein were 
identified and specificity shown to associate with major histocompatibility complex 
haplotype, rather than PRRSV strain. Finally, a vaccine study was conducted using 
M and NSP5 proteins as T cell antigens formulated as a particulate vaccine with a 
molecular adjuvant. Vaccination primed antigen-specific CD4 but not CD8 T cell 
responses and did not confer significant protection of animals from viraemia upon 
challenge infection. Analysis of the lungs during the resolution of infection showed 
high levels of virus and M/NSP5 specific CD8 T cell IFN-γ responses, suggesting 
that vaccine priming of a CD8 T cell response is required for protection from 
PRRSV infection. It is hoped that this work will inform future PRRSV vaccine 
design, as well as contributing to the wider field of T cell vaccinology. 
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General Introduction 
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Chapter 1. General Introduction 
 
1.1. Porcine Reproductive and Respiratory Syndrome  
Porcine reproductive and respiratory syndrome virus (PRRSV) is the 
causative agent of the porcine reproductive and respiratory syndrome (PRRS), also 
historically called pig blue ear disease or swine infertility and respiratory syndrome. 
First described as ‘mystery swine disease’ in the late 1980’s and first isolated in 
1991 [Wensvoort et al, 1991; Terpstra et al, 1991], PRRSV infection demonstrates a 
multifaceted clinical presentation, depending on the age of the pig. In sows, infection 
causes abortion, premature farrowing, stillborn piglets and mummified foetuses, as 
well as fever, lack of appetite and cyanosis of the mammary gland and ears (hence 
blue-ear pig disease) [Done et al, 1996; OIE Ad Hoc Group on PRRS, 2008]. Piglets 
that survive are often born both viraemic and seropositive for PRRSV and have low 
birth weights and vitality, difficulties breathing and suckling and present with 
oedema around the eyes [Mengeling et al, 1998; Nielsen et al, 2003; OIE Ad Hoc 
Group on PRRS, 2008].  In addition to the reproductive aspect of the disease seen in 
sows and gilts, PRRSV also plays an important role in the Porcine Respiratory 
Disease Complex (PRDC) [Thacker, 2001; Choi et al, 2003; Hansen et al, 2010]. 
Infection with PRRSV causes clinical respiratory signs, but most importantly it 
greatly enhances the pigs’ susceptibility to secondary viral and bacterial infections 
which define the PRDC. Subsequently the disease has a huge economic impact due 
to the increased mortality and reduced growth rate in growers and finishing pigs, as 
well as indirect costs such as treatment and control of outbreaks and disruption to 
breeding programmes. 
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The respiratory syndrome coupled with the reproductive problems make 
PRRSV one of the most economically significant swine pathogens in the world 
today. A 2005 study estimated that the annual economic impact of PRRSV in the US 
alone was $66.75 million in breeding pigs, and $493.57 million in growing pig 
populations, adding up to a loss of around $560 million each year [Neumann et al, 
2005]. A more recent study recalculated this loss at over $600 million per annum 
[Holtkampt et al, 2011]. Estimates of the impact on the UK pig industry indicate that 
the cost of respiratory disease is £52,180 and reproductive disease is £93,590 per 
herd of 500 animals [Richardson, 2011]. Considering that an estimated 30% of herds 
are infected with PRRSV [source: BPEX: http://www.bpex.org.uk/R-and-D/R-and-
D/PRRS.aspx] are there  are around 5 million pigs on commercial farms in the UK 
[source: Defra: https://www.gov.uk/government/publications/farming-statistics-
livestock-populations-at-1-december-2013-uk] the potential cost of PRRS to UK 
agriculture is not to be underestimated. 
Since the simultaneous emergence of PRRSV in the US and Europe in the 
late 1980’s and early 1990’s, the virus spread rapidly throughout the continents and 
outbreaks of the disease were seen in most of the swine-producing areas of the world 
[Wensvoort et al,, 1993]. Recent studies have put the seroprevelance in non-
vaccinated herds in the UK to be between 35% [Velasova et al, 2012] and 40% 
[Evans et al, 2008]. Two distinct genotypes of the virus are generally observed, 
depending on the origin, and these are designated the European genotype (genotype 
1) and the North American genotype (genotype 2). Both genotypes are found 
circulating globally and have distinctive clinical presentations and genetic and 
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antigenic characteristics. Within each of these two genotypes there also exists 
variability in nucleotide sequence, as well as a genetic shift, as demonstrated by the 
lack of historical field isolates circulating today [Murtagh et al, 2001].  
PRRSV is currently endemic in most swine-producing countries since the 
virus can persist subclinically in pig populations and can still be shed when clinical 
signs are no longer observed. Acute outbreaks can also occur, usually when a novel 
serotype is introduced into a population, for example, in the case of the ‘pig high 
fever disease’ outbreak in China in 2006 [Tian et al, 2007]. 
 
1.2. Control of PRRS by biosecurity 
To effectively contain PRRSV spread, it is important to understand the 
methods of transmission. The only other animal aside from pigs that have the 
potential to be productively infected with PRRSV is the wild boar, however infection 
of wild boar and other feral pigs is not considered to be significant in the context of 
PRRSV control due to the low prevalence of PRRSV in wild pig populations [Reiner 
et al, 2009]. PRRSV may be transmitted in semen and via items/equipment or 
personnel in contact with different herds [Robertson, 1992]. However, even with 
strict controls in place to prevent herd to herd spread, reinfection can still occur 
which suggests the possibility that the virus can be transmitted via aerosols [Dee et 
al, 2005; Torremorell et al, 1997]. Indeed, quantities of virus sufficient for 
productive infection have been detected as far as 9.1 km away from the source 
population [Cutler et al, 2011; Otake et al, 2010]. 
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Although PRRSV has a prolonged persistence in the host, the virus is 
eventually cleared and this allows ‘herd closure’, a method of control in which a 
herd is vaccinated and then kept in isolation until the virus is deemed to be cleared 
from all animals (typically about 200 days). Any further outbreaks in the herd are 
caused by the introduction of a new strain of the virus. Physical control measures for 
keeping PRRSV outbreaks in check start with both active and passive surveillance, 
and any suspected cases are confirmed in the laboratory by immunohistochemistry 
and RT-PCR [OIE Ad Hoc Group on PRRS, 2008]. Upon confirmation of PRRSV 
infection, quarantine measures should be imposed and pig movement should not be 
allowed. Air filtration methods have also been suggested for preventing virus spread 
by aerosol [Alonso et al, 2013]. In theory these measures plus good biosecurity on 
farms (perimeter fences, only introducing pigs from PRRSV negative herds, minimal 
visitors, regular disinfection of equipment and vehicles etc.) should generally be 
sufficient to contain an outbreak. Zoning is also a useful way of preventing spread of 
PRRSV from an endemic area to a disease-free zone [Carlsson et al, 2009]. In reality 
however, these measures are not always enforceable, especially in areas that are 
made up of small-holdings and village farms rather than the larger commercial 
facilities. 
 
1.3. Control of PRRS by vaccination 
According to www.vetvac.org, an online database of commercially available 
livestock vaccines, there are currently 25 commercially available PRRSV vaccines; 
15 live or live attenuated and 10 killed or inactivated vaccines. These are derived 
from both North American and European genotype viruses.  
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Modified live vaccines (MLV) can confer good protection from disease 
following challenge with a homologous strain of the virus but have shown limited 
efficacy upon challenge with heterologous strains [Park et al, 2012, Geldhof et al,  
2012] and inability to completely control viraemia, even when challenged with a 
relatively homologous virus [Scortti et al,  2006b]. Poor protection is unsurprisingly 
also observed between American and European genotypes [Han et al, 2014], and 
whilst there is more protection conferred within the European genotype [Labarque et 
al, 2004], variable protection is seen even within the same virus cluster or subtype 
[Prieto et al, 2008]. Vaccination with MLV can cause long lasting viraemia and viral 
shedding and therefore the vaccine strain can be transmitted to unvaccinated pigs and 
across the placenta of pregnant sows leading to congenitally infected litters [Scortti 
et al, 2006a]. In the context of protection from emerging viruses, only partial 
protection was observed against a highly pathogenic European subtype 3 virus [Trus 
et al, 2014]. There are major safety concerns about the potential of the MLV to 
revert to virulence; vaccine related isolates have been shown to cause disease in 
experimentally infected pigs [Opriessnig et al,  2002] and vaccine strains have been 
linked to PRRSV outbreaks [Botner et al,  1999]. Emergence of a novel variant in 
China has been shown to be the result of recombination between the highly 
pathogenic PRRSV-2 strains and vaccine strains [Li et al, 2009a; Shi et al,, 2013] 
and in the UK it has been demonstrated that there are circulating strains which have 
resulted from recombination events [Frossard et al,  2013]. Reversion of vaccine 
strains to virulence in the field has also been seen both with genotype 1 [Storgaard et 
al, 1999] and 2 viruses [Allende et al, 2000]. In addition there is a difficulty in 
distinguishing infected from MLV vaccinated animals (DIVA).  
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Inactivated/killed PRRSV vaccines are very safe but there is some debate 
over their efficacy. Inactivated vaccines generally afford little to no protection from 
heterologous challenge [Scortti et al, 2007, Zuckerman et al, 2007]. Induction of cell 
mediated immunity (CMI) after vaccination with inactivated vaccine in an oil 
adjuvant and challenge with a homologous virus strain has been reported [Piras et al,  
2005] but little induction of neutralising antibody (NA) was seen by Vanhee et al,  
[2009] using the virus without adjuvant. 
 
1.4. Molecular biology of PRRSV 
PRRSV is a small enveloped virus with a positive sense single stranded RNA 
genome [Wensvoort et al, 1991; Benfield et al, 1992]. It has been classified as a 
member of the Arteriviridae family in the order Nidovirales due to its similarity with 
other members such as equine arteritis virus (EAV), simian haemorrhagic fever virus 
(SHFV) and lactate dehydrogenase-elevating virus (LDV). The virion itself is 
composed of a host derived lipid envelope measuring 50-72 nm in diameter encasing 
an isometric nucleocapsid of 20-30 nm diameter [Benfield et al, 1992].  
The linear single stranded RNA genome of PRRSV is 15 kb in length and 
encodes at least 9 open reading frames (ORFs) [Meulenberg et al, 1995]. ORF 1a 
and 1b compose 75% of the genome and encode 15 non-structural proteins including 
the viral RNA dependent RNA polymerase (RdRp), replicase and protease. ORF1a 
overlaps ORF1b and the region contains a slippery sequence and pseudoknot 
structure so that ORF1b can be expressed by a ribosomal frame-shift mechanism 
[Brierley et al, 1989]. These ORFs encode two poly proteins (pp1a and 1b) that are 
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processed into non-structural proteins (NSPs) by the four protease domains encoded 
by the ORF1a. Figure 1.1 shows the organisation of the PRRSV genome. 
 
Figure 1.1 Schematic representation of the PRRSV genome. The top panel shows 
the open reading frames (ORFs) of the genome from 5’ to 3’. The positive sense 
single stranded RNA genome has a 3’ polyadenylated tail (AAA), a 5’ cap and both 
ends have an untranslated region (UTR). The orange ORFs encode for the non-
structural polyproteins which are then cleaved by viral proteases into the 14 non-
structural proteins shown in the bottom panel (grey). The blue ORFs encode sub-
genomic mRNAs for the 7 structural proteins of PRRSV, including the E protein that 
is encoded by an alternative ORF inside ORF 2a and the most recently identified 
alternative ORFs; ORF5a and NSP2TF.  
NSP1a consists of an N terminal zinc finger domain, a papain-like cysteine 
protease α domain and a C terminal extension. Besides its activity as an accessory 
protease, this protein acts as a regulator of subgenomic mRNA synthesis controlling 
expression of the structural protein genes [Nedailkova et al, 2010]. NSP1a also 
possesses type I interferon (IFN) antagonist properties [Chen et al, 2010a] acting 
through various mechanisms including, but probably not limited to, inhibition of the 
IFN and the JAK-STAT signalling pathways [Yoo et al, 2010, Sun et al, 2012], 
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affecting the interferon regulatory factor 3 (IRF3) and nuclear factor κB (NFκB) 
mediated IFN production pathways [Beura et al, 2012, Han et al, 2013] and reducing 
the activity of  NFκB [Song et al, 2010, Subramanian et al, 2010]; and degrading 
CREB-binding protein (CBP) in a proteasome dependant manner in the nucleus by 
inhibiting its association with IRF3 (likely via a mediator) [Han et al, 2013, Kim et 
al, 2010]. NSP1b also exhibits IFN antagonist activity, again affecting the IRF3 and 
NFκB mediated pathways [Li et al, 2013, Subramanian et al, 2010], and also by 
degrading karyopherin-α1 (KPNA1) and blocking nuclear translocation of  interferon 
stimulated gene factor  3 (ISGF3) [Patel et al,  2010, Wang et al, 2013b]. NSP1b 
also acts as an accessory protease via a papain-like cysteine protease β domain. 
NSP2 is the largest PRRSV protein at around 1000aa in length and is variable in 
length between strains. This transmembrane protein contains an N terminus cysteine 
protease domain as well as a deubiquitinating enzyme, and is involved in 
transmembrane modification [Sun et al, 2010]. NSP2 is also implicated in 
modulation of the type I IFN response by inhibiting NFκB signalling and 
deconjugating ISG15 [Sun et al, 2012]. Certain regions of NSP2 can induce strong 
antibody responses, although this area is hypervariable and subject to various 
insertions and deletions in different strains [Feng et al, 2008]. In EAV, NSP3 has a 
putatively essential role in remodelling the intracellular membrane and has been 
postulated to have the same function in PRRSV [Posthuma et al, 2008]. NSP4 is a 
3C-like serine protease, which is the main protease involved in the cleavage of the 
viral polyprotein [Tian et al, 2009]; it also has an inhibitory effect on IFN-β 
transcription [Chen et al, 2014]. Little is known about the function of the NSP5 but it 
has been postulated to possess the same functions as NSP3 as it displays prominent 
hydrophobic domains [Posthuma et al, 2008, Fang and Snijder 2010]. There is 
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currently no function attributed to the proteins NSP6, NSP7α and β, NSP8 and 
NSP12, although the NSP7 has been found to be the target of a strong antibody 
response [Brown et al, 2009]. The RdRp or NSP9 is the catalytic subunit of the viral 
replication complex [den Boon et al, 1991, Beerens et al, 2007]. The NSP10 is a 
viral helicase containing an N-terminal zinc-binding domain with the ability to unzip 
dsRNA and DNA in a 5’ to 3’ direction [Seybert et al, 2005, Bautista et al, 2002]. 
NSP11 is an endoribonuclease that is only found in the Nidovirales with unknown 
cellular targets; it can also inhibit IFN-β and IRF-3 [Shi et al, 2011]. Recently a 
transframe protein ‘NSP2TF’ has been identified which is encoded by a transframe 
ORF of ORF1a via programmed ribosomal frameshifting [Fang et al, 2012]. This 
protein consists of two thirds of the NSP2 protein fused to the C-terminal region 
which is encoded by the transframe ORF and has been shown to be nonessential for 
replication but required for efficient growth rates [Fang et al, 2012]. 
ORFs 2-7 encode seven structural proteins via six nested subgenomic 
mRNAs (reviewed in Pasternk et al, 2006 and Sawicki et al, 2007), that form the 
nucleocaspid and the viral envelope (Table 1.2). The envelope is composed of five 
structural proteins, two major proteins; GP5 and the matrix protein (M), and three 
minor proteins; GP2, GP3 and GP4. Expression of all structural proteins is required 
for infectious virion formation [Wissink et al, 2005]. 
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Table 1.2. The structural proteins of PRRSV 
ORF Protein Function 
2a GP2 Minor envelope protein, essential for infectivity 
2b E Non-glycosylated minor envelope protein, essential for 
infectivity, functions as an ion channel to facilitate release 
of the viral genome 
3 GP3 Minor envelope protein, essential for infectivity 
4 GP4 Minor envelope protein, essential for infectivity 
5a ORF5a 
protein 
Unknown, but essential for viability 
5 GP5 Major envelope protein, forms a disulphide linked 
heterodimer with M protein, essential for infectivity and 
virion formation 
6 M Non-glycosylated major membrane protein, possibly 
involved in virus assembly and budding, essential for 
infectivity and virion formation 
7 N Nucleocapsid protein, highly immunogenic, essential for 
infectivity and virion formation 
[Dea et al,  2000; Meulenberg et al,  1994; Lee and Yoo, 2006; Wissink et al,  2005, 
Sun et al, 2013] 
PRRSV N protein is abundantly expressed, making up between 20 and 40% 
of the virion and it interacts with the RNA genome to form the icosahedral virion 
core. It is also highly immunogenic but antibodies directed against N are non-
neutralising [Murtaugh et al, 2002]. The M and GP5 proteins form disulphide linked 
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heterodimers in the endoplasmic reticulum (ER) of infected cells. Both proteins have 
short ectodomains exposed on the virion surface and large endodomains which have 
been hypothesised to interact with the nucleocapsid [Dokland, 2010]. M is the most 
well conserved structural protein of PRRSV whereas GP5 is poorly conserved 
between the PRRSV strains [Murtaugh et al,  2005] and has a hypervariable N-
terminal region [Meng et al,  1995]. GP2 is a minor envelope protein and may 
interact with CD163 on the host cell surface [Das et al, 2010]. The hydrophobic E 
protein is an ion channel protein similar to the M2 protein of influenza A virus [Pinto 
et al, 1992] which facilitates the release of the viral genome into the endosome [Lee 
and Yoo, 2006]. GP3 is heavily glycosylated and forms multimeric complexes with 
GP2 and GP4 [Das et al, 2010; Wissink et al, 2005]. GP4 is another immunogenic 
protein which contains a variable neutralising epitope [Meulenberg et al, 1997] that 
is not cross-protective between strains [Vanhee et al, 2010]. A recently identified 
novel structural protein, designated ORF5a is expressed by an ORF that overlaps the 
5’ end of ORF5 [Firth et al, 2011]. This protein is present in low levels in both 
infected cells and virions [Johnson et al, 2011] and it appears to be essential for virus 
viability [Sun et al, 2013].  
 
1.5. The replication cycle of PRRSV 
PRRSV displays a specific tropism for mononuclear phagocyte cells of the 
myeloid lineage, including macrophages and dendritic cells (DC), with the primary 
target cell generally considered to be the porcine alveolar macrophage (PAM) [Duan 
et al,  1997a, Duan et al,  1997b]. The host cell receptors necessary for PRRSV 
attachment and entry have been identified as CD169 (sialoadhesin) and CD163 
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[Vanderheijden et al, .2003; Calvert et al, 2007 and Van Garp et al, 2008]. Heparin 
sulphate (HS) serves as an initial binding receptor, as seen with many other viruses, 
with the M protein binding HS on the cell surface [Delputte et al, 2002] followed by 
CD169 mediated internalisation and uncoating of the genome. Viral replication 
occurs in the cytoplasm of the host cell [Benfield et al, 1992]. Initially, translation of 
ORF 1a/b occurs giving two large polyproteins that are cleaved by viral encoded 
proteinases into the viral replicase. These proteins then form a replication complex 
with the genome and synthesise a negative sense RNA (the antigenome) which is 
used as the template for genomic copies for the progeny virions. Subgenomic 
negative sense messenger RNAs are also transcribed in six nested sets which are 
then translated into the viral structural proteins [Meulenberg et al, 1993]. The 
membrane proteins localise to the endoplasmic reticulum while the genome is 
encapsulated by the nucleoproteins in the cytoplasm. The nucleocapsid then buds 
into the ER or the Golgi apparatus, where the virion acquires its lipid envelope, 
complete with glycoproteins correctly modified, and the progeny virion is then 
released from the cell via intracellular vesicles. 
 
1.6. Innate immune responses to PRRSV infection 
PRRSV infection elicits a remarkably weak innate immune response which is 
no doubt a key factor in the prolonged persistence of the virus in infected pigs. A 
varied induction of cytokines has been reported over the years, sometimes differing 
by cell type, virus strain or even different clones of the same isolate, as seen with 
interferon-α (IFN-α) [Lee et al, . 2004; Chung et al,  2004; Wang et al, 2013a], 
interleukin 10 (IL-10) and tumour necrosis factor alpha (TNF-α) [Gimeno et al, 
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2011]. Interestingly, IFN-α induction upon PRRSV infection appears to be minimal 
[Van Reeth, et al, 1998; Loving et al, 2007] while the presence of IFN-α at the time 
of infection has a significant protective effect in vivo [Brockmeier et al, 2009; 
Albina et al, 1998]. As IFN-α secretion is a crucial factor in downstream immune 
responses, including NK cell activation, induction of monocyte to DC differentiation 
and maturation, activation of naive T cells and memory T cell proliferation, the 
PRRSV-specific down-regulation of the IFN- response has important repercussions 
for the immunocompetency of the infected pig. 
TNF-α is secreted by a range of leukocyte cell types including activated 
macrophages and it is a prototype proinflammatory cytokine inducing expression of 
other cytokines and inflammatory mediators. A number of studies have shown that 
PRRSV has the ability to impair TNF-α production both in the lung of the infected 
pig [van Reeth et al, 1999;] and at the cellular level in PAMs in vitro [Chiou et al,  
2000; Thanawongnuwech et al,  2001]. Other studies have elaborated on this by 
showing that induction of TNF-α production upon PRRSV infection could vary 
depending on other factors such as virus strain [Hou et al, 2012] or pig breed. For 
example, there was a significantly reduced level of PRRSV replication seen in PAMs 
derived from Landrace pigs when compared to other breeds which was attributed to 
higher levels of TNF-α induction [Ait-Ali et al, 2007]. It is also of note that while 
TNF-α has a negative effect on PRRSV replication [Chang et al, 2005], the addition 
of TNF-α to cells already treated with IFN-α did not further reduce the ability of the 
virus to replicate [Lopez-Fuertes et al,  2000] showing that the two cytokines do not 
work synergistically to down-regulate viral replication. 
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Nuclear factor κB (NFκB) is a pleiotropic transcription factor important in 
activating many genes involved in the immune response including regulation of 
type-1 IFN and other cytokine production [Mogensen and Paludan, 2001]. NFκB 
activity can be induced by PRRSV infection by a mechanism that degrades IKB 
which would otherwise block the nuclear localisation signal of NFκB [Lee and 
Kleiboeker, 2005]. This shows that the NFκB signalling pathway is not affected by 
PRRSV infection and therefore the modulation of type-1 interferons occurs at the 
transcriptional or post-transcriptional level. 
IL-10 is one of the most debated cytokines in the context of PRRSV 
immunomodulation. It is secreted by activated Th2 cells, B cells and macrophages 
and it has many functions. It is known to regulate cell mediated immune responses, 
including T cell, NK cell and macrophage activity, promote the proliferation and 
antibody production of B cells and inhibit production of proinflammatory cytokines, 
so has the ability to rescue cells from apoptosis [reviewed in Moore et al,  1993; 
Cohen et al,  1997]. It is hypothesised that induction of IL-10 would be an effective 
and simple mechanism by which PRRSV could control the host pro-inflammatory 
response, especially in the first two weeks post infection, but the experimental data 
are not conclusive. PRRSV infection has been reported to induce IL-10 gene 
expression in PBMC [Suradhat and Thanawongnuwech, 2003], monocytes 
[Charerntantanakul et al, 2006b] and PAMs [Suradhat et al,  2003] as well as 
increased IL-10 mRNA levels in the lungs of PRRSV infected pigs [Chung and 
Chae, 2003]. On the other hand, some studies have reported that there was no 
significant IL-10 production upon PRRSV infection of PAMs [Thanawongnuwech et 
al, 2001] or monocyte derived DCs (moDC) [Wang et al, 2007b]. 
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A recent study by Gimeno et al, [2011] investigating the cytokine profiles of 
different antigen presenting cells infected with 39 different strains of PRRSV-1 
yielded interesting results. TNF-α and IL-10 were both detected and not detected in 
all possible combinations depending on the virus strain and/or cell type, whereas 
IFN-α was not detected at all, and there was no correlation between the cytokine 
levels measured and the viral titre. 
PRRSV-associated immunomodulation of the innate immune response, 
especially of IFN-α, may have severe repercussions for the immune status of the 
infected animal and can pave the way for other viral and non-viral pathogens in the 
lungs, which would otherwise be controlled by induction of a normal immune 
function [Renukaradhya et al, 2010; Thanawongnuwech et al, 2000]. It could also 
cause disruption or failure of vaccines for diseases like pseudorabies virus [De Bruin 
et al, 2000] and CSFV [Li and Yang, 2003; Suradhat et al, 2006].  
PRRSV also has the ability to modulate host cell receptors. Transfection of 
CD163 into non-PRRSV permissive cell lines allowed them to become infected by 
both genotype1 and -2 PRRSV [Lee et al, 2010] showing that CD163 expression is 
essential or sufficient to allow PRRSV infection. It is known that IL-10 can induce 
the expression of CD163 [Patton et al, 2009] indicating that PRRSV may enhance 
the availability of susceptible host cells through the induction of IL-10. Some strains 
of PRRSV have been shown to upregulate CD163 expression [Calvert et al,  2007; 
Van Gorp et al, 2008] however there was no correlation between the ability of the 
PRRSV strain to induce IL-10 and the upregulation of CD163 [Gimeno et al,  2011]. 
PRRSV has been shown to downregulate major histocompatibility molecules 
class I (MHC-I) and II (MHC-II) expression on dendritic cells (DC) and 
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subsequently PBMC cultured with PRRSV infected DCs were not efficiently 
stimulated suggesting that MHC downregulation affects the ability of the DC to 
present antigen [Park et al,  2008]. In the same study, TNF-α and IL-12 were seen to 
be induced suggesting that the downregulation of MHC-I/II could be responsible for 
the impaired response to PRRSV infection, rather than the lack of cytokines able to 
co-stimulate T cell responses. The costimulatory molecules CD80/86 which work in 
tandem to prime T cells have been shown to be downregulated in PRRSV infected 
monocyte derived DCs [Flores-Mendoza et al, 2008], however, contradictorily, 
expression on bone marrow derived DCs was upregulated [Peng et al,  2009] along 
with a simultaneous downregulation of MHC-I molecules [Chang et al, 2008].  
Natural killer (NK) cells are cells of the innate immune system that can 
identify and kill infected cells via a complex network of activating or inhibitory 
signals [reviewed in Lanier, 2005]. Little is known about the interaction of PRRSV 
and NK cells but it has been shown that PRRSV-infected PAMs were reduced in 
their susceptibility to NK mediated lysis and NK cells incubated with PRRSV 
infected PAMs did not increase expression of the cytotoxic degranulation marker 
CD107a [Cao et al, 2013]. This impairment of NK cell responses could contribute to 
the failure of the innate immune response to effectively control PRRSV infections. 
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1.7. Adaptive immune responses to PRRSV infection 
1.7.1. Antibody responses to PRRSV infection 
The PRRSV-specific antibody (Ab) responses can be observed a week to ten 
days post infection [Loemba et al, 1996] but the antibodies found at this stage do not 
neutralise PRRSV infectivity [Yoon et al,  1994] and their development occurs in 
conjunction with B cell activation, especially in the tonsils [Lamontagne et al, 2001]. 
It typically takes at least four weeks for a neutralising antibody (NA) response to 
arise [Meier et al, 2000; Meier et al, 2003]. However, low levels of virus replication 
can be found in lungs and some lymphoid tissues, even in the presence of NA, 
suggesting that other immune responses, most likely T cell responses, are involved 
in the complete clearance of the virus [Labarque et al, 2000].  
A study carried out using 8 isolates of varying pathogenicity observed that 
more virulent strains of PRRSV have higher levels of viral replication and elicit a 
more intense and rapid antibody response in vivo compared to more attenuated 
strains. The level of antibody response seems therefore to be linked to the levels of 
viral replication and potentially abundance of antigen, but it was also speculated that 
there may be antigenic differences between the strains tested [Johnson et al, 2004].  
In addition to inconsistent induction of antibodies, isolates of PRRSV have 
also shown variable ability to facilitate antibody-dependant enhancement of infection 
(ADE) [Yoon et al, 1997] and this has been shown to be mediated by the FCγRIIb 
receptor in simian MARC-145 cells [Qiao et al, 2011]. Infection via this method has 
subsequently been shown to occur in PAMs and is associated with a down-regulation 
in the induction of key antiviral cytokines TNF-α and IFN-β [Bao et al, 2013].  
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1.7.2. T cell responses to PRRSV infection 
Upon PRRSV infection, virus specific IFN-γ secreting T cells (SC), which 
are considered as important effector cells of anti-viral cell mediated immunity 
(CMI), exhibit a delayed response profile that can take up to four weeks to be 
detected, along with a measurable lymphoproliferative response [Bautista and 
Molitor, 1997; Lopez-Fuertez et al,  1999; Meier et al,  2003]. This belated response 
was observed upon infection with both genotype 1 and genotype 2 strains of PRRSV 
[Diaz et al, 2005; Meier et al, 2003]. 
Meier et al, [2003] demonstrated the gradual increase of the PRRSV specific 
IFN-γ response in parallel to the ‘two-step’ antibody response by inoculating 8 week 
old piglets with wild type virulent PRRSV. They found that an initial influx of non-
neutralising antibodies was followed by the development of virus neutralising 
antibodies as the non-NA began to wane at around four weeks post-infection. The 
IFN-γ response showed the exact opposite temporal response; the initial observation 
of IFN-γ-SC occurring at 2-3 weeks post infection, then increasing gradually over 
time to reach a peak at the point when the experiment was terminated at 48 weeks 
post-infection. In addition, the differential induction of IFN-γ was measured in 
response to either a modified live PRRSV vaccine or a control modified live 
pseudorabies virus (PRV) vaccine and it was found that IFN-γ induction by the 
PRRSV vaccine strain was much lower than by the PR vaccine strain. Xiao et al,  
[2004] also observed a similar delayed and weak development of PRRSV-specific T 
cell response, with IFN-γ-SC not detected until at least 2 weeks post infection, which 
is also in keeping with the investigations of others [Yoon et al,  1994; Diaz et al,  
2005]. 
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IFN-γ is known to inhibit PRRSV replication in vitro [Bautista and Molitor, 
1999; Rowland et al, 2001] and IFN-α is a major component contributing to the 
induction of T cells to become IFN-γ-SC [Cousens et al, 1999; Kadowaki et al, 
.2000]. Considering PRRSV has the ability to impair IFN-α production it is plausible 
that this could be an important factor in the initial weak IFN-γ response. Meier et al, 
[2003] suggested that the induction of just a few IFN-γ-SC could cause the 
subsequent induction of naive T cells into IFN-γ-SC via a positive feedback 
mechanism, leading to the gradual observed increase in IFN-γ-SC. A recent study 
showed that a highly pathogenic PRRSV-1 subgenotype 3 strain induced a much 
stronger IFN-γ response than classical strains and this T cell response was associated 
with enhanced clearance of the virus [Morgan et al, 2013, Weesendorp et al,  2013]. 
Regarding the phenotype of the cells mounting the T cell response, Bautista and 
Molitor [1997] found that it was CD4 T cells that were driving the proliferative 
response, however, Morgan et al, [2013] observed both CD4 and CD8 T cells 
produce IFN-γ over the course of infection. 
Investigation into which PRRSV proteins contribute to the induction of CMI 
is important in expanding the current knowledge of T cell responses and how they 
are affected by different virus strains. Jeong et al, [2010] investigated the T cell 
responses induced by the PRRSV M or N proteins fused to GM-CSF and found that 
the M protein construct elicited higher levels of T cell proliferation and IFN-γ 
production than the N protein construct. In earlier studies, Bautista et al, [1998] also 
showed that the M protein was the strongest inducer of a lymphoproliferative 
response. This study also identified GP5 and N as inducers of proliferation and 
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another study identified GP3 as able to induce T cell proliferation in mice [Jiang et 
al, 2007].  
Identification of T cell epitopes has been approached in several different 
ways to date. A study by Vashisht et al, [2008] synthesised the entire GP5 protein as 
a series of overlapping peptides and tested their ability to induce IFN-γ production in 
cells from pigs infected with North American strains of PRRSV. Two antigenic 
regions were identified using this method; GP5117-131 and GP5149-163. Wang et al, 
[2010] also employed synthesis of overlapping peptides, this time of the M protein, 
to identify immunodominant T cell epitopes. They identified 4 peptides on the M 
protein that elicited a significant IFN-γ response and confirmed this by real-time 
PCR. Diaz et al, [2009] employed an in silico method to identify potential T cell 
epitopes on GP4, GP5 and the nucleocapsid protein (N) using the bioinformatic tools 
SYPEITHY matrix [http://www.syfpeithi.de] and the IEBD resource 
[http://www.iedb.org/]. Peptides identified in this way were then synthesised and 
their ability to stimulate IFN-γ production in cells from PRRSV vaccinated pigs was 
tested. Four epitopes were identified on the N protein, two on GP4 and one large 
immunodominant region on GP5. It was also concluded that N elicited the greatest T 
cell response followed by GP5 and then GP4. It is worthy of note that the epitopes 
identified here on GP5 corresponded to one of the epitopes identified by Vashisht et 
al, [2008].  
Figure 1.2 shows a representation of the kinetics of antibody and T cell 
responses when pigs are infected with PRRSV [adapted from Lopez & Osario, 
2004]. Viral load in tissues can be detected up to 5 months post infection whereas 
viraemia only lasts around one month. The IFN-γ SC response and the neutralising 
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antibody response are both delayed however the IFN-γ response gradually increases 
over time in contrast to the NA response which increases rapidly but then begins to 
decrease soon after. 
 
 
Figure 1.2. Representation of the kinetics of the adaptive immune response in 
pigs following PRRSV infection. [adapted from Lopez & Osario, 2004]. 
 
1.7.3. γδ T cell responses to PRRSV infection 
Like ruminants, it is known that pigs possess a large number of γδ T cells 
compared to humans and rodents and that these cells possess the characteristic of 
non-MHC restricted cytotoxic T lymphocytes [Tanaka et al,  1994] allowing their 
involvement in both innate and adaptive immune responses [Yang et al,  2000; 
Borghetti et al,  2006; Takamatsu et al,  2006]. In response to PRRSV infection, it 
has been shown by Olin et al,  [2005] that the percentage of peripheral γδ T cells 
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increased and that they were able to produce IFN-γ until 10 weeks post infection. 
Upon restimulation with PRRSV, both CD4+ and γδ-TcR+ T lymphocytes from 
infected pigs produced IFN-γ, suggesting that γδ T cells are capable of 
demonstrating memory responses; however this data is not conclusive. Interestingly, 
Xiao et al, [2004] found that the levels of γδ T cells present in the lungs and various 
lymph tissues decreased upon PRRSV infection. 
 
1.7.4. Regulatory T cell responses to PRRSV infection 
Regulatory T cells (Tregs) have been implicated in the ability of PRRSV to 
persist and evade the host immune system. They are conventionally defined as 
CD4+FoxP3+CD25+, and in pigs can be described as CD8α-MHC-II- or CD8α+MHC-
II-; corresponding to ‘natural’ or ‘induced’ Tregs, respectively [Kaser et al,  2008]. 
Yet again we come across contradictory evidence for the induction of Treg responses 
to PRRSV infection, but these differences may be genotype dependent. A 2009 study 
by Silva-Campa et al, showed that FoxP3+CD25+ Tregs could be induced by North 
American genotype PRRSV infected DCs. Another study in 2010 by Wongyanin et 
al, claimed that even the presence of PRRSV could increase the number of 
FoxP3+CD25+ Tregs in PBMC both in vitro and in vivo, and that when monocyte-
derived DCs (MoDCs) were included in the culture, there was a significant 
additional expansion of FoxP3+CD25+ Tregs. This study also used North American 
genotype isolates. On the contrary, a study in 2010 by Silva-Campa et al, this time 
using several European genotype isolates showed that while PRRSV was able to 
infect and replicate in MoDCs, these cells were incapable of inducing Tregs. 
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1.8. Next generation vaccine development for PRRSV 
In addition to vaccines derived from whole virus, there are a variety of other 
experimental approaches that have been and are currently being developed as next-
generation PRRSV vaccines. Different molecular adjuvants including cytokines (IL-
2, IL-4, IL-12, IFN-α and IFN-γ), pathogen-associated molecular patterns (PAMPs) 
such as the double-stranded RNA analogue poly(I:C), CpG oligodeoxynucleotides 
(CpG ODN), lipopolysaccharide (LPS) and other bacterial products, such as cholera 
toxin, have been investigated for their ability to enhance the efficacy of experimental 
PRRSV vaccines. Plasmid DNA vaccines have to date mainly focussed on ORFs 5 
(GP5) and 7 (N protein), with GP5 expressing plasmid conferring limited protection 
from infection in pigs [Pirzadeh et al, 1998]. A neutralising antibody response was 
induced by NSP2, GP4 and GP5 in pigs vaccinated with ORF1, 4 or 5 [Barfoed et al, 
2004] while the co-expression of GP5 and M increased the magnitude of T cell and 
Ab responses, when compared with GP5 or M alone [Jiang et al, 2006b]. Plasmids 
expressing cytokines such as IL-2, IL-4 and IFN-γ in combination with ORFs 5 and 
7 have also been studied. IL-2 and IFN-γ were found to have a positive effect on 
virus specific T cell responses and reduction of viraemia in pigs, whereas IL-4 
suppressed these responses [Romparto et al, 2006; Xue et al, 2004]. GP5 in 
combination with IL-18 enhanced T cell responses, but was not comparable to a live 
vaccine [Zhang et al, 2013]. Cytotoxic T lymphocyte-associated protein 4 (CTLA4) 
with GP5 could enhance both Ab and T cell responses in mice [Wang et al,  2013c] 
and a plasmid co-expressing swine ubiquitin and GP5 could improve the T cell but 
not the Ab response [Hou et al, 2008]. Various adenoviral vectored vaccines have 
been tested in pigs, including granulocyte macrophage-colony stimulating factor 
(GM-CSF)-GP5/3 [Wang et al,, 2009], heat-shock protein 70 (HSP70)-GP5/3 [Li et 
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al, 2009b] and CD40 Ligand (CD40L)-GP5/3  [Cao et al, 2010], all of which 
induced T cell and Ab responses in pigs. Adenoviral vectored constructs such as 
GP5/M and GP5/3 or GP3/4/5 constructs have also been tested in mice, where they 
induced both T cell responses and antibody responses [Jiang et al,  2008, Jiang et al, 
2006a].  In addition, an adenoviral vectored GP5/M construct induced T cell and NA 
in mice [Cai et al, 2010]. A Modified Vaccinia Ankara (MVA) vectored GP5/M 
construct induced T cell and Ab responses in mice [Zheng et al, 2007]. GP5 vectored 
in a pseudorabies virus (PRV) conferred protection from clinical signs in piglets 
without induction of anti-PRRSV Ab, suggesting a role for T cell responses [Qiu et 
al,  2005]. Baculovirus expressed GP2 and GP4 elicited high NA titres in mice 
[Karauppannan et al, 2013] whereas GP5 (with PCV2 capsid protein as a bivalent 
vaccine) and GP5/M constructs induced NA as well as T cell IFN-γ responses but 
had poor expression levels [Wang et al, 2007a; Xu et al, 2012].  Other subunit 
vaccines such as recombinant GP5 expressed in E. coli or in transgenic tobacco 
plants failed to provide protection and also exacerbated disease upon challenge (E. 
coli-expressed; Prieto et al,  2011) but could induce a gradual increase in Ab 
responses and a NA response after 4 doses of vaccine (tobacco plant-expressed; Chia 
et al, 2010). A recent study using the Nisin controlled expression system of 
Lactococcus lactis was employed to successfully induce produce M protein-specific 
mucosal T cell and Ab responses in mice [Wang et al, 2014]. Whilst this result and 
those from other studies are encouraging many have failed to translate successfully 
to the porcine system. In addition, the viral vectors used in a number of these studies 
pose their own issues such as the risk of recombination with wild type viruses and 
potential pre-existing host immunity rendering the vaccine inactive [Reviewed in 
Ura et al,  2014]. 
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1.9. Vaccination approaches targeting T cell immunity 
An effective anti-viral vaccine should induce a strong T cell response made 
up of both CD4+ helper T cells and CD8+ cytotoxic T cells. The induction of T cell 
responses depends on the presentation of antigen and associated co-stimulatory 
signals provided by an antigen presenting cell (APC). Therefore the focus of such a 
vaccine should be to target and activate the APC to induce the desired T cell 
response. Dendritic cells (DC) are ‘professional’ APC and are the only APCs to 
effectively activate naive T cells. While there are two major lineages of DC, myeloid 
DC (mDC) and plasmacytoid DC (pDC), it is mDC that are the true APCs, whereas 
the pDC function primarily through the action of the cytokines they secrete. Mature 
mDC secrete a chemokine called CCL22, which is a chemoattractant that recruits 
naive T cells. When a foreign agent is detected, the DC coordinate the host response, 
beginning with the immediate immune response by recruiting effector cells of the 
innate immune response. Memory T cells are then recruited, followed by naive T 
cells and B cells that are primed by the presentation of antigen [Piqueras et al,  
2006]. At this stage, it is thought that Treg cells are attracted to keep the immune 
response ‘in check’. When a DC encounters an exogenous antigen, the antigen gets 
phagocytosed or endocytosed, processed by proteases and transported to the 
endosome, where fragments are loaded into the binding sites of MHC-II molecules. 
The MHC-II/antigen complexes are then transported to the cell surface where the 
antigen is presented to CD4+ T helper cells. On the other hand, when a DC 
encounters an endogenous antigen, such as a newly synthesised viral protein, the DC 
ubiquitinates the antigen before processing by the proteasome (which only 
recognises ubiquitinated proteins). The antigen is then processed into small peptides 
between 8 and 15aa long and transported via a transporter protein (transporter for 
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antigen processing; TAP) to the ER. Here the short peptides are degraded until they 
fit into the MHC-I binding groove and are then carried to the surface for presentation 
to CD8+ cytotoxic T cells. [Reviewed in Savina and Amigorena, 2007].  However, it 
is possible for exogenous antigen to be processed and presented via the MHC-I 
pathway, through a mechanism called cross-presentation. The finer details of this 
pathway are the subject of much study but two pathways are generally referred to; 
the ‘cytosolic’ and the ‘vacuolar’. Following the cytosolic pathway, internalised 
proteins access the cytosol and subsequently the proteasome, which then leads to 
MHC-I loading via TAP. In the vacuolar pathway, degradation and MHC-I loading 
occur in the phagosome. [Reviewed in Joffre et al, 2012]. Cross-presentation is 
important in the context of viral vaccines as stimulation of both CD4 and CD8 T 
cells is critical to achieve protection. In the porcine system the DC subsets and 
receptors expressed are not currently well defined and this could be a potential 
barrier to vaccine design.  
Immunity can be conferred and can persist by vaccination with peptide 
epitopes fused to GM-CSF to target DCs. T cell immunity specific to the vaccine 
antigen was induced as evidenced by epitope spreading [Disis et al, 2002]. Delivery 
of genetic sequences encoding for single T cell epitopes (either p53 or HIVgp120) 
by particle bombardment mediated DNA transfer can also induce T cell immunity 
[Ciernick et al, 1996]. Approaches such as these have been employed for 
investigating the induction of a T cell immune response in a number of different 
infectious and non-infectious diseases, including HIV [Nchinda et al, 2009; Garcia et 
al, 2010] and other viral diseases such as hepatitis B [Chen et al, 2009], intracellular 
bacterial infections like tuberculosis [McShane et al, 2002] and cancers [Gilboa and 
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Vieweg, 2004; Mayordomo et al, 1995 and reviewed in Melief, 2008]. The potential 
of DC to coordinate such a complex immune response makes them ideal targets for 
vaccine development. Their ability to take up exogenous foreign proteins and present 
them via both of the MHC pathways, thus priming both CD4+ and CD8+ T cells can 
be used to illicit strong, long-term protection [Jung et al, 2002; Thery and 
Amigorena, 2001]. Currently, DC vaccines consist of DCs loaded with antigen ex 
vivo and then re-administered to the patient, with promising potential [Gatza, and 
Okada, 2002]; however, this approach is less than ideal for many reasons and 
methods must be developed to target DC in vivo. The maturation state of the DC ex 
vivo is a debated topic, as it has been suggested that fully matured DC when re-
injected cannot return to the lymph node however reinjection of immature DC results 
in tolerance to the cells and inhibition of immune response [Shimizu et al,  2001]. 
Investigation into targeting antigens using ligands for specific surface receptors on 
DCs in vivo show encouraging results. Specific surface receptors such as DC-SIGN 
have been targeted, for example, inducing specific responses to HIV [Dai et al,  
2009] and CD11c has also been targeted showing promise in preventing tumours in 
mice [Wei et al,  2009]. It has also been shown that targeting to the DCIR (a tyrosine 
based inhibitory motif containing DC immunoreceptor) initiates antigen specific 
CD8+ T cell immune responses [Klechevsky et al, 2010]. Trumpfheller et al, [2005] 
used a DEC-205 targeted approach to deliver HIV gag protein to DCs. In mice this 
approach induced high levels of IFN-γ and IL-2 producing CD4+ T cells. It also 
induced higher levels of CD4+ T cells than vaccination with plasmid DNA or 
recombinant adenovirus vectors. 
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1.10. Nanoparticulate vaccine formulations  
Nanoparticles (NPs) are simply particles of a ‘nano’ size i.e. 1000nm or less. 
These can be formulated from numerous materials and have a diverse range of 
applications, such as in solar cells, silver NPs that kill bacteria in fabrics and iron 
NPs used to clean-up ground water. NPs are particularly interesting to the medical 
world due to their potential for specific design. This allows for various particle 
compositions and sizes, depending on the intended use. Because the NPs have a 
larger surface area to weight ratio than normal material, they have different 
electronic, optical and chemical reactivity properties when formed into NPs, making 
them highly reactive [reviewed in Discher and Eisenberg, 2002]. 
Molecules such as proteins or drugs can be encapsulated inside a 
biodegradable particle which allows for sustained release after administration [Song 
et al, 1997; Corrigan and Li, 2009]. In addition the particle may be magnetic or 
labelled or have antigens conjugated to their surface [Nobs et al, 2004; Aline et al, 
2009; Park et al, 2010]. The particle itself can also trigger an immunogenic response 
which is useful in activating DC. Specific conjugates on the surface of the particle 
can further enhance the DC response, leading to T cell induction. DNA loaded NPs 
have also been used to deliver nucleic acid to various target sites, increasing the 
bioavailability and decreasing the degradation of the DNA [Bivas-Benita et al,  
2004; Giger et al,  2010]. DC pulsed with nanoparticles containing hepatitis B 
surface antigen have been used as a vaccine and showed induction of antibodies in 
mice [Bharali et al, 2008]. 
The internalisation of the particle is a distinct advantage and if taken up by 
DC it allows the cargo of antigen to be potentially processed via the MHC-I or the 
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MHC-II pathway and present antigens leading to CD4+ and CD8+ T cell immune 
responses. Nanoparticles have great potential as vaccines due to their size and their 
capacity for conjugation to antigens, molecular adjuvants and to ligands for DC 
specific surface receptors. This allows the delivery of antigen and 
activation/maturation of the DC which induces both antibody and T cell responses; 
as well as the potential for sustained delivery. Indeed, nanoparticulate formulations 
have previously been used to successfully deliver antigen for cross-presentation 
[Hirosue et al,, 2010] and sustained release of antigen has been achieved [Shen et al, 
2006]. Nanoparticulate vaccines have also been employed in the context of PRRSV, 
with killed PRRSV encapsulated inside poly(lactic, glycolic acid) (PLGA) particles 
and administered intranasally to pigs resulting in enhanced Ab and T cell responses 
that are potentially cross-protective between strains [Dwivedi et al, 2013; 
Binjawadaqi et al, 2014].   
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1.11. Aims and Objectives 
It is clear from previous work that the immunobiology of PRRSV infection is 
complex and there is a need for a better understanding to facilitate the development 
of new safe and efficacious PRRSV vaccines. There is evidence to suggest that T 
cell responses play an important role in protection against PRRSV [Zuckermann et 
al, 2007] and therefore this project focussed on improving our understanding of the 
PRRSV-specific T cell response. The hypothesis that PRRSV induces T cell 
responses that are crucial for protection from infection was explored through 
investigation into the kinetics and phenotype of the T cell response following 
PRRSV infection as well as the identification of proteins and peptides that are targets 
of the T cell response. Finally, the major PRRSV T cell antigens identified were 
evaluated for their vaccine potential using a novel particulate vaccine formulation. 
The three specific objectives below are addressed in the following experimental 
results chapters: 
1. To characterise the specificity of the T cell response to PRRSV utilising a 
proteome-wide synthetic peptide library (Chapter 3). 
2. To further characterise the T cell response to PRRSV, including the 
specificity, kinetics and phenotype, and identify vaccine candidate antigens 
(Chapter 4). 
3. To evaluate the vaccine potential of identified PRRSV T cell antigens using a 
rationally formulated particulate delivery system (Chapter 5). 
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Chapter 2. Materials and Methods 
 
2.1. Ethics Statement 
All work was approved by the AHVLA Ethics Committee and conducted in 
accordance with the UK Animals (Scientific Procedures) Act 1986 under Project 
Licence numbers PPL 70/7057 and 70/7209. The experiments on pigs at the Institute 
of Virology and Immunology (IVI), Mittelhäusern, Switzerland, were performed in 
compliance with the Swiss Animal Protection Law and approved by the Animal 
Welfare Committee of the canton of Berne, Switzerland (authorization number 
BE89/11).  
 
2.2. Virus Stocks 
The PRRSV-1 subgenotype 1 MARC-145 cell adapted strain; Olot/91 [Plana 
et al, 1992, Plana-Durán, et al, 1997] was kindly provided by Dr Sonia Zúñiga Lucas 
and Prof Luis Enjuanes, Centro Nacional de Biotecnología, Madrid, Spain, and 
propagated in MARC-145 cells. The PRRSV-1 subgenotype 3 virulent strain; SU1-
Bel [Morgan et al,  2013] was isolated from material kindly provided by Dr Tomasz 
Stadejek, Warsaw University of Life Sciences, Poland; the prototype PRRSV-1 
subgenotype 1 Lelystad strain (LV; Wensvoort  et al,  1991) was kindly provided by 
Drs Eefke Weesendorp and Annemarie Rebel, Central Veterinary Institute, Lelystad, 
The Netherlands; and a PRRSV-1 subgenotype 1 UK isolate; 215-06 [Morgan et al,  
2013], kindly provided by Dr Jean-Pierre Frossard, AHVLA Virology Department, 
were all propagated in porcine alveolar macrophages (PAMs; AHVLA Cell and 
Tissue Culture Unit). All four viruses were propagated in vitro by inoculation of T75 
34 
 
flasks containing sub-confluent MARC-145 cell or PAM monolayers. MARC-145 
cells were maintained in Dulbecco’s Minimum Essential Medium (D-MEM) 
(Invitrogen, Paisley, UK) supplemented with 100 IU/ml penicillin, 100 μg/ml 
streptomycin (Invitrogen) and 10% FBS (Autogen Bioclear, Calne, UK) (cDMEM). 
PAMs were maintained in RPMI-1640 medium (Invitrogen) supplemented as above 
(cRPMI). Seventy two hours post-inoculation at 37oC in a 5% CO2 humidified 
atmosphere, the supernatant was collected, freeze/thawed twice at -80°C and 
clarified by centrifugation at 524 x g for 10 minutes, aliquoted and stored at -80°C. 
Mock virus supernatants were prepared in the same way but without inoculation of 
virus. Virus titres were obtained by log10 serial dilution of the virus suspension on 
MARC-145 cell or PAM monolayers followed by immunoperoxidase (IPX) staining 
to identify infection rates as described by Van der Linder et al, [2003]. Briefly, log10 
serial dilutions of virus were added to 95% confluent cells in octuplicate wells of a 
96 well flat bottomed tissue-culture plate (Nunc, Fisher Scientific, Loughborough, 
UK) and incubated for 72 hours. Cell monolayers were washed with 0.15 M NaCl, 
air dried and then frozen at -80°C. A 1:100 dilution of the pan-PRRSV specific 
monoclonal antibody SDOW17-A (Rural Technologies, Brookings, USA) diluted 
1/100 in PBS supplemented with 0.01% Tween-80 (Sigma-Aldrich, Poole, UK) and 
4% normal goat serum (Life Technologies) (IPX serum conjugate buffer) was added 
to cells which were then incubated for 1 hour at 37°C. Cell monolayers were washed 
3 times in PBS with 0.5% Tween-80 (IPX wash buffer) and polyclonal rabbit anti-
mouse horseradish peroxidase (HRP) conjugated secondary antibody was diluted 
1:150 in IPX serum conjugate buffer and added to cells. After incubation for 1 hour 
at 37°C, cells were again washed 3 times in IPX wash buffer and freshly prepared 
carbazole substrate buffer (containing 0.06% 3 amino-9-ethylcarbazole, 0.01% 
35 
 
hydrogen peroxide, 0.08% glacial acetic acid in 0.04 M anhydrous sodium acetate; 
all Sigma-Aldrich) was added to the cells. Cells were incubated for 15 min at 37°C 
then examined under a light microscope and PRRSV-infected cells were observed by 
the presence of reddish brown cytosolic staining. Virus titres were calculated as 
log10TCID50/ml using the Spearman-Karber method [Drew, 2008]. 
 
2.3. PRRSV-1 peptide library 
A synthetic overlapping peptide library of 1275 pentadecamer peptides off-
set by four amino acids was synthesised  (JPT Peptide Technologies, Berlin, 
Germany) using the predicted amino acid sequences of the structural proteins of 
PRRSV-1 Olot/91 strain (GenBank Accession No.X92942.1) and the non-structural 
proteins of the closely related Lelystad strain (GenBank Accession No. 
AY588319.1) since the non-structural protein encoding open-reading frame 
sequences were not available for Olot/91 at this time. Lyophilised peptides were 
reconstituted in 10 mM N-2-Hydroxyethylpiperazine-N'-2-Ethanesulfonic Acid 
(HEPES) (Life Technologies) buffered 40% (v/v) acetonitrile at a concentration of 
1.65 mg/ml. Peptides were combined into pools representing 19 proteins of PRRSV-
1: 
 NSP1 – 96 peptides; NSP 2 – 269 peptides; NSP3 – 58 peptides; NSP4 – 51 
peptides; NSP5 – 42 peptides; NSP6 – 4 peptides; NSP7 – 67 peptides; NSP8 – 12 
peptides; RdRp –173 peptides; helicase – 110 peptides; NSP11 – 56 peptides; 
NSP12– 37 peptides; GP2 – 60 peptides; E – 15 peptides; GP3 – 64 peptides; GP4 – 
43 peptides; GP5 – 48 peptides; M – 41 peptides; and N – 30 peptides. 
36 
 
Analysis conducted during Animal Experiment 1 to identify antigenic 
peptides from within these pools involved testing individual peptides for GP5 and M, 
whereas peptides for NSP1 NSP2 and RdRp were tested in pools of 10 due to the 
large number of peptides. Once positive pools of 10 NSP1, NSP2 and RdRp peptides 
were identified, the constituent peptides were tested individually to identify the 
antigenic peptides. In Animal Experiment 3, antigenic M and NSP5 peptides were 
identified by screening peptides using a two-way matrix system as previously 
described [Franzoni et al, 2014]. 
 
2.4. Generation of experimental PRRSV vaccine formulations 
2.4.1. Preparation of vaccine antigens  
PRRSV-1 Olot/91 was grown up in bulk on MARC-145 cells in serum free 
RPMI-1640 then purified and concentrated using a 300 kDa MicroKros Filter 
Module (Spectrum Labs, Breda, The Netherlands).  Virus was then inactivated by 
incubation with a 1:1000 dilution of β-propriolactone (Sigma-Aldrich) at 37°C for 2 
hours with continuous shaking. The infective titre of the virus preparation before and 
after inactivation was determined by microtitration and IPX as described above.  
Overlapping 20mer peptides, offset by 10 amino acids, encompassing the 
entire M and NSP5 proteins from PRRSV-1 Olot/91 strain were designed (Appendix 
B), synthesised (Mimotopes, Heswall, UK) and reconstituted in sterile DMSO at a 
concentration of 25 mg/ml. 
  A recombinant fusion protein EM4 that consisted of the portion of the 
PRRSV-1 GP5 ectodomain (MSSTYQYIYNLTICELNGTDWLSNHA) fused 
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directly to the C-terminal region of the PRRSV-1 Olot/91 M protein 
(MDAHHVKSAAGLHSIPASGNRAYAVRKPGLTSVNGTLVPGLRSL) was 
kindly provided by Dr Margarita Garcia-Duran, Ingenasa, Madrid, Spain. The 
protein was designed to express a potential neutralizing antibody epitope on GP5 
[Ostrowski et al, 2002] and an immunogenic M protein antibody epitope, however, 
subsequent analysis showed that this fusion protein induced only non-neutralising 
anti-PRRSV antibodies when used to immunise pigs (Dr Margarita Garcia-Duran, 
personal communication). In brief, the EM4 protein was constructed by PCR 
amplification of the correspondent sequences from PRRSV-1 Olot/91 strain. The 
PCR product was cloned in the baculovirus vector pAcHLTA which has a His-tag 
for purification. Recombinant baculovirus were selected by plaque assay and grown 
to generate the appropriate virus stock. To produce the protein, Sf9 cells were 
infected at an MOI=2. Infected cells were collected by centrifugation, the cellular 
pellet was lysed and EM4 purified by ion metal affinity chromatography (IMAC) 
with Ni2+ charged resin. The bound EM4 was eluted with imidazole and detected by 
Western blotting with anti-His antibody. 
 
2.4.2. Formulation of vaccine antigens in chitosan particles 
Particulate vaccine formulations were prepared with the help and supervision 
of Dr Satyranayrana Somaravarapu at the UCL School of Pharmacy, London. Three 
particulate formulations were prepared: (1) virus loaded particles (Virus-P), (2) 
peptide loaded particles (Peptide-P) and (3) control empty particles (Empty-P). For 
each vaccine dose of particles, 50mg of octanyl chitosan (Heppe Medical Chitosan 
GmbH, Halle Germany) was added to 715µl chloroform (Sigma-Aldrich) and 
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sonicated in a water bath until dissolved. The following components were then added 
to the chitosan in chloroform solution: For each vaccine dose of Virus-P: 50µg 
Adilipoline™ (Source Bioscience, Nottingham, UK), 200µl containing 106 TCID50 
equivalent of β-propriolactone inactivated PRRSV-1 Olot/91 and 500µl 15% PVA. 
For each dose of Peptide-P: 50µg Adilipoline, 132µl of M and NSP5 peptide pool 
containing 100µg of each individual peptide, 500µl 15% PVA and 226µl sterile 
deionised water. For each dose of Empty-P: 600µl 15% PVA and 1.4ml sterile 
deionised water. The resultant mixtures were homogenised for 1 minute followed by 
probe sonication for 2 minutes (amplitude 17 microns). The mixtures were then 
added drop-wise to 20ml 1% PVA whilst homogenising for 4 minutes. The 
formulations were then set on magnetic stirring blocks in a fume hood and solvent 
was allowed to evaporate for 6 hours at room temperature. Prior to vaccination, the 
following was adsorbed onto the surface of the particles by adding drop wise whilst 
on a magnetic stirring block: To the Virus-P formulation - 50µg Adilipoline in 200µl 
sterile water/dose. To the Peptide-P formulation: 50µg Adilipoline in 200µl sterile 
water/dose and then subsequently, 200µg EM4 protein in 150µl sterile water/dose. 
All vaccine formulations were then made up to 4ml per dose with sterile water. 
Aliquots of each formulation were removed for quality control assessments.  
 
2.4.3. Quality control of particulate vaccine formulations 
2.4.3.1. Assessment of the physical properties of the particulate vaccine 
formulations 
The surface charge of the particles was measured using a Zeta Sizer 3000 
(Malvern Instruments, Malvern, UK).  Particles were dispersed in distilled water and 
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analysed in a disposable zeta cell (Malvern Instruments) at 25°C. 20 readings of each 
sample were made in triplicate and each sample was measured in duplicate. 
Particle morphology and size was assessed using scanning electron 
microscopy which was kindly performed by Mr Bill Cooley, AHVLA Pathology 
Department. In brief, particles were air dried onto poly-L-lysine coated coverslips 
(BD Biosciences) for 15 min at 37oC. The cover slip was then applied to double 
sided carbon (Agar Scientific, Stansted, UK) attached to a 13 mm aluminium stub 
(Agar Scientific) and sputter coated with gold to a thickness of 15 nm using an 
Emitech K550X Sputter Coater (Quorum Technologies Ltd, Ashford, UK). Particles 
were visualized using a Zeiss Evo LS10 scanning electron microscope (Zeiss, 
Welwyn Garden City, UK) at an accelerating voltage of 10-20 Kv. 
 
2.4.3.2. Assessment of the antigen loading efficiency of particulate vaccine 
formulations  
Aliquots of each formulation were centrifuged at 14000 rpm for 5 min and 
supernatants were harvested and stored at -80°C until analysed. ELISA and 
biochemical assay analyses of particle-free supernatants were conducted to 
determine the efficiency of virus or peptide encapsulation and coating with EM4 
protein. Absorption of EM4 to particle surfaces was additionally assessed by flow 
cytometric staining and analyses of particles.  
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2.4.3.3. Assessment of EM4 in particle supernatants by ELISA  
ELISA plates (MAXISorb, Nunc, Fisher Scientific) were coated (100 
µl/well) overnight at 4°C with titrations of particle-free supernatants from Peptide- 
and Empty-P formulations in carbonate-bicarbonate buffer. A titration of 
recombinant EM4 protein (a kind gift from Dr Margarita Garcia-Duran, Ingenasa, 
Madrid, Spain) of known concentration was included as a standard. Plates were 
washed three times with 200 µl wash buffer (PBS, 0.05% Tween) and blocked by 
addition of 200 µl reagent diluent (PBS, 0.05% Tween, 5% BSA) for 1 hour at room 
temperature. 100 µl anti-EM4 mAb (EM11E10; a kind gift from Dr Margarita Garcia 
Duran, Ingenasa, Madrid Spain) diluted to 1 µg/ml in reagent diluent was then added 
at 100 µl/well and incubated for 1h at room temperature. After washing as before, 
100 µl of rabbit-anti-mouse IgG-HRP antibody (Dako, Ely, UK), diluted 1 in 2000 in 
reagent diluent, was incubated for 1h at room temperature. Subsequently, plates were 
washed three times, followed by the addition of 100 µl of TMB substrate (Sigma-
Aldrich). The substrate was incubated for a maximum of ten minutes in the dark 
before the reaction was stopped with 100 µl of 0.5 M H2SO4. The absorbance at 450 
nm was finally read on a Victor4 microplate reader (Perkin Elmer, Seer Green, UK). 
 
2.4.3.4. Assessment of PRRSV-1 in particle supernatants by ELISA  
The ELISA was performed as described for the assessment of EM4 with the 
following modifications. Plates were coated with particle-free supernatants from 
Virus- and Empty-P formulations. For the standard, inactivated PRRSV Olot/91 at 
an equivalent titre of 106.45 TCID50/ml was titrated in carbonate-bicarbonate buffer. 
Anti-PRRSV mAb clone 1AC7 (a kind gift from Dr Margarita Garcia Duran, 
41 
 
Ingenasa, Madrid Spain) was used as a primary antibody at a concentration of 10 
µg/ml. The secondary rabbit-anti-mouse IgG-HRP antibody was diluted 1 in 2000 in 
reagent diluent. 
 
2.4.3.5. Assessment of M and NSP5 peptides in particle supernatants by OPA 
assay 
The biochemical fluorometric OPA assay was performed according to 
manufacturer’s instructions (Fluoraldehyde (o-phtalaldehyde, OPA) Reagent 
Solution, Thermo Scientific, UK) with minor changes described as follows. Particle-
free supernatants from Peptide- and Empty-P formulations were serially diluted two-
fold in water. A two fold serial dilution of the M and NSP5 peptide pool with a 
starting concentration of 500 µg/ml was used as the standard. 20 µl of samples and 
standards were mixed with 200 µl of Fluoraldehyde Reagent Solution in black 96 
well microplates (OptiPlate; PerkinElmer) and the fluorescence was read 
immediately on a Victor4 microplate reader (Perkin Elmer) using excitation and 
emission wavelengths of 340 and 455 nm, respectively.  
 
2.4.3.6. Assessment of EM4 binding to particles by flow cytometry  
Particles were washed twice in PBS and then stained using an anti-EM4 mAb 
(E10C7) at 1 µg/ml or equivalent concentration of isotype control purified IgG2b 
antibody (AbD Serotec) by incubation for 30 min at 4oC. After two washes in 
particles were stained with anti-mouse IgG2-PE conjugated secondary antibody (BD 
Biosciences, Oxford, UK) and incubated as before. After a final two washes, 
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particles were analysed on a MACSQuant Analyzer flow cytometer (Miltenyi 
Biotec). Particles were gated on by assessing forward and side scatter measurements 
with logarithmic scaling. EM4 staining was assessed by setting a gate based on 
isotype control mAb background staining.  
 
2.5. Experimental infection of pigs with PRRSV 
The first study (Animal Experiment 1) was carried out at the Institute of 
Virology and Immunology (IVI), Mittelhäusern, Switzerland. Three specific 
pathogen free Large White pigs were rendered immune to PRRSV-1 Olot/91 by 
repeated experimental infection. The pigs were inoculated intranasally with 105 
TCID50 (pigs 52 and 53) or 106 TCID50 (pig 54) of MARC-145 cell adapted Olot/91 
PRRSV  at 9 weeks, 18 weeks and 14 months of age. The third inoculation was 
administered two weeks prior to the analysis of T cell responses [Mokhtar et al, 
2014]. 
The second study (Animal Experiment 2) was carried out at the AHVLA. 
Porcine circovirus type 2 (PCV-2) free Yorkshire cross Dutch Landrace pigs, were 
obtained from an isolated, high-health pig farm. Animals were randomly distributed 
so as to ensure an even genetic background amongst the groups (n=8). At seven 
weeks of age the pigs were inoculated intra-nasally with 105 TCID50 of LV or SU1-
Bel PRRSV-1 in 1.5 ml of cell culture medium, with controls mock-infected with 1.5 
ml of PAM cell supernatant diluted in RPMI [Morgan et al,  2013; Mokhtar et al,  
2014]. 
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The third study (Animal Experiment 3) was also carried out at the AHVLA. 
PCV-2 free, PRRSV antibody negative Large White/Landrace cross-bred pigs 12 
weeks of age were inoculated intranasally with either MARC-145 cell lysate (mock) 
(n=2), 106 TCID50 PRRSV-1 Olot/91 (n=5) or 104 TCID50 PRRSV-1 SU1-Bel (n=5). 
Thirty five days post inoculation, pigs were inoculated again but with increased 
doses of the homologous virus; 107 TCID50 PRRSV-1 Olot/91 and 105 TCID50 
PRRSV-1 SU1-Bel. Monitoring of clinical scores and rectal temperatures was 
performed daily from -2 day post-infection (dpi) until the end of the study, 60 dpi. 
Clinical parameters relevant for PRRSV infection were scored between 0 (normal) 
and 3 (severe), as previously described by Morgan et al, 2013 (Appendix A).  These 
scores were added up to obtain a total score per pig and day. Heparinised blood and 
serum samples were taken at 0, 7, 14, 21, 30, 35, 42 and 50 dpi. Serum samples were 
stored at -80°C for later analysis to quantify virus and antibody levels, and 
heparinised blood was used immediately for isolation of peripheral blood 
mononuclear cells (PBMCs). 
 
2.6. Experimental vaccination of pigs and challenge with PRRSV 
Animal Experiment 4 was carried out at the AHVLA using 18 PRRSV 
antibody negative Large White/Landrace male piglets 8 weeks of age. Pigs were 
randomly assigned to three groups (n=6) which were vaccinated subcutaneously 
behind each ear with 2ml of either the (1) Virus-P, (2) Peptide-P or (3) Empty-P 
formulations prepared as described above. An identical boost vaccination was given 
on day 21 post-primary vaccination. Animals were challenged intranasally on day 42 
post primary vaccination with 105 TCID50 of 215-06, a UK field PRRSV-1 strain. 
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Heparinised blood and serum samples were taken at -2, 0, 7, 14, 21, 28, 35, 42, 49, 
56 and 61 days post-primary vaccination. Serum samples were stored at -80oC for 
later analysis to quantify antibody levels and for the quantification of PRRSV RNA. 
Heparinised blood was used immediately for isolation of peripheral blood 
mononuclear cells (PBMCs) for analysis of T cell responses. Monitoring of clinical 
scores and rectal temperatures was performed daily as described above from day -2 
post-challenge until the termination of the study on day 21 post-challenge (day 63 
post primary vaccination).  
 
2.7. RNA isolation and PRRSV detection by quantitative RT-PCR 
This analysis was kindly performed by Drs Miriam Pedrera and Jean-Pierre 
Frossard, AHVLA Virology Department. RNA was isolated from serum using the 
QIAamp Viral RNA Mini Kit (Qiagen, Crawley, UK) and PRRSV RNA was 
quantified by quantitative real-time reverse transcription PCR (qRT-PCR) as 
described Morgan et al, 2013, using the QuantiTect® Probe RT-PCR kit (Qiagen) 
according to the manufacturer’s instructions. Standard PRRSV RNA was 
synthesised by amplifying complementary DNA of the PRRSV ORF 7 region of 
both Olot-91, 215-06 and SU1-Bel by conventional PCR using an ORF7 forward 
primer -5’-GAA ATT AAT ACG ACT CAC TAT AGG GGC CGG TAA AAA 
CCA GAG-3’ with a T7 promoter region [Cazenave and Uhlenbeck, 1994] and an 
ORF7 reverse primer -5’-CGC ACT GTA TGA GCA ACC-3’ (both from Sigma-
Aldrich). The complete procedure was carried out as described by Morgan et al, 
2013. Briefly, cDNA was amplified from 3 µl of RNA (extracted from infected cells 
using the QIAamp Viral RNA Mini Kit); for one reaction the PCR mastermix was 
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prepared with 3.2 µl 25 mM MgCl2, 5 µl 10 x buffer, 1 µl 10nM dNTPs, 0.4 µl Taq 
polymerase, 36.3 µl Milli-Q nuclease free water (all Promega) and 0.4 µl each of the 
ORF7 forward and reverse primers. The thermal profile used consisted in 3 cycles of 
94oC 2 min, 46oC 1 min and 72oC 2 min followed by 35 cycles of 94oC 30 s, 53.4oC 
1 min, 72oC 1 min and 72oC 5 min. The amplification product was visualised in a 
2% agarose-Tris-acetate-EDTA (TAE) gel, DNA was purified from the gel using a 
QIAquick gel extraction kit (Qiagen) according to the manufacturer’s instructions 
and quantified with the NanoDrop® ND-1000 spectrophotometer (Thermo 
Scientific). ORF7 DNA was in vitro transcribed into RNA (Ambion® 
MEGAshortscriptTM T7 kit, Life Technologies) and purified (Ambion® 
MEGAclearTM kit, Life Technologies) both according to the manufacturer’s 
instructions. The product was quantified and assessed for integrity using the 2100 
Bioanalyzer (Agilent), and then serially diluted 10-fold in Milli-Q nuclease-free 
water and stored at -70oC. For detection of PRRSV RNA, 23 µl of PCR mastermix 
(12.5 µl Quantitect Mix, 0.25 µl RT enzyme, 0.5 µl each of the EU forward primer, 
EU reverse primer and the EU probe (EU forward primer: 5’ GAT GAC RTC CGG 
CAY C 3’; EU reverse primer: 5’ CAG TTG CTG CGC CTT GAT 3’ and EU probe: 
5’ FAM-TCG AAT CGA TCC AGA CGG CTT-Tamra, R=A+G Y=C+T) and 8.75 
µl Milli-Q nuclease free water) was added to 2 µl of viral RNA. The RT-PCR was 
performed on an Mx3000 Real Time PCR System (Agilent, Stockport, UK) using 
the PCR thermal profile detailed in Table 2.1.  
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Table 2.1. PRRSV-1 Quantitative RT-PCR thermal profile 
Segment Temperature (°C) Time No. of cycles 
1 50 30 mins 1 
2 95 15 mins 1 
3-touchdown 
94 20 sec 
17 
72↓* 45 sec 
4 
94 20 sec 
38 
55 45 sec 
*↓ indicates the touchdown section which is a decrease of 1°C in annealing 
temperature for each of the 17 cycles.  
 
2.8. Detection of PRRSV-specific antibody responses 
2.8.1. Detection of PRRSV-specific antibody responses by ELISA 
PRRSV-specific antibody responses in serum samples from Animal 
Experiment 3 were determined using the HerdCheck PRRS X3 ELISA Kit (IDEXX 
Laboratories, Wetherby, UK), whereas, serum samples from Animal Experiment 4 
were analysed using the INgezim PRRS 2.0 ELISA (Ingenasa). Both ELISA were 
conducted according to the manufacturer’s instructions.  
 
2.8.2. Detection of PRRSV EM4-specific antibody responses by ELISA  
Serum samples from Animal Experiment 4 were analysed for specificity to 
EM4 using an in-house developed ELISA. ELISA plates (MAXISorb, Nunc) were 
coated (100 µl/well) overnight at 4°C with anti-EM4 mAb (clone EM11E10; a kind 
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gift from Dr Margarita Garcia Duran, Ingenasa, Madrid, Spain) at a concentration of 
1 µg/ml in carbonate-bicarbonate buffer (Sigma-Aldrich). The following day, plates 
were washed three times with 200 µl/well wash buffer (PBS, 0.05% Tween) and 
blocked for 1h in 200 µl reagent diluent (PBS, 0.05% Tween, 5% BSA (Sigma-
Aldrich,). Subsequently, 100 µl serum, diluted 1 in 100 in reagent diluent was 
incubated for 1 h at RT. After three further washing steps, the secondary goat anti-
swine IgG-HRP antibody (Jackson ImmunoResearch, Stratech Scientific Limited, 
Newmarket, UK) was incubated at a dilution of 1 in 20,000 for 1 h at RT. Three 
more washing steps followed, before 100 µl of TMB substrate (Sigma-Aldrich) was 
added to each well. After a maximum of ten minutes in the dark the reaction was by 
the addition of 100 µl 0.5 M H2SO4. The absorbance was then measured on a Victor4 
microplate reader (PerkinElmer) at 450 nm. 
 
2.8.3. Detection of PRRSV-neutralizing antibody responses 
This analysis was kindly performed by Drs Miriam Pedrera (Animal 
Experiment 3) and Lucia Biffar (Animal Experiment 4), AHVLA Virology 
Department. PRRSV neutralizing antibody (NA) titres (VNT) in serum samples were 
determined according to a previously described method [Weesendorp et al, 2013] 
with minor modifications. Sera were heat inactivated for 30 min at 56oC and 
duplicate serial 2-fold dilutions from 1/2 to 1/128 were then made in cRPMI. An 
equal volume of the homologous PRRSV strains containing 400 TCID50 in cRPMI 
were added to each dilution and then incubated at 37oC for 60 min. Since the Olot-91 
PRRSV strain is adapted to grow in MARC-145 cells and SU1-Bel PRRSV strain is 
adapted to grow in PAMs, both cell types were used to analyse sera from Animal 
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Experiment 3. MARC-145 cells (5x103 cells/well) and PAMs (2x105 cells/well) were 
cultured in cRPMI in 96 well plates with the virus-serum mixture for 3 days at 37oC, 
5% CO2. After 3 days, the cells were washed in 0.15 M NaCl solution, dried and 
frozen. The monolayers were IPX stained as described in Section 2.1. Each sample 
was analysed in duplicate and the mean titre was calculated; positive and negative 
sera were included and back titration of PRRSV was performed each time to confirm 
that the dose of virus used was within the accepted range for this assay, 80-8000 
TCID50/ml. NA titres were expressed as log2 of the reciprocal of the serum dilution 
that fully neutralized the viral replication in 50% of the wells. Sera from Animal 
Experiment 4 were only analysed for their ability to neutralise PRRSV-1 Olot/91 
infection of MARC-145 cells. 
 
2.9. Isolation of peripheral blood mononuclear cells and magnetic bead based 
cell sorting to enrich and deplete cell populations 
2.9.1. Isolation of peripheral blood mononuclear cells  
Heparin blood was obtained from pigs by venopuncture of the external 
jugular vein and diluted 1:2 in HBSS (Invitrogen). 30 ml of blood was layered over 
20 ml of room temperature 1.077 g/ml Histopaque (Sigma-Aldrich) and centrifuged 
for 25 min at 1000 x g at room temperature with the brakes off in a rotating bucket 
centrifuge (Beckman Coulter, High Wycombe, UK). Peripheral blood mononuclear 
cells (PBMC) were harvested from the interface and washed 3 times in cold sterile 
PBS (Invitrogen); spun for 5 min at 525 x g at 4oC. Cells were finally resuspended in 
cRPMI. Cell density was determined by analyzing 50 µl of cell suspension using a 
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MACSQuant Analyzer volumetric flow cytometer (Miltenyi Biotec, Bisley, UK) and 
gating on events with typical forward scatter (FSC) and side scatter (SSC) for 
PBMC. 
 
2.9.2. Cryopreservation of peripheral blood mononuclear cells  
PBMC were cryopreserved for future analyses by resuspending cells at a 
density of 1-2x107 cells/ml in cold 10% dimethylsulfoxide (DMSO) (Sigma-Aldrich) 
in FBS. Cells were dispensed into pre-cooled cryovials (maximum 3.6x107 
cells/vial), which were placed into a pre-cooled Cryo 1°C Freezing Container 
(Nalgene, Fisher Scientific) containing 250 ml of 100% isopropyl alcohol (Sigma-
Aldrich), which was transferred into a -80°C freezer for 24 hours. Cryotubes were 
then transferred directly into a liquid nitrogen storage container. To thaw cells, vials 
were transferred to a pre-heated 37°C water bath for rapid thawing, and washed in 
50ml pre-warmed cRPMI. Cell density was then determined using volumetric flow 
cytometry, as described above, and density adjusted appropriately for downstream 
analysis. 
 
2.9.3. Magnetic bead based depletion of CD4+ and CD8β+ T cells from 
peripheral blood mononuclear cells  
In selected experiments, freshly isolated PBMC were incubated with 100 μl 
anti-porcine CD4 (clone 74-12-4; VMRD, Pullman, USA) or CD8-β mAb (clone 
PG1 64A; VMRD) in 1 ml PBS supplemented with 2% FBS (PBS/2% FBS) per 108 
cells, for 15 min at room temperature. Cells were then washed twice in PBS/2% FBS 
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and then incubated with anti-mouse IgG microbeads (10 µl/107 cells; Miltenyi 
Biotec) for 15 min at room temperature. The cells were then washed twice in 
PBS/2% FBS and resuspended in 1 ml PBS/2% FBS with 5 mM EDTA (MACS 
buffer) and an aliquot was removed for subsequent analysis of labelled cells pre-
depletion. Cells were then applied to LD columns (Miltenyi Biotec) held in a 
MidiMACS magnet (Miltenyi Biotec), the flow-through and 2 x 3 ml washes with 
MACS buffer were collected, centrifuged, and cells resuspended in cRPMI. Two 
aliquots were removed; one for cell counting and one for post-depletion analysis. 
Pre- and post-depletion samples were analysed by staining with 5 µl anti-mouse 
IgG2-PE conjugated secondary antibody (BD Biosciences, Oxford, UK) for 10 
minutes at room temperature, washed in PBS and analysed by flow cytometry. 
 
2.9.4. Isolation of monocytes and enrichment of dendritic cells from peripheral 
blood mononuclear cells 
Porcine monocytes were isolated from PBMC by magnetic bead based 
sorting. In brief, PBMC were incubated with mouse anti-human CD14 coated 
microbeads (10 µl/107cells; Miltenyi Biotec) at room temperature for 15 min. Cells 
were passed through a 70 μm cell strainer (BD Biosciences) to remove any cell 
aggregates prior to being added to a LS column (as per manufacturer’s instructions) 
held on a MidiMACS magnet (both Miltenyi Biotec). The column was washed 3 
times with 3 ml of MACS buffer and the CD14+ cells were eluted into 5 ml of 
cRPMI and subsequently counted on a volumteric flow cytometer and adjusted to the 
required density prior to use.  
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Dendritic cells (DCs) were enriched from PBMC by two rounds of magnetic 
bead based cell sorting. PBMC were first depleted of CD14+ cells by incubation with 
mouse anti-human CD14 coated microbeads and washed as described above. Cells 
were resuspended at 2.5x108 cells/ml MACS buffer and applied to a LD column (1 
ml per column, as per manufacturer’s instructions) as described above. The negative 
flow through and two washes of 1 ml MACS buffer was collected, washed with 50 
ml PBS/2% FBS and then incubated with 10 μg/108 cells of mouse anti-porcine 
CD172a (clone 74-22-15A, Washington State University Monoclonal Antibody 
Center (WSUMAC), Pullman, USA) diluted in PBS/ 2% FBS to the volume of 10 
times the volume of antibody to ensure adequate mixing of cells and antibody. After 
incubation at 4°C for 30 min, the cells were washed twice in PBS/2% FBS and 
further incubated with 10 µl/107 cells anti-mouse IgG-coated microbeads (Miltenyi 
Biotec) for 15 min at 4°C. After washing twice in PBS/2%FBS, CD172a+ cells were 
enriched using an LS column as described above. The column was washed 3 times 
with 3 ml of MACS buffer and the CD172a enriched cells were eluted into 5 ml of 
cRPMI, counted and adjusted to the required density prior to use. 
 
2.10. Porcine IFN-γ ELISpot assay 
ELISpot plates (96 well Multiscreen-IP Filter Plates; Millipore, Watford, 
UK) were prepared by pre-wetting each well with 15 µl of 35% ethanol for 1 min 
then washing 3 times with sterile PBS. The capture antibody (anti-porcine IFN-γ 
mAb, BD Biosciences) was prepared at 0.5 µg/ml in PBS and 50 µl added per well. 
The plates were then incubated at 4oC overnight. Capture antibody was then 
decanted and plates washed 3 times with unsupplemented RPMI-1640 medium. 
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Plates were blocked by addition of 100 µl/well cRPMI and incubation for 1 hr at 
37oC. Freshly isolated PBMC or in selected experiments T cell subset depleted-
PBMC were suspended at 1x107 /ml (Animal Experiment 1) and 5x106 /ml (Animal 
Experiments 2 and 3) in cRPMI and 100 μl of cells was added to each well. 
Experimental and control stimuli were added to each well and the total volume of 
each well was made up to 200 µl. Concanavalin A (ConA, Sigma-Aldrich) at 10 
µg/ml was used as a positive control. Negative controls were: wells with media only, 
wells with cells and media or with Mock-virus supernatants prepared from cultures 
of uninfected MARC-145 cells or PAMs as described above. Viruses were diluted in 
cRPMI and added at a multiplicity of infection (MOI) of 0.1. Peptides were added at 
1 µg/ml unless otherwise stated. All conditions were tested in triplicate. Plates were 
incubated at 37oC in a 5% CO2 humidified atmosphere for 24 hours. Well contents 
were discarded and 100 µl of cold deionised water was added to each well and 
incubated at 4oC for 5 min. Wells were then washed 5 times with PBS with 0.05% 
Tween 20 (ELISpot Wash Buffer). Biotinylated anti-porcine IFN-γ mAb (BD 
Biosciences) was diluted to 0.05 µg/ml in ELISpot Wash Buffer with 1% FBS and 
added 50 µl/well. Plates were then incubated at 37oC for 2 hours or 4oC overnight. 
Plates were washed 3 times with ELISpot Wash Buffer and incubated with 
streptavidin-HRP (R&D Systems, Abingdon, UK; 0.5 µg/ml ELISpot Wash Buffer 
with 1% FBS; 50 µl/well) for 1hr at 37oC. Plates were washed 5 times and substrate 
was added; Animal Experiment 1 - DAB and Urea solution (Sigma-Aldrich) or 
Animal Experiments 2 and 3 - BCIP/NBT (R&D Systems) and incubated at room 
temperature in the dark until spots became visible, typically 15 – 60 min. The 
substrate was then discarded and the plates washed extensively with deionised water 
and left to dry in the dark. Spots were visualised using an automated ELISpot reader 
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(AutoImmun Diagnostika, Strassberg, Germany). The unstimulated-corrected mean 
was obtained by calculating the mean IFN-γ SFC in the media- or mock-virus-
stimulated wells, and subtracting this from each experimental value for each animal.  
 
2.11. Assessment of antigen-specific cytokine responses from peripheral blood 
mononuclear cells 
PBMC were stimulated with antigens or corresponding negative and positive 
controls as described above. Cultures were incubated at 37oC in a 5% CO2 
humidified atmosphere for 18 hours. Cultures were mixed by repeat pipetting, 
centrifuged at 930 x g for 2 minutes at 4°C, and cell free-supernatants collected and 
stored at -80oC until analysed.  Cytokines were quantified in culture supernatants 
using a commercial ELISA kits for porcine IL-2 (Life Technologies), IL-4 and IL-10 
(both R&D Systems). ELISAs were carried out according to the manufacturers’ 
instructions and absorbance measurements were read using a Victor4 microplate 
reader (Perkin Elmer). 
 
2.12. Multiparameter flow cytometric analysis of cytokine responses 
2.12.1. Stimulation of peripheral blood mononuclear cells to assess antigen-
specific T cell responses 
Freshly isolated or previously cryopreserved PBMC were suspended in 
cRPMI at a density of 2x107 /ml and seeded 50 µl/well in 96 well round bottom 
plates (Costar, Fisher Scientific). PBMC were then stimulated with 50 μl of either; 
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peptide pool or individual peptide (1 µg/ml, unless otherwise stated), PRRSV 
(MOI=0.1), or mock virus, Virus-, Peptide- or Empty-P formulations (1.5 x106 
particles/well), cRPMI or pokeweed mitogen (PWM; Sigma-Aldrich 5µg/ml) and 
incubated at 37oC in a 5% CO2 humidified atmosphere. PBMC stimulated with 
peptides or media were incubated for 2 hours before addition of brefeldin A (0.1 
µl/well) (GolgiPlug, BD Biosciences) and further incubation overnight. PBMC 
stimulated with PRRSV, mock virus or PWM were incubated overnight (18 hours) 
before addition of brefeldin A and further incubation of six hours. For detection of 
cytotoxic degranulation by surface detection of CD107a, monensin (0.067 µl/well; 
GolgiStop, BD Biosciences, Oxford, UK) and mouse anti-porcine CD107a-FITC 
(clone JM2E5) or mouse IgG1 isotype control-FITC mAbs (10 μl/well) (both AbD 
Serotec, Oxford, UK) were added upon addition of brefeldin A. After incubation, 
PBMC were washed in PBS ready for antibody staining. All washes were performed 
as follows: plates were centrifuged at 930 x g for 2 minutes at 4°C; supernatant was 
flicked off, cells mixed by vortex and either 200 μl/well PBS or Perm/Wash buffer 
(BD Biosciences) added as detailed below.  
 
2.12.2. Flow cytometric staining of peripheral blood mononuclear cells to assess 
antigen-specific T cell responses 
PBMC were stained for 30 min at 4°C with combinations of the following 
directly conjugated mAbs: CD4-PerCP-Cy5.5 (clone 74-12-4, BD Biosciences), 
CD8α-PE (clone 76-2-11, BD Biosciences) or CD8α-FITC (clone MIL12, AbD 
Serotec), CD44-eFluor450 (clone IM7, eBioscience, Hatfield, UK) or the following 
mAbs conjugated to fluorochromes using Zenon® Mouse IgG Labelling Kits (Life 
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Technologies): CD62L (clone CC32, AbD Serotec),  CD27 (clone b30c7, kindly 
provided by Dr Wilhelm Gerner, University of Veterinary Medicine, Vienna, 
Austria; Reutner et al,  2012), CD25 (clone K231.3B2, AbD Serotec), as well as 
with the Near Infra-Red Fixable Live/Dead Viability Dye (Life Technologies) or the 
Zombie Near Infra-Red Fixable Viability Kit (Biolegend, London, UK). After 
incubation, PBMC were washed twice in PBS and then either resuspended in PBS 
2% FBS with 0.09% sodium azide (FACS buffer) ready for flow cytometric analysis; 
or fixed and permeabilised by incubating in CytoFix/CytoPerm solution (100 
µl/well; BD Biosciences) for 20 min at 4°C for intracellular staining. 
Fixed/permeabilised PBMC were washed twice in Perm/Wash Buffer (BD 
Biosciences) and then stained with the following directly conjugated mAbs: IFN-γ-
Alexa Fluor 647 (clone CC302, AbD Serotec) and TNF-α-Brilliant Violet 421 (clone 
MAb11, Biolegend) or the respective isotype controls (Alexa Fluor 647 mouse IgG1 
isotype control, AbD Serotec, and Brilliant Violet 421 mouse IgG1 isotype control, 
Biolegend) for 30 min at 4°C. PBMC were then washed twice in Perm/Wash Buffer 
and resuspended in 200 µl FACS Buffer per well ready for flow cytometric analysis.  
2.12.3. Flow cytometric analysis of peripheral blood mononuclear cells to assess 
antigen-specific T cell responses 
Flow cytometric analysis was performed either using a MACSQuant 
Analyser and the MACSQuantify analysis software (both Miltenyi Biotec), a CyAn 
ADP flow cytometer and the Dako Summit analysis software (both Beckman 
Coulter). Analyses of stained PBMC were performed by first excluding any doublets 
based on area and height measurements of forward scatter (FSC) and selection of 
live cells by gating on Live/Dead Fixable Stain negative events. Lymphocytes were 
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then selected based on their FSC and side scatter (SSC) properties. CD4+CD8int 
(CD4) and CD4-CD8high (CD8) T cell populations were gated upon and IFN-γ+ cells 
within these populations were analysed for co-expression of cell surface markers or 
TNF-α. Gates were set based primarily on the corresponding isotype control and then 
adjusted using the relevant biological negative control (media or mock stimulated). 
The gating strategies are illustrated in Figures 2.1 and 2.2. The unstimulated-
corrected mean was obtained by calculating the mean % of IFN-γ secreting cells in 
the media- or mock-virus-stimulated wells, and subtracting this from each 
experimental value for each animal. 
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Figure 2.1. Flow cytometric gating strategy used to interrogate cytokine 
responses of PBMC. Responses to PRRSV, proteins or peptides were assessed in 
freshly isolated or previously cryopreserved PBMC. Single cells were gated upon 
using FSC-A vs FSC-H and then lymphocytes were gated upon using typical FSC vs 
SSC properties (top panel). Live/Dead stain- cells were assessed for CD4 and CD8α 
expression and the two populations CD4 (CD4+CD8αlow) and CD8 (CD4-CD8αhigh) 
T cells were assessed for IFN-γ and TNF-α expression. Gates were set using 
corresponding isotype controls and unstimulated biological controls.  
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Figure 2.2. Flow cytometric gating strategies used to interrogate expression of 
various T cell markers. CD4 or CD8 T cell populations were gated as shown in 
Figure 2.1 and assessed for expression of IFN-γ and either CD44, CD62L, CD27. 
CD25 or CD107a. Unstimulated shows cells incubated with media alone as a 
biological control, with the exception of CD107a which shows stimulated cells 
stained with IgG1-FITC isotype control. This figure shows CD8 T cells stimulated 
with either peptide (M and NSP5) or media.  
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2.12.4. Stimulation of mixed cultures of monocytes and dendritic cells to assess 
cytokine responses induced by pathogen-associated molecular patterns or 
vaccine formulations 
Enriched blood DCs and purified monocytes were mixed at a ratio of 70:30 
and suspended at a density of 4x106 cells/ml in cRPMI supplemented with 20 ng/ml 
of recombinant porcine IL-3 (a kind gift from Kirsten Morris, CSIRO Biosecurity 
Flagship, Australian Animal Health Laboratory, Geelong, Australia) to maintain 
pDC viability in vitro. Cells were seeded 50 µl/well in 96 well round bottom plates 
(Costar, Fisher Scientific) and stimulated with a panel of pathogen recognition 
receptor (PRR) agonists synthetic multi-TLR2 and -7 agonists CL513 (working 
concentration 10 µg/ml) and Adilipoline (working concentration 10 µg/ml; 
Invivogen); TLR-9 agonists CpG ODNs 21798 (class P; working concentration 2 
µM; Miltenyi Biotec), 2216 (class A; working concentration 2 µM; Invivogen) and 
2007 (class B; working concentration 2 µM;  Invivogen); TLR-7 agonist imiquimod 
(working concentration 1 µg/ml; Invivogen), and TLR-3/RIG-I/MDA-5 agonist 
poly(I:C) (working concentration 10 µg/ml; Invivogen)) or with a titration of Virus-, 
Peptide- or Empty-P formulations, and incubated at 37oC in a 5% CO2 humidified 
atmosphere. Cells were incubated for 2 hours before addition of monensin (0.067 
µl/well; GolgiStop, BD Biosciences) and further incubation overnight.  
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2.12.5. Flow cytometric staining of mixed cultures of monocytes and dendritic 
cells to assess cytokine responses induced by pathogen-associated molecular 
patterns or vaccine formulations 
Cells were stained for 30 min at 4°C with combinations of the following 
directly conjugated mAbs: CD4-PerCP-Cy5.5 (clone 74-12-4, BD Biosciences), 
CD1-FITC (clone 76-7-4, Southern Biotec, Cambridge Bioscience, Cambridge, UK), 
CD14-PE-Texas Red (clone TüK4, Life Technologies), CD172a (clone 74-22-15A, 
WSUMAC) conjugated to PE using the Zenon® Mouse IgG2b Labelling Kit (Life 
Technologies), as well as with the Near Infra-Red Fixable Live/Dead Viability Dye 
(Life Technologies). After incubation, cells were washed twice in PBS and fixed and 
permeabilised using CytoFix/CytoPerm solution (BD Biosciences) as described 
above. After washing twice in Perm/Wash Buffer (BD Biosciences), cells were  
stained with the following mAbs: TNF-α-Pacific Blue (clone MAb11, Biolegend), 
IFN-α (clone K9, R&D Systems) conjugated to Alexa Fluor-647 using the Zenon® 
Mouse IgG1 Labelling Kit, and IL-12-biotin (clone 116211, R&D Systems) by 
incubation for 30 min at 4°C. After two further washes in Perm/Wash Buffer cells 
were incubated for 30 min at 4°C with streptavidin-PE-Cy7 (Biolegend). Cells were 
finally washed twice in Perm/Wash Buffer and resuspended in 200 µl FACS Buffer 
per well ready for flow cytometric analysis. 
 
 
61 
 
2.12.6. Flow cytometric analysis of mixed cultures of monocytes and dendritic 
cells to assess cytokine responses induced by pathogen-associated molecular 
patterns or vaccine formulations 
Flow cytometric analysis was performed either using a CyAn ADP flow 
cytometer and the Dako Summit analysis software (both Beckman Coulter), or a BD 
LSRFortessa™ (BD Biosciences) and the Kaluza analysis software (Beckman 
Coulter). Analysis of enriched DCs and monocytes were performed again by 
excluding any doublets and selecting only live cells, as described above for PBMC. 
DCs were identified as possessing a CD14-CD172int phenotype and monocytes as 
CD14+CD172ahi.  DCs were further delineated based on CD1 and CD4 expression to 
reveal the two populations of myeloid DCs (mDCs), CD4-CD1- and CD4-CD1+, and 
plasmacytoid DCs (pDCs) CD4+CD1-. The cytokine secretion profile by each DC 
population was determined by gating on each population and assessing expression of 
IFN-α, TNFα and IL-12 as shown in Figure 2.3. 
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Figure 2.3. Flow cytometric gating strategy used to interrogate cytokine 
responses of antigen presenting cells. Responses were assessed in mixed cultures 
of enriched DCs and monocytes stimulated with PAMPs or vaccine formulations. 
Single cells were gated upon using FSC-A vs FSC-H and then cells with high 
forward scatter were gated. Cells that stained negative for Live/Dead stain (shown 
here against IL-12-PE-Cy7 for compensation reasons) were selected and 
CD14+CD172ahigh cells monocytes and CD14-CD172alow DCs gated, DCs were then 
further gated as CD1-CD4+ DCs, CD1-CD4- mDCs and CD1+CD4- mDCs. Each 
individual population was then assessed for expression of IL-12. IL-12 negative and 
positive populations were finally assessed for co-expression of TNF-α and IFN-α.  
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2.13. Assessment of cytokine responses of monocytes or enriched dendritic cell 
cultures to stimulation with vaccine formulations 
Enriched blood DCs or purified monocytes were suspended at a density of 
4x106 cells/ml in cRPMI, which was further supplemented for DC cultures with 20 
ng/ml of recombinant porcine IL-3. Cells were seeded 50 µl/well in 96 well round 
bottom plates (Costar, Fisher Scientific) and titrations of Virus-, Peptide- or Empty-P 
formulations, diluted in 50 µl of cRPMI added. Addition of cRPMI or Adilipoline 
(10 µg/ml) was included as negative and positive controls respectively. Cultures 
were incubated at 37oC in a 5% CO2 humidified atmosphere for 18 hours. Cultures 
were mixed by repeat pipetting, centrifuged at 930 x g for 2 minutes at 4°C, and cell 
free-supernatants collected and stored at -80oC until analysed.  Cytokines were 
quantified in culture supernatants using commercial ELISA kits for porcine IL-8, IL-
10 and IL-12 (all R&D Systems). Type I IFN bioactivity was quantified from culture 
supernatants using an Mx/CAT reporter gene assay originally developed for the 
quantification of bovine IFN-α/β [Fray et al, 2001]. Cultures were grown as above, 
but in DMEM medium (Life Technologies) supplemented with blasticidin (10 μg/ml; 
Life Technologies); and cell free supernatants were added to reporter bovine kidney 
cells (MDBK-t2) for 24 hours. A titration of recombinant porcine IFN-α (R&D 
Systems) was added as a standard. Lysates were prepared from the cultures and CAT 
enzyme measured by ELISA (Roche, Welwyn Garden City, UK). Absorbance 
measurements for all ELISAs were read using a FLUOstar OPTIMA (BMG Labtech, 
Aylesbury, UK) or Victor4 microplate reader (Perkin Elmer). 
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2.14. Analysis of T cell responses from the bronchoalveolar lavage fluid from 
vaccinated and challenged pigs.  
At the termination of Animal Experiment 4 on day 21 post-challenge (day 63 
post-primary vaccination), all animals were euthanized. Animals vaccinated with 
Peptide-P were euthanized by electrical stunning followed by exsanguination, 
however, it became apparent that this was resulting in oedema and hemorrhages in 
the lungs and so animals vaccinated with Virus- and Empty-P were euthanized by 
intravenous injection with pentobarbital. The left lung lobes were removed at the 
main bronchus. The bronchus end was washed with 70% ethanol to remove blood 
clots and clamps were used to secure the ends of the blood vessels. Both lobes of the 
lung were filled with 4 x 50ml aliquots of sterile PBS. After each addition of PBS, 
lungs were massaged gently 10-15 times and the bronchoalveolar lavage fluid 
(BALF) was collected into a sterile bottle. To determine the cellularity of the BALF 
an aliquot was analyzed directly on the volumetric MACSQuant Analyzer flow 
cytometer. To assess the T cell composition of the BALF a second aliquot was 
stained by incubation for 30 minute at 4oC with mAbs CD3-FITC (clone BB23-8E6-
8C8), CD4-PerCP-Cy5.5 (clone 74-12-4) and CD8α-PE (clone 76-2-11) (all BD 
Biosciences). Cells were washed twice in PBS before being analysed by flow 
cytometry. To assess antigen-specific T cell responses, mononuclear cells were 
isolated by density gradient centrifugation (as described for PBMC isolation), 
washed with sterile PBS, counted and then stimulated with PRRSV-1 Olot/91 
(MOI=0.1) or a pool of synthetic peptides representing the M and NSP5 proteins 
(each peptide used at a final concentration of 1µg/ml). Mock virus and cPRMI were 
again used as the respective negative controls. As described in Sections 2.12.1-3, 
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cells were incubated, before IFN-γ and TNF-α expression by CD4 and CD8 T cells 
was assessed by flow cytometry.   
 
2.15. Sequence analysis of PRRSV 
This analysis was kindly performed by Drs Jean-Pierre Frossard and Bhudipa 
Choudhury, AHVLA Virology Department, and Dr Richard Ellis, AHVLA Central 
Sequencing Unit. Total RNA was extracted from the vaccine strain Porcilis, 195-06 
and SU1-Bel virus stocks following a previously described protocol [Rasmussen et 
al, 2010]. RNA was sequenced using the GS FLX system (454 Life Sciences, 
Burgess Hill, UK); reads were assembled with Newbler v.2.6 software and saved in 
Fasta format for downstream analysis. The sequences of the identified T cell 
antigenic peptides were aligned against the predicted sequences from the virus 
genomes and an additional 12 PRRSV isolates (GenBank accession numbers shown 
in parentheses): Genotype 1 subtype 1 – Olot/91 (X92942), H2 (AY035938, 
JN862511, KJ769653, KJ769654 and KJ769655), Lelystad (AY588319), Porcilis 
(KF991509), Cresa3266 (JF276434), 195-05 (KJ769656, JN862404, KJ769657, 
KJ769658 and KJ769659), Cresa3249 (JF276433), Cresa3267 (JF276435), 
Cresa3256 (JF276432), Cresa3262 (JF276431) Cresa2982 (JF276430) and 07V063 
(GU737264); Genotype 1 subtype 3 - Lena (JF802085) and SU1-Bel (KJ769660, 
KJ769661, KJ769662, KJ769663 and KJ769664); and Genotype 2 - VR2332 
(EF536003), using the clustal W algorithm on MegAlign (DNAStar Lasergene 9 
Core Suite, Madison, USA).  
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2.16. MHC haplotype determination by low-resolution PCR-based analysis 
This analysis was kindly performed by Dr Sabine Essler, University of 
Veterinary Medicine Vienna, Austria. Genomic DNA was extracted from PBMC 
using a QIAamp DNA extraction mini kit, according to the manufacturer’s protocols 
(Qiagen, Crawley, UK) and genotyped for their swine leukocyte antigen (SLA) class 
I and II haplotypes by running low-resolution PCR screening assays (PCR-SSP) as 
previously described [Essler et al, 2013]. In brief, this method relies on 47 
discriminatory PCR primer pairs, which are designed to amplify the SLA class I 
alleles by groups that have similar sequence motifs and amplify products of 114–316 
bp. This method is used to type alleles at the three classical SLA class I loci (SLA-1, 
SLA-3 and SLA-2). All typing primers were previously validated and were 
optimized to be used at the same annealing temperature (65°C) and concentration (5 
pmol/each). Typing of each animal included a negative control without DNA to 
check for reagent contamination, and was electrophoresed in a standard 96-well 
format. Result interpretation is based on the presence of a smaller PCR product than 
the positive control in each lane [Ho et al, 2009]. 
2.17. Statistical analysis 
GraphPad Prism 6.01 (GraphPad Software, La Jolla, USA) was used for 
graphical and statistical analysis of data sets. Analysis of variance (ANOVA) was 
employed to analyse fixed effects on different traits with various post-hoc tests as 
detailed in figure legends. A p value < 0.05 was considered statistically significant. 
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Chapter 3. Proteome-wide screening of the porcine reproductive 
and respiratory syndrome virus reveals a range of T cell antigen 
reactivity 
 
This work has in part been published in H. Mokhtar, M. Eck, S.B. Morgan, 
S.E. Essler, J.P. Frossard, N. Ruggli, S.P. Graham. 2014. Proteome-wide screening 
of the European porcine reproductive and respiratory syndrome virus reveals a broad 
range of porcine T cell antigen reactivity; Vaccine doi: 
10.1016/j.vaccine.2014.04.054 and is reproduced with permission from Elsevier 
Limited, license number 3443860057893. 
 
3.1. Rationale 
The economic impact of PRRSV and the threat of emerging highly 
pathogenic strains necessitate the development of improved vaccines. Immunity to 
PRRSV remains relatively poorly understood, although there are data suggesting that 
virus-specific T cell IFN-γ responses play an important role in clearance of and 
protection from the virus. In light of this, identification of the PRRSV proteins that 
induce a strong T cell response is paramount to allow for their incorporation into 
next generation vaccines.  Recent efforts to elucidate the specificity of T cell 
responses to PRRSV have led to the identification of antigenic regions/epitopes on 
the structural proteins M, N, GP3, GP4, GP5 [Wang et al, 2011, Diaz et al, 2009, 
Vashisht et al, 2008, Bautista et al, 1999] and the non-structural proteins NSP2, 
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NSP5, NSP9 (the viral RNA-dependent RNA polymerase, RdRp) and NSP10 
[Parida et al, 2012, Burgara-Estrella, et al,  2013]. However, studies to date have 
focussed their analysis on pre-defined PRRSV antigens or used predictive 
bioinformatics to pre-screen putative antigenic peptides in silico, and in most 
instances the phenotypes of the responding T cell populations were not discerned. In 
contrast, this study aimed for a comprehensive analysis of the antigen specificity of 
the T cell response induced by PRRSV-1 infection and to ascribe a phenotype to 
cells responding to defined antigenic peptides using a synthetic peptide library 
spanning the PRRSV proteome. T cell reactivity was initially investigated in a small 
cohort of pigs following experimental infection with an attenuated PRRSV-1 strain, 
Olot/91. The pattern of T cell antigen reactivity was then assessed in groups of pigs 
experimentally infected with the related prototype PRRSV-1 strain Lelystad, and a 
divergent pathogenic genotype 1 subtype 3 strain, SU1-Bel, in an attempt to identify 
conserved T cell antigens. 
 
3.2. Results 
3.2.1. Summary 
Work presented in this chapter aimed to better characterise the T cell 
response to PRRSV-1 by utilising a synthetic peptide library spanning the proteome 
and a small cohort of pigs rendered immune to PRRSV-1 Olot/91 by repeated 
experimental infection. Using an IFN-γ ELISpot assay as a read-out, 9 antigenic 
regions on 5 of the viral proteins were identified and the corresponding responder T 
cell phenotype determined. The diversity of the IFN-γ response to the PRRSV 
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proteins suggests that antigenic regions are scattered throughout the proteome and no 
one single antigen dominates the T cell response. To address the identification of 
well-conserved T cell antigens, groups of pigs infected with a closely related 
avirulent PRRSV-1 strain (Lelystad) and a divergent virulent subtype 3 strain (SU1-
Bel) were subsequently screened. Whilst T cell responses from both groups were 
observed against many of the antigens identified in the first study, animals infected 
with the SU1-Bel strain showed the greatest response against peptides representing 
NSP5. The proteome-wide peptide library screening method used here, as well as the 
antigens identified, warrant further evaluation in the context of next generation 
vaccine development. 
 
3.2.2. Screening of the proteome-wide synthetic peptide library with pigs 
immune to PRRSV-1 Olot/91 
PBMC from three PRRSV-1 Olot/91 immune pigs were stimulated in vitro 
with peptide pools representing 19 proteins of PRRSV-1 and responses measured by 
IFN-γ ELISpot assay (Figure 3.1). Results showed that all animals mounted 
significant IFN-γ responses to the structural proteins M, N and GP3. Pig 52 only 
responded to these proteins, whereas pigs 53 and 54 also showed significant 
responses to other structural proteins, GP4 and GP5, as well as non-structural 
proteins NSP1, NSP2 and the viral polymerase RdRp (NSP9). In addition, pig 54, 
which interestingly had initially been infected with the higher doses of PRRSV 
Olot/91, showed reactivity to NSP7, NSP11 and GP2. Due to the large numbers of 
PBMC required, it was not possible to pursue the further examination of all positive 
peptide pools and therefore based on these results as well as the current literature, 
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GP5 and M were selected as representative structural proteins and NSP1, NSP2 and 
RdRp selected as representative non-structural proteins. For confirmation and 
mapping of the T cell responses to specific antigenic regions, overlapping peptides 
representing GP5 (Figure 3.2) and M (Figure 3.3) were screened individually, and 
peptides making up the NSP1 (Figure 3.4), NSP2 (Figure 3.5) and RdRp (Figure 3.6) 
protein pools were screened in pools of 10 due to their long length. Peptides that 
stimulated significant IFN-γ responses compared to unstimulated controls in two or 
more pigs were identified (Table 3.1) and their recognition confirmed by titration of 
peptides using a 10-fold dilution series starting at 1μg/ml (Figure 3.7).  
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Figure 3.1. T cells from PRRSV-1 Olot/91 immune pigs display broad profiles 
of antigen reactivity. PBMC from three PRRSV-1 Olot/91-immune pigs were 
stimulated in vitro with synthetic peptides pooled to represent 19 PRRSV-I proteins 
and IFN-γ secreting cells enumerated by ELISpot assay. Representative data of one 
of two experiments are presented as the unstimulated-corrected mean IFN-γ spot 
forming cells (SFC)/106 PBMC for triplicate cultures. Error bars represent SEM. 
Values for each peptide pool-stimulated condition were compared to the 
corresponding unstimulated control using a one-way ANOVA followed by a 
Dunnett’s Multiple Comparison Test; ***p<0.001, **p<0.01, *p<0.05. 
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Figure 3.2. Identification of individual antigenic peptides from PRRSV GP5. 
PBMC isolated from three PRRSV-1 immune pigs were stimulated in vitro with 
individual overlapping 15mer peptides comprising the GP5 protein. Data are 
presented as the unstimulated-corrected mean IFN-γ spot forming cells (SFC)/106 
PBMC for triplicate cultures and error bars represent SEM. Values for each peptide 
stimulated condition were compared to the corresponding unstimulated control using 
a one way ANOVA followed by a Dunnett’s Multiple Comparison Test; 
****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. 
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Figure 3.3. Identification of individual antigenic peptides from PRRSV M 
protein. PBMC isolated from three PRRSV-1 immune pigs were stimulated in vitro 
with individual overlapping 15mer peptides comprising the M protein. Data are 
presented as the unstimulated-corrected mean IFN-γ spot forming cells (SFC)/106 
PBMC for triplicate cultures and error bars represent SEM. Values for each peptide 
stimulated condition were compared to the corresponding unstimulated control using 
a one way ANOVA followed by a Dunnett’s Multiple Comparison Test; 
****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. 
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Figure 3.4. Mapping of antigenic peptides from PRRSV NSP1. PBMC isolated 
from three PRRSV-1 immune pigs were stimulated in vitro with pools of ten 15mer 
peptides comprising the NSP1 protein. Data are presented as the unstimulated-
corrected mean IFN-γ spot forming cells (SFC)/106 PBMC for triplicate cultures and 
error bars represent SEM. Values for each peptide stimulated condition were 
compared to the corresponding unstimulated control using a one way ANOVA 
followed by a Dunnett’s Multiple Comparison Test; ****p<0.0001, ***p<0.001, 
**p<0.01, *p<0.05. 
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Figure 3.5. Mapping of antigenic peptides from PRRSV NSP2. PBMC isolated 
from three PRRSV-1 immune pigs were stimulated in vitro with pools of ten 15mer 
peptides comprising the NSP1β protein. Data are presented as the unstimulated-
corrected mean IFN-γ spot forming cells (SFC)/106 PBMC for triplicate cultures and 
error bars represent SEM. Values for each peptide stimulated condition were 
compared to the corresponding unstimulated control using a one way ANOVA 
followed by a Dunnett’s Multiple Comparison Test; ****p<0.0001, ***p<0.001, 
**p<0.01, *p<0.05. 
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Figure 3.6. Mapping of antigenic peptides from PRRSV RNA dependant RNA 
polymerase (RdRp). PBMC isolated from three PRRSV-1 immune pigs were 
stimulated in vitro with pools of ten 15mer peptides comprising the RdRp protein. 
Data are presented as the unstimulated-corrected mean IFN-γ spot forming cells 
(SFC)/106 PBMC for triplicate cultures and error bars represent SEM. Values for 
each peptide stimulated condition were compared to the corresponding unstimulated 
control using a one way ANOVA followed by a Dunnett’s Multiple Comparison 
Test; ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. 
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Figure 3.7. Identification of PRRSV-1 antigenic peptides recognised by primed 
T cells. Ten-fold dilutions of putative antigenic peptides were screened using PBMC 
from three PRRSV-1 Olot/91 immune pigs and T cell responses enumerated by IFN-
γ ELISpot assay. Pools of 10 peptides from NSP1β, NSP2 and RdRp, previously 
identified to elicit an IFN-γ response were tested, whereas for GP5 and M, individual 
putative antigenic peptides were evaluated. Data are presented as the unstimulated-
corrected mean IFN-γ spot forming cells (SFC)/106 PBMC for triplicate cultures and 
error bars represent SEM. 
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Table 3.1. Summary of individual peptides, representing GP5 and M, or peptide 
pools, representing NSP1, NSP2 and RdRp, able to induce IFN-γ release from 
PBMC from Olot/91 immune pigs 
Protein IFN-γ inducing peptides/peptide pools 
GP5 38, 39 
M 4, 5, 16, 24, 38, 40, 41 
NSP1 Pool 1, pool 4, pool 9 
NSP2 Pool 3, pool 7 
RdRp Pool 5 
  
Pig 52 showed statistically significant IFN-γ responses to NSP1β peptide 
pools 1 and 4, and peptides GP561-75 (peptide 38; FDWAVETFVLYPVAT), M13-27 
(peptide 4; AAQKLVLAFSITYTP) and the overlapping peptides M159-173 (peptide 
40) and M161-175 (peptide 41), suggesting that the antigenic region lay within the 
consensus sequence of RAVKRGVVNLVKY. This pig also showed reactivity to 
NSP2 peptide pool 3 and to a lesser degree pool 7, although not deemed statistically 
significant. Pig 54 showed a similar response with an additional reactivity detected 
against RdRp peptide pool 5. Pig 53 showed a significant response to NSP1 peptide 
pool 1, RdRp peptide pool 5 and peptide GP561-75 (peptide 38).  
The pools of ten peptides from NSP1, NSP2 and RdRp that elicited a 
significant IFN-γ response were subsequently screened individually to attribute the 
response to specific antigenic peptides (Figure 3.8). Rather unexpectedly, the 
responding peptides in NSP1 pool 1 were different for each pig; NSP1149-163 (peptide 
5; DQPFPGATHVLTNSP) in pig 53, NSP169-83 (peptide 3; ECTPSGCCWLSAVFP) 
in pig 52 and NSP1129-143 (peptide 1; YPITGPVPGMGLFAN) in pig 54. In NSP1 
pool 4, the responding peptide was NSP1349-363 (peptide 10; 
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DDDVTPGFVRLTSLR), and in NSP2 pools 3 and 7 were NSP2393-407 (peptide 4; 
AATTTLVREQTPDNP) and NSP2725-739 (peptide 5; QRLMTWVFEVFSHLP), 
respectively. Two non-overlapping peptides from the RdRp pool 5 gave a positive 
response: RdRp142-156 (peptide 4; HGAGNMGVDGSIWDF) and RdRp262-276  
(peptide 5; YSVMEYLDSRPDTPF). 
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Figure 3.8. Resolution of individual antigenic peptides from NSP1 peptide pool 
1. PBMC isolated from the three PRRSV-1 immune pigs were stimulated in vitro 
with each individual peptide that comprised the identified antigenic NSP1 peptide 
pool 1. Data are presented as the unstimulated-corrected mean IFN-γ spot forming 
cells (SFC)/106 PBMC for triplicate cultures and error bars represent SEM. Values 
for each peptide stimulated condition were compared to the corresponding 
unstimulated control using a one way ANOVA followed by a Dunnett’s Multiple 
Comparison Test; ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. 
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Figure 3.9. Resolution of individual antigenic peptides from NSP1, NSP2 and 
RdRp pools of ten peptides. PBMC isolated from the three PRRSV-1 immune pigs 
were stimulated in vitro with each individual peptide that comprised the identified 
antigenic pool 4 of NSP1, pools 3 and 7 of NSP2 and pool 5 of the RdRp. Data are 
presented as the unstimulated-corrected mean IFN-γ spot forming cells (SFC)/106 
PBMC for triplicate cultures and error bars represent SEM. Values for each peptide 
stimulated condition were compared to the corresponding unstimulated control using 
a one way ANOVA followed by a Dunnett’s Multiple Comparison Test; 
****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. 
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3.2.3. Assessment of the phenotype of T cells responding to identified PRRSV-1 
antigenic peptides 
In order to determine the phenotype of the T cells responding to the identified 
individual or pools containing antigenic peptides, PBMCs were depleted of either 
CD4+ or CD8β+ T cells and then stimulated with antigenic or irrelevant control 
peptides or pools (Figure 3.10). Responses were considered to be from CD4 or CD8 
T cells when a statistically significant decrease in the response to peptide was 
observed upon depletion. Although IFN-γ responses were waning in magnitude by 
this time-point post-infection, it was still discernible for at least one of the responder 
pigs that CD4 T cells were responsible for responses to peptides GP561-75 and M13-27 
and to the NSP2 peptide pools, whereas, CD8 T cells responded to NSP1 peptide 
pool 1, RdRp peptide pool 5 and the overlapping peptides M159-173 and M161-175. 
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Figure 3.10. Elucidation of the phenotype of PRRSV-1 antigenic peptide-
specific T cells. Antigenic peptides were used to stimulate PBMC (grey bars) or 
PBMC depleted of CD4+ (black bars) or CD8β+ (white bars) T cells from three 
PRRSV-I Olot/91 immune pigs and remaining IFN-γ secreting T cells enumerated 
by ELISpot assay. Pools of 10 peptides from NSP1, NSP2 and RdRp, previously 
identified to elicit an IFN-γ response were tested, whereas for GP5 and M, individual 
antigenic peptides were evaluated. Data are presented as the unstimulated-corrected 
mean IFN-γ spot forming cells (SFC)/106 PBMC for triplicate cultures. Error bars 
represent SEM and asterisks denote statistical significance (p<0.05) of responses 
compared to the other depleted PBMC population. 
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3.2.4. Determination of porcine MHC (SLA) haplotypes and assessment of 
association with T cell specificity.  
In order to determine whether the T cell responses to particular peptides 
could be attributed to a certain haplotype, animals were MHC typed. All three 
animals were heterozygous and a number of haplotypes were shared: MHC class I – 
Pig 52 (Lr-27.0/24.0), Pig 53 (Lr-05.0/24.0), Pig 54 (Lr-05.0/24.0) and MHC class II 
- Pig 52 (Lr-0.23/0.14), Pig 53 (Lr-0.27/0.02) and Pig 54 (Lr-0.23/0.02). It is 
therefore possible that the common MHC class I haplotype 05.0, shared by pigs 53 
and 54, could restrict the CD8 T cell response to RdRp142-156 and RdRp262-276 (Figure 
3.9). Despite pigs 53 and 54 being MHC class I haplomatched only the latter 
responded, at the point of testing, to the overlapping M peptides and since the 
response was also observed with pig 52 (Figure 3.10), it may only be speculated that 
this response was restricted by Lr-24 in 2/3 animals. With regards to the CD4 
responses, the MHC class II haplotype 0.23, shared by pigs 52 and 54, could restrict 
the CD4 T cell responses to and M13-27. Since CD4 T cell responses to GP561-75 were 
detected in all pigs, it suggests that this peptide may be presented by MHC class II 
molecules present in more than one haplotype (Figure 3.10). However, the testing of 
additional MHC typed animals is required to confirm these associations. 
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3.2.5. Assessment of sequence conservation of identified antigenic peptides 
amongst PRRSV strains.  
The level of amino acid sequence conservation of the antigenic regions was 
investigated amongst 14 PRRSV-1 strains, two of which were divergent subtype 3 
strains, SU1-Bel and Lena, and the PRRSV-2 reference strain, VR2332 (Table 3.2 
and 3.3). The analysis revealed that the NSP1β149-163 and M antigenic peptides were 
highly conserved amongst PRRSV-1 isolates and only two or three amino acid 
substitutions were seen in VR2332. NSP1349-363, the two RdRp antigenic regions and 
GP561-75 were also well conserved within genotype 1 strains, but less well conserved 
in PRRSV-2. NSP169-83 and NSP1129-143 were not well conserved, even within 
PRRSV-1 strains however the most variable sequences were found within the NSP2 
protein. Conservation of antigen sequence between and within genotypes is an 
important consideration when evaluating antigens for incorporation into potential 
PRRSV vaccines. The analysis shows that, while certain antigens may induce a 
superior cellular immune response, e.g. GP5, these may not be the best antigens to 
generate an immune response against the repertoire of PRRSV strains in the field. 
Further studies could be conducted to assess whether the mutations in these T cell 
antigenic peptides would have a functional consequence in terms of MHC binding 
and T cell recognition.  
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Table 3.2. Assessment of the conservation of identified T cell antigenic regions of the non-structural proteins among different PRRSV-1 isolates 
and the prototype PRRSV-2 strain 
PRRSV 
Strain 
Geno-
type 
GenBank 
Acc. No. 
NSP169-83 
ECTPSGCCWLSAVFP 
NSP1129-143 
YPITGPVPGMGLFAN 
NSP1149-163 
DQPFPGATHVLTNSP 
NSP1349-363 
DDDVTPGFVRLTSLR 
NSP2393-407 
AATTTLVREQTPDNP 
NSP2725-739 
QRLMTWVFEVFSHLP 
RdRp142-156 
HGAGNMGVDGSIWDF 
RdRp262-276  
YSVMEYLDSRPDTPF 
Olot-91 1 X92942 ............I.. ............... ............... ............... .T............L .H............. ............... ............... 
Lelystad 1 AY588319 ............... ............... ............... ............... ............... ............... ............... ............... 
H2 1 
KJ769653 
KJ769654 
KJ769655 
............... ............... ............... ............... ............... ............... ............... ............... 
Porcilis 1 KF991509 ............... ............... ............... N.............. ............... ............... ............... ............... 
Cresa3266 1 JF276434 ............... ............... ............... .............I. ............... ............... ............... ............... 
195-06 1 
KJ769657 
KJ769658 
KJ769659 
............I.. ............... ............... N.N............ .V.P........... ..F............ ............... ..............L 
Cresa3249 1 JF276433 ..S.........I.. ..........A.Y.. ............... .NS............ ............... .H............. ...........V... ..............P 
Cresa3267 1 JF276435 ............I.L ............... ............... ..N............ .T............L .H............. ............... ..............P 
Cresa3256 1 JF276432 ....I.......IL. ............Y.. ............... ...........V... ...K....R.MSN.. .H..A.......... ............... ..............P 
Cresa3262 1 JF276431 ............I.. ............... ............... E.............. VT..A.E.K.VL... .........IV.... .......I....... ............... 
Cresa2982 1 JF276430 ............I.. ............... ............... E.............. ......E.K.VL... .........IV.... .......I....... ............... 
07V063 1 GU737264 ..S........VI.. ...........V... ............... E..........A... VV..G.......CDL ....A....IV.... ...........V... ..............P 
Lena 1.3 JF802085 ............I.. ............Y.. .K............. N.............. S.GAN.MD.D..GGW .Y..A.....Y.... ...........V... ...L..........L 
SU1-Bel 1.3 
KJ769662 
KJ769663 
KJ769664 
............I.. .........I..Y.. .K............. S..........V.I. LIQQIS.GR.L.T.. .H........Y.... ..........T.... ...L..........L 
VR2332 2 EF536003 ..S.A.A.....I.. ...V..A..VAVY.. .K...........L. AGEPSYS..ED.LRI. PVKSLPE.KPV.APR DQ.SRQ..DLV.... ..P..T.I..TL... A..LD.......C.K 
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Table 3.3. Assessment of the conservation of identified T cell antigenic regions of the 
structural proteins among different PRRSV-1 isolates and the prototype PRRSV-2 
strain 
PRRSV 
Strain 
Geno-
type 
GenBank 
Acc. No. 
GP561-75 
FDWAVETFVLYPVAT 
M13-27 
AAQKLVLAFSITYTP 
M161-173 
RAVKRGVVNLVKY 
Olot-91 1 X92942 ............... ............... ............. 
Lelystad 1 AY588319 .G............. ............... ............. 
H2 1 AY035938 JN862511  
.G............. ............... ............. 
Porcilis 1 KF991509 .G.......F..... ............... ............. 
Cresa3266 1 JF276434 .G............. ............... ............. 
195-06 1 KJ769656 JN862404  .G............. ............... ............. 
Cresa3249 1 JF276433 .Y............. ............... ............. 
Cresa3267 1 JF276435 ............... ............... ............. 
Cresa3256 1 JF276432 ....A.......... .....A...C..... ............. 
Cresa3262 1 JF276431 .H...........V. .V............. ............. 
Cresa2982 1 JF276430 .R............. ............... ............. 
07V063 1 GU737264 .Y............. ............... ...R......... 
Lena 1.3 JF802085 ......S..F...V. ....V.......... ............. 
SU1-Bel 1.3 KJ769660 KJ769661  
.G.V..S..F...V. ....IL......... ............. 
VR2332 2 EF536003 ......S..IF..L. .P..VL......... K...Q........ 
 
 
3.2.6. Assessment of T cell antigen reactivity in pigs experimentally infected 
with the prototype PRRSV-1 strain Lelystad or the divergent SU1-Bel strain.  
The peptide library screening was expanded to assess the T cell antigen 
specificity from pigs infected with two different PRRSV-1 strains; Lelystad serving 
as a highly conserved strain (overall 95.2% nucleotide identity with Olot/91) and the 
pathogenic SU1-Bel as a divergent strain (overall 76.4% nucleotide identity with 
Olot/91). Stimulation of PBMC, isolated on day 28 post-infection, with the pools 
representing the 19 PRRSV proteins showed that irrespective of the inoculation 
strain the response profile was broadly similar to the previous experiment (Figures 
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3.11 and 3.12). All but one of the animals (7/8) infected with the Lelystad strain 
mounted a significant IFN-γ response to NSP1 and 2, whereas only 2/8 and 1/8 
showed a significant response to M and GP5, respectively (Figure 3.11). A 
significant proportion of pigs infected with the divergent SU1-Bel strain responded 
to these four antigens (NSP1 – 3/8, NSP2 – 6/8, M and GP5 – both 4/8) (Figure 
3.12).  In spite of these pigs being tested for T cell reactivity after a single infection, 
in contrast to the animals in the previous experiment, which were tested after 
repeated inoculation, a very similar profile of T cell reactivity was observed. These 
results do not show any obvious focussing of the immune response towards a 
particular protein, however, further in depth phenotyping of the responding T cell 
populations in each case may reveal differences. Interestingly, the non-structural 
protein 5 (NSP5) elicited a strong IFN-γ response in 6/8 SU1-Bel-infected pigs 
(Figure 3.12) compared to the insignificant response seen in all but one of the pigs 
infected with the Lelystad strain (Figure 3.11). Comparison of the deduced NSP5 
amino acid sequences from SU1-Bel and Lelystad showed these proteins to be well 
conserved sharing 88.8% identity. Comparison of Olot/91 NSP5 showed 97.6% and 
89% identity with the Lelystad and SU1-Bel sequences, respectively (Figure 3.13). 
In addition, amongst the pigs infected with Lelystad strain, one pig responded to 
GP2; as well as 2/8 pigs showing a response to NSP3 and one pig to NSP8. Amongst 
the pigs infected with the SU1-Bel strain, 4/8 pigs additionally showed a significant 
response to GP2, 2/8 pigs showed significant responses to the N protein and viral 
polymerase (RdRp), and single pigs responded to NSP7 and helicase. 
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Figure 3.11. Recognition of PRRSV-1 proteins by T cells from pigs 
experimentally infected with the closely related PRRSV Lelystad strain. PBMC 
from pigs experimentally infected with PRRSV-1 Lelystad (n=8) were stimulated in 
vitro with synthetic peptides pooled to represent 19 PRRSV proteins and IFN-γ 
secreting cells enumerated by ELISpot assay. Data are presented as the mean 
unstimulated-corrected IFN-γ spot forming cells (SFC)/106 PBMC (triplicate 
cultures) for each animal and error bars show the SEM. Values for each peptide 
pool-stimulated condition were compared to the corresponding unstimulated control 
using a one-way ANOVA followed by a Dunnett’s Multiple Comparison Test; 
***p<0.001, **p<0.01, *p<0.05. 
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Figure 3.12. Recognition of PRRSV-1 proteins by T cells from pigs 
experimentally infected with the divergent PRRSV SU1-Bel strain. PBMC from 
pigs experimentally infected with PRRSV-1 SU1-Bel (n=8) were stimulated in vitro 
with synthetic peptides pooled to represent the PRRSV proteins and IFN-γ secreting 
cells enumerated by ELISpot assay. Data are presented as the mean unstimulated-
corrected IFN-γ spot forming cells (SFC)/106 PBMC (triplicate cultures) for each 
animal and error bars show the SEM. Values for each peptide pool-stimulated 
condition were compared to the corresponding unstimulated control using a one-way 
ANOVA followed by a Dunnett’s Multiple Comparison Test; ***p<0.001, 
**p<0.01, *p<0.05. 
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Figure 3.13. Assessment of the conservation of the predicted amino acid 
sequences of NSP5 between Lelystad, Olot/91 and SU1-Bel strains of PRRSV-1.  
 
4.3. Discussion 
The work presented in this chapter represents the first comprehensive 
approach to mapping of the specificity of the T cell response to PRRSV. Using T 
cells from pigs immune to PRRSV-1 Olot/91, it was possible to screen a proteome-
wide synthetic peptide library to identify antigenic peptides recognised by CD4 or 
CD8 T cells. Screening of peptide pools representing 19 PRRSV proteins showed 
that antigenic peptides were scattered throughout the proteome and no one protein 
stood out that was recognised by all animals. An apparently immunodominant CD4 
T cell epitope that was recognised by Pig 52 and 54 was readily defined on the M 
protein (M13-27), but no one immunodominant epitope was identified for Pig 53. 
Resolution of peptide pools was possible only through a two-step process of 
screening the individual peptides at a single concentration followed by titration of 
peptides to remove ‘false positive’ peptides. On reflection it may have been more 
effective to have screened the single peptides at a lower concentration to reduce the 
non-specific reactivity against a number of peptides. Peptides which showed 
significant reactivity following titration were then subjected to screening with 
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PBMC depleted of either CD4+ or CD8β+ cells by magnetic sorting. This approach 
had the advantage that the cells utilised in the assay had not been labelled with 
magnetic beads. The resulting data showed that removal of either T cell population 
ablated the response to a particular peptide suggesting that the depleted population 
contained the peptide-specific T cells. An alternative strategy to magnetic sorting of 
T cell populations would be to use intracellular cytokine staining and flow 
cytometry, which would have the advantage of allowing assessment of multiple 
parameters. The antigenic sequences identified in this study showed no overlap with 
those previously mapped [Diaz et al, 2009,Vashisht et al, 2008, Bautista et al, 1999, 
Parida et al, 2012, Burgara-Estrella et al, 2013] with the exception of M13-27, which 
showed significant overlap with an antigenic peptide identified in a highly 
pathogenic PRRSV-2 strain [Wang et al,  2011]. The different MHC haplotypes of 
the animals studied most likely accounts for the multitude of antigens identified in 
different studies as it is known that the porcine MHC is highly polymorphic [Lunney 
et al, 2008]. Algorithms developed to predict peptide binding to human MHC 
molecules, SYFPEITHI [http://www.syfpeithi.de] and PropPred 
[www.imtech.res.in/raghava/propred], have been used to pre-screen PRRSV 
sequences for potential T cell epitopes [Diaz et al, 2009, Burgara-Estrella et al,  
2013]. The NetMHCpan prediction server [www.cbs.dtu.dk/services/NetMHCpan/] 
has recently been expanded to predict peptide binding to a broad range of porcine 
MHC class I molecules and was used to successfully identify a CD8 T cell epitope 
on foot-and-mouth disease virus [Hoof et al, 2009, Patch et al, 2011]. To further test 
this immunoinformatics approach, we examined the ability of the NetMHCpan to 
predict the binding of the identified CD8 T cell antigenic peptides to the MHC class 
I alleles potentially expressed by the responder pigs. The consensus antigenic peptide 
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M161-173 (RAVKRGVVNLVKY) was predicted to bind strongly to allele SLA-
3*0401 and the RdRp262-276 peptide was predicted to bind strongly to 2 alleles (SLA-
1*0401 and SLA-1*0801). However, neither the NSP1149-163 nor the RdRp142-156 
peptides were predicted to bind any of the potential alleles, suggesting that these 
algorithms would currently fail to predict all antigenic peptides from PRRSV. 
While the peptide library approach was intended to be a comprehensive 
analysis of the antigen-specificity of PRRSV-specific T cells, it has recently come to 
light that PRRSV expresses an additional two proteins, ORF5a [Johnson et al, 2011] 
and NSP2TF [Fang et al, 2012], which are both expressed by a ribosomal frame shift 
mechanism. The ORF5a protein is of potential interest as it is a structural protein 
encoded by an alternative ORF within the immunogenic GP5 genome region, even 
though a non-protective non-neutralising antibody response was induced upon 
immunisation of pigs with the ORF5a protein [Robinson et al, 2013]. The NSP2TF 
is derived from an alternative coding region of NSP2, another immunogenic protein 
[Chen et al, 2010b]. Future analysis of PRRSV-specific T cell specificity should 
include both ORF5a and NSP2TF. 
In conclusion, this study has shown that PRRSV infection induces a T cell 
response with a broad-range of antigen specificities. The in-depth study of the three 
Olot/91 inoculated pigs revealed CD8 T cell responses to the M protein, the viral 
polymerase and NSP1β, and CD4 T cell responses to NSP1β, NSP2, GP5 and M 
proteins. The results of the experiments described here validate the use of this 
proteome-wide screening approach for the comprehensive identification of PRRSV-
specific T cell epitopes. Both M and GP5 have been described in the literature as 
vaccine candidate antigens, and their identification by this study serves to confirm 
95 
 
both the approach and the importance of these proteins in future vaccine 
development. However, the study also highlights the potential of non-structural 
proteins, most notably NSP1, NSP2 and NSP5, as additional vaccine candidate 
antigens. Further deployment of this proteome-wide library screening approach in 
future larger studies will help further identify, characterise and prioritise PRRSV T 
cell antigens to aid next generation vaccine development. 
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Chapter 4. Detailed characterisation of the T cell response to two 
major PRRSV antigens 
4.1. Rationale 
The experiments described in Chapter 3 served as a starting point for the 
characterisation of the T cell responses to PRRSV utilising the synthetic peptide 
library approach. It is well known that both neutralising antibodies (NA) and T cell 
responses are vital for resolution of many viral infections, however in the case of 
PRRSV, there are varying and sometimes conflicting reports as to the contributions 
of each response. Studies have shown clearance of viral RNA in the absence of NA 
suggesting that T cell responses play an important part in protective immunity to 
PRRSV [Kim et al, 2007, Zuckermann et al, 2007]. A better understanding of the 
kinetics of infection and immunological correlates of protection may help tease apart 
the contribution of immune responses to PRRSV and subsequently inform rational 
vaccine design. Whilst not the only measurable indicator of T cell responses, IFN-γ 
is considered a suitable parameter to quantify virus-specific T cell responses, as well 
as being a potential correlate of protection from PRRSV [Lowe et al, 2005, 
Charerntantanakul et al, 2006a]. Chapter 3 described a broad range of IFN-γ 
reactivity to the PRRSV proteins, most notably the M protein, as well as the viral 
polymerase, NSPs 1, 2 and 5, and GP5; all of which have been previously identified 
in the literature [Wang et al, 2011, Diaz et al,, 2009, Vashisht et al, 2008, Bautista et 
al,, 1999, Parida et al, 2012, Burgara-Estrella, et al, 2013]. The objective of the 
study reported in this Chapter was to utilise the proteome-wide synthetic peptide 
screening method validated in Chapter 3 to further characterise T cell responses to 
PRRSV in terms of specificity, phenotype and function. To address this, both the 
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conventional Olot/91 and divergent pathogenic SU1-Bel PRRSV strains were used 
in an experimental infection and re-challenge model. T cell reactivity was monitored 
longitudinally and antigen reactivity assessed after each infection by screening of the 
PRRSV peptide library. Two antigens that were strongly recognised by both groups 
of animals were selected for further characterisation. In addition to defining and 
characterising antigenic peptides, flow cytometric antibody panels were deployed to 
quantitatively and qualitatively assess the antigen-specific T cell responses.  
 
4.2. Results 
4.2.1. Summary 
Groups of pigs (n=5) were infected with either an attenuated PRRSV-1 
subtype-1 strain (Olot/91) or a pathogenic subtype-3 strain (SU1-bel) and then 
challenged after 35 days with the homologous virus. PBMC were stimulated with 
homologous PRRSV ex vivo and IFN-γ responses assessed by ELISpot assay or 
multi-parameter flow cytometry. Virus-specific CD4 and CD8 T cell IFN-γ 
responses were detected from day 14 post-infection and peaked at 35 days post-
infection. PBMC were stimulated ex vivo with pools of synthetic peptides 
representing 19 PRRSV proteins. In both groups, significant T cell reactivity was 
observed against the structural M protein and the non-structural protein 5 (NSP5), 
which were significantly boosted following the re-challenge infection, and these two 
antigens were selected for further study. CD4 T cell responses were identified in 
3/10 animals and were directed against a single antigenic region on the M protein. 
CD8 T cell responses were directed against three antigenic regions on NSP5 and one 
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epitope on the M protein, with animals showing distinct reactivity profiles associated 
with specific MHC haplotypes. Further characterisation of IFN-γ producing M and 
NSP5-specific CD4 and CD8 T cells showed them to predominantly express the 
phenotype CD44highCD62Llow CD27low CD25- which suggests a mixed population of 
effector and effector memory T cells. Significantly, many of these cells were dual-
functional with co-expression of TNF-α and appeared to have a cytotoxic function as 
assessed by surface mobilisation of the degranulation marker CD107a. Overall, this 
data has shown that M and NSP5 represent well-conserved targets of primarily 
cytotoxic CD8 T cell responses from PRRSV-immune pigs and warrant further 
evaluation as vaccine candidate antigens. 
 
4.2.2. Outcome of experimental infection and subsequent re-challenge with 
PRRSV-1 Olot/91 or SU1-Bel 
Groups of 5 pigs were inoculated intranasally with 106 TCID50 of the 
attenuated PRRSV-I subtype 1 strain Olot/91 and 5 pigs were inoculated with a 
lower dose of 104 TCID50 of the divergent subtype 3 PRRSV strain with the aim of 
infecting animals but with a reduced likelihood of severe clinical disease. On day 35 
post-infection, all animals were challenged by inoculation of the ten-fold higher dose 
of homologous virus that was used in the primary infection (Olot/91: 107 TCID50; 
SU1-Bel: 105 TCID50). As predicted both groups showed mild clinical scores 
throughout the experiment (Figure 4.1A), with the SU1-Bel group displaying greater 
clinical scores than the Olot/91 group, despite the lower inoculation dose 
(statistically significant on 2, 6, 7, 9, 10, 17 and 18 days post-infection; dpi). In the 
SU1-Bel group, clinical scores peaked around 7 dpi (becoming statistically different 
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to pre-infection scores from 2 dpi) and slightly later (between days 10-20 dpi) for the 
Olot/91 group (not statistically significant). Importantly there was no increase in 
clinical scores upon re-challenge at 35 dpi in the Olot/91 group and only mild 
clinical scores observed on 37 and 38 dpi in the SU1-Bel group. Quantitative RT-
PCR analyses of serum samples showed low (statistically insignificant) viral copy 
numbers in the Olot/91 group, peaking on 14 dpi and resolving completely by 30 dpi 
(Figure 4.1B). Statistically significant viral copies were seen on 7 dpi in the SU1-Bel 
group but these were rapidly cleared by 14 dpi. There was also no detectable 
viraemia upon re-challenge, which taken together with the clinical scores suggests 
that the initial infection affords a high-degree of protection against re-infection. 
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Figure 4.1. Outcome of infection and subsequent re-challenge infection with an 
attenuated PRRSV-1 strain (Olot/91) or a virulent sub-genotype 3 strain (SU1-
Bel). Pigs were experimentally infected intranasally with either PRRSV-1 Olot/91 
(closed circles; n=5) or SU1-Bel (open circles; n=5) strains on day 0 and day 35 post 
infection (marked with ↓). Clinical signs were scored daily (A) and viral copy 
number in serum was assessed on days 0, 7, 14, 21, 30, 35, 42, 50 and 56 (B). 
Results are expressed as the mean data for each group, error bars represent the 
standard error of the mean (SEM) and values were compared to the corresponding 
value on day 0 using a two-way analysis of variance (ANOVA) followed by a 
Bonferroni’s multiple comparison test; **** p < 0.0001. 
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4.2.3. Association of neutralising antibody and T cell responses with clearance 
of PRRSV-1 infection and immunity to re-challenge 
In the PRRSV-1 Olot/91 infected group, NA were detectable from 14 dpi and levels 
steadily increased to a statistically significant peak at 30 dpi, upon which levels 
began to wane (Figure 4.2A). However there appeared to be a boosting effect upon 
re-challenge at 35 dpi. Conversely in the PRRSV-1 SU1-Bel infected group, no 
neutralising antibody titres were measurable until after the re-challenge (42 dpi, 
Figure 4.2B) and the resolution of the viraemia associated with the primary infection. 
Assessment of PRRSV-specific T cell IFN-γ responses was conducted by flow 
cytometry following ex vivo stimulation of PBMC with the homologous virus. Both 
groups showed a higher magnitude of IFN-γ expressing CD4 (CD4+CD8αlow) T cells 
in response to homologous virus stimulation than CD8 (CD4-CD8αhigh) T cells 
(Figure 4.2 C and D). The Olot/91 group showed an increase in CD4 T cell 
responses from 14 dpi, and compared to 0 dpi these responses were statistically 
significant (p=0.05) from 30 dpi onwards and began to wane by 56 dpi. The SU1-Bel 
group displayed a higher overall magnitude of PRRSV-specific CD4 T cell 
responses (statistically significant on 21 dpi; p = 0.0001) which were statistically 
significant (p = 0.01) by 14 dpi, reaching a peak at 21 dpi (p = 0.0001). There was a 
slight rise in IFN-γ CD4 T cell responses after re-challenge (statistically significant 
at 50 dpi; p = 0.01). There were no statistically significant increases over time in 
CD8 T cell responses in either group. Analysis of T cell IFN-γ responses of 
individual animals to homologous virus confirmed the finding that the response 
measured was dominated by CD4 T cells in all animals (Figure 4.3). Statistically 
significant CD4 T cell responses were seen as early as 14 dpi (Olot/91 infected pig 
87; p = 0.0001, and SU1-Bel infected pigs 72, 73, 88, 89 and 01; p ≤ 0.05) and 
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reached a peak at various different time points post-infection (30 dpi - pigs 70, 71 
and 86; 35 dpi - pigs 00 and 73). Some animals showed evidence of boosting of T 
cell IFN-γ responses after re-infection (SU1-Bel group: pigs 72, 88 and 01). Certain 
animals also displayed a statistically significant CD8 T cell IFN-γ response (Olot/91 
group: pigs 70; days 14, 35, 42 and 51 dpi; p ≤ 0.05, and pig 87; days 14 and 51; p ≤ 
0.01). There were no statistically significant CD8 T cell responses to virus re-
stimulation in any animal from the SU1-Bel infected group. 
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 Figure 4.2. Assessment of the association between neutralising antibody and T 
cell responses and the clearance of PRRSV viraemia following experimental 
infection and re-challenge with Olot/91 and SU1-Bel. Serum was collected weekly 
from pigs and neutralising antibody (NA) titres were assessed by testing the ability 
of the serum to neutralise homologous virus using an in house serum neutralisation 
assay (A). PRRSV NA titre is plotted against the left y-axis and the PRRSV viraemia 
as assessed by qRT-PCR is plotted against the right y-axis. PBMC were collected 
weekly from pigs and stimulated ex vivo with the homologous virus or a mock 
supernatant. IFN-γ expression by CD4+CD8αlow (CD4) and CD4-CD8αhigh (CD8) T 
cells was assessed by flow cytometry using the gating strategy detailed in Figure 2.1 
(B). The mean % of mock-corrected IFN-γ+ T cells is plotted against the left y axis 
and PRRSV viraemia data are again plotted on the right y-axis. Data is presented as 
the mean for each group and error bars show the SEM. Cells used in this experiment 
were previously cryopreserved and subsequently thawed for analysis. 
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Figure 4.3. Assessment of the longitudinal PRRSV-specific IFN-γ T cell responses over the 
course of infection and re-challenge with Olot/91 and SU1-Bel strains of PRRSV-1. PBMC 
were collected weekly from pigs and stimulated ex vivo with the homologous virus or a mock 
supernatant. IFN-γ expression by CD4+CD8αlow (CD4; open circles) and CD4-CD8αhigh (CD8; 
closed circles) T cells was assessed by flow cytometry. The mean % of mock-corrected IFN-γ+ T 
cells from duplicate cultures are presented and error bars show the SEM. Cells used in this 
experiment were previously cryopreserved and subsequently thawed for analysis. 
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4.2.4. Screening of the PRRSV-1 proteome-wide synthetic peptide library to 
identify T cell antigens 
The synthetic peptide library composed of overlapping 15mers spanning the 
PRRSV-1 proteome were pooled to represent their respective proteins and their 
recognition by PBMC were assessed using an ex vivo IFN-γ ELISpot assay, as in 
Chapter 3. Figures 4.4 and 4.5 show the IFN-γ responses to each protein after 
infection (21 dpi) and re-challenge (51 dpi and 21 days post-re-challenge), for the 
Olot/91 and SU1-Bel groups, respectively. Pigs in the Olot/91 group displayed in 
general a greater magnitude of response to peptide pools after re-challenge as well as 
an increase in the number of pigs mounting significant responses to certain proteins 
(Figure 4.4). The most prominent response was to the M protein, which all pigs 
showed a statistically significant response to after both infection and re-challenge. 
Peptides representing NSP5 also induced significant IFN-γ responses, with 80% 
(4/5) of pigs responding after infection and all pigs then responding after re-
challenge. Other proteins of note especially given their identification in the studies 
reported in Chapter 3 were NSP2 (80% responding after infection and after re-
challenge), RdRp (40% then 40%), helicase (60% then 60%) and GP5 (40% then 
60%).  
Similar to the Olot/91 group, the SU1-Bel group also displayed greater 
responses after re-challenge (Figure 4.5). The magnitude of the response to the NSP5 
after re-challenge was the most striking observation in all animals except pig 89 
which did not react to NSP5 peptides. Interestingly, pig 88 did not mount a 
significant response to NSP5 after infection but this pig’s response to NSP5 after re-
challenge infection had the greatest magnitude of all pigs in this group. In addition to 
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significant responses to NSP5 after both infections (40% responding after infection; 
80% responding after re-challenge infection), significant responses of note were also 
observed against NSP2 (80% then 60%), GP5 (40% then 60%) and the M protein 
(80% then 100%). 
Considering both groups together, the frequency of T cell IFN-γ responder 
animals to the most dominant antigens after both infection and re-challenge were: M 
protein - 90% responding after infection and 100% responding after re-challenge; 
NSP5 - 60% responding after infection and 90% responding after re-challenge; 
NSP2 - 80% responding after infection and 70% responding after re-challenge; and 
GP5 - 40% responding after infection and 60% responding after re-challenge.  
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Figure 4.4. Recognition of PRRSV-1 proteins by T cells from pigs experimentally infected 
with the Olot/91 strain. PBMC from pigs experimentally infected with PRRSV-1 Olot/91 
(n = 5) were isolated on day 21 post-infection and day 51 post-infection (16 days post-
rechallenge), and stimulated in vitro with synthetic peptides pooled to represent 19 PRRSV-1 
proteins. IFN-γ secreting cells were enumerated by ELISpot assay. Data are presented as the 
mean unstimulated-corrected IFN-γ spot forming cells (SFC)/5x105 PBMC (triplicate cultures) 
for each animal and error bars show the SEM. Values for each peptide pool-stimulated 
condition were compared to the corresponding unstimulated control using a one-way ANOVA 
followed by a Bonferroni’s multiple comparison test; **** p < 0.0001, ***p < 0.001, 
**p < 0.01, *p < 0.05. 
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Figure 4.5. Recognition of PRRSV-1 proteins by T cells from pigs experimentally 
infected with the SU1-Bel strain. PBMC from pigs experimentally infected with 
PRRSV-1 SU1-Bel (n = 5) were isolated on day 21 post-infection and day 51 post-
infection (16 days post-rechallenge), and stimulated in vitro with synthetic peptides 
pooled to represent 19 PRRSV-1 proteins. IFN-γ secreting cells were enumerated by 
ELISpot assay. Data are presented as the mean unstimulated-corrected IFN-γ spot 
forming cells (SFC)/5x105 PBMC (triplicate cultures) for each animal and error bars 
show the SEM. Values for each peptide pool-stimulated condition were compared to the 
corresponding unstimulated control using a one-way ANOVA followed by a Bonferroni’s 
multiple comparison test; **** p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05 
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Whilst IFN-γ is a good indicator of anti-viral type 1 T cell (Th1) responses, there are 
other cytokines that could provide additional information on the responses induced 
by each viral protein. IL-2 is another marker of the type 1 response, inducing 
proliferation and maintenance of antigen specific T cells whose expression is 
associated with the presence of polyfunctional T cells. IL-10 is a pleiotropic cytokine 
that can have immunosuppressive effects on type 1 T cells. IL-4 is an autoregulatory 
cytokine which drives the type 2 CD4 T cell (Th2) response and inhibits the 
induction of the Th1 response. To assess the ability of peptides representing PRRSV 
proteins to induce these cytokines, ELISAs were performed on culture supernatants 
of PBMC stimulated with the peptide pools after re-challenge as above (Figure 4.6). 
One pig was chosen as a representative of each group and cell free supernatants were 
assessed for presence of IL-2, IL-4 and IL-10 (IFN-γ ELISpot data is shown in the 
top panel for direct comparison). IL-2 and IL4 expression was low in both pigs, but 
statistically significant IL-2 responses were detected against NSP2 (SU1-Bel 
infected pig 01) and NSP4 (Olot/91 infected pig 86) and IL-4 responses to NSP3 and 
E (pig 01) and GP2 and E (pig 86). Pig 01 mounted a significant IL-10 response to 
more viral proteins (NSP2, RdRp and helicase) than pig 86 whose only significant 
IL-10 response was to RdRp. Based on these results and the results of the IFN-γ 
ELISpot it was decided to take the M protein and NSP5 forward for further analysis 
due to their ability to induce consistent and/or high levels of IFN-γ in a large number 
of animals from both groups. NSP2 was considered as another potential T cell 
antigen however its comparatively large size (269 15mer peptides), coupled with the 
induction of IL-10 seen above and the hypervariable regions and deletions described 
in different strains made it less attractive for further testing and evaluation as a 
vaccine candidate antigen. 
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 Figure 4.6. Cytokine secretion by PBMC upon stimulation with PRRSV-1 
protein pools. PBMC were isolated from two representative pigs; one 
experimentally infected with Olot/91 (pig 86) and one experimentally infected with 
SU1-Bel (pig 01) and stimulated ex vivo with synthetic peptides pooled to represent 
19 PRRSV-1 proteins. IFN-γ secreting cells were enumerated by ELISpot assay. 
Levels of IL-2, IL-4 and IL-10 in cell supernatants after 24 hours were measured 
using commercial ELISA kits. Data shown is the mean unstimulated mean corrected 
values for triplicate cultures and error bars show the SEM. Values were compared to 
the unstimulated control using a one way ANOVA followed by a Bonferroni’s 
multiple comparisons test; **** p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. 
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4.2.5. In-depth characterisation of the IFN-γ T cell response to PRRSV-1 M and 
NSP5 proteins 
4.2.5.1. Longitudinal assessment of M and NSP5-specific T cell responses over 
the course of PRRSV-1 infection and re-challenge 
The T cell responses to peptide pools representing M and NSP5 proteins 
were measured longitudinally over the time-course of infection/re-challenge using 
previously cryopreserved cells and flow cytometry. The IFN-γ response to the M 
protein differed significantly between individual animals both in terms of magnitude 
and phenotype (Figure 4.7). The frequency of M-specific IFN-γ secreting CD8 T 
cells observed in pigs 86, 87 and 00, all infected with Olot/91, were of an order of 
magnitude greater than the other animals and are therefore presented with a different 
y-axis scaling (Figure 4.7). These 3 animals all mounted a significant CD8 T cell 
response to the M protein, as did the remaining animals in the Olot/91 group; pigs 71 
and 70. These animals however also mounted a CD4 T cell response greater in 
magnitude than their CD8 T cell response. Within the SU1-Bel group, pig 72 also 
mounted a CD4 T cell response to the M protein. Pigs 73, 89 and 01 did not mount a 
significant response to the M protein at any time point tested with the preserved 
cells. The earliest statistically significant T cell response was seen on 7 dpi in pigs 71 
(CD8) and 72 (CD4) and significant responses continued until 51 dpi (pig 70 and 72 
- CD4; pig 87 and 00 - CD8). Unexpectedly, no boosting of T cell responses was 
observed subsequent to re-challenge infection, with the exception of pig 72 which 
showed a slight increase in the proportion of IFN-γ secreting CD4 T cells. 
As with the response to the M protein, there was a variation in the magnitude 
and kinetics of T cell IFN-γ responses to the NSP5 protein between individual 
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animals (Figure 4.8). Compared to M-specific responses, the IFN-γ response to 
NSP5 was in the majority of animals greater and in all cases was exclusively from 
the CD8 T cells. As had been shown in the IFN-γ ELISpot assay data, all pigs 
responded to NSP5 with the exception of pig 89. Pigs 70, 71 and 86 (all infected 
with Olot/91) presented with exceptionally strong responses to NSP5, peaking at a 
frequency of 1:10 CD8 T cells expressing IFN-γ in response to NSP5. As before, 
these animals are shown with a different y-axis scaling in Figure 4.8. Responses 
tended to peak between days 21-35 after infection and there was no evidence of 
boosting after re-infection. 
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Figure 4.7. Assessment of the longitudinal M protein-specific IFN-γ T cell 
responses over the course of infection and re-challenge with Olot/91 and SU1-
Bel strains of PRRSV-1. PBMC were collected weekly from pigs and stimulated ex 
vivo with a synthetic peptide pool representing the M protein or medium alone. IFN-
γ expression by CD4+CD8αlow (CD4; open circles) and CD4-CD8αhigh (CD8; closed 
circles) T cells was assessed by flow cytometry. The mean % of unstimulated-
corrected IFN-γ+ T cells from duplicate cultures are presented and error bars show 
the SEM. Cells used in this experiment were previously cryopreserved and 
subsequently thawed for analysis. 
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Figure 4.8. Assessment of the longitudinal NSP5-specific IFN-γ T cell responses 
over the course of infection and re-challenge with Olot/91 and SU1-Bel strains 
of PRRSV-1. PBMC were collected weekly from pigs and stimulated ex vivo with a 
synthetic peptide pool representing NSP5 or medium alone. IFN-γ expression by 
CD4+CD8αlow (CD4; open circles) and CD4-CD8αhigh (CD8; closed circles) T cells 
was assessed by flow cytometry. The mean % of unstimulated-corrected IFN-γ+ T 
cells from duplicate cultures are presented and error bars show the SEM. Cells used 
in this experiment were previously cryopreserved and subsequently thawed for 
analysis. 
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4.2.5.3. Assessment of the phenotype and polyfunctionality of PRRSV-1 M and 
NSP5-specific T cell responses  
PBMC isolated from 30 dpi were stimulated with either, the homologous 
virus, M or NSP5 peptide pools in order to determine the specific phenotype of 
antigen-specific T cells. After stimulation, cells were stained with the surface 
markers CD4, CD8α, CD62L; also known as L-selectin, a lymph node homing 
receptor typically expressed on naïve T cells that have not yet encountered antigen; 
CD44; a lymphocyte adhesion and homing molecule; CD25; the receptor for IL-2 
and CD27; part of the TNF receptor superfamily. Antigen specific co-expression of 
IFN-γ and each marker was assessed after exclusion of non-responding pigs based on 
Figures 4.7 and 4.8. Statistically significant phenotypes were identified through the 
use of a two-way ANOVA with Bonferroni’s post hoc test. Figures 4.9 and 4.10 
show that the majority of IFN-γ positive cells express high levels of CD44 and low 
levels of CD62L, regardless of CD4/CD8 phenotype or stimulus (with the exception 
of virus specific CD8 T cells which show equal proportions of both CD44high and 
CD44low cells, possibly due to the very low frequency of stimulated IFN-γ 
expressing CD8 T cells. IFN-γ expressing T cells also predominantly showed a 
CD27low phenotype, with the majority of the remaining IFN-γ+ T cells falling into the 
CD27- gate (Figure 4.11). Antigen-specific T cells were either CD25+ or IFNγ+ with 
the exception of M-specific CD8 and virus-specific CD4 T cells which showed small 
double positive populations (Figure 4.12). T cells that were positive for the cytotoxic 
degranulation marker CD107a were also positive for IFN-γ and the highest 
proportions were seen in the M and NSP5 stimulated T cells, whereas virus 
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stimulated cells showed a higher proportion of both CD4 and CD8 IFN-γ single 
positive cells (Figure 4.13). M specific CD4 and NSP5-specific CD8 T cells showed 
higher proportions of IFN-γ+TNF-α+ (double positive) cells, whereas M specific 
CD8 T cells showed more TFN-α single positive T cells (Figure 4.14). Both virus 
specific CD4 and CD8 T cells had higher proportions of IFN-γ single positive cells 
although all antigen specific cells had significant proportions of double positive T 
cells. 
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Figure 4.9. Assessment of the expression of CD44 and IFN-γ on antigen-specific 
T cells. PBMC were isolated from previously identified T cell responder pigs on day 
30 post-infection and stimulated with either synthetic peptides representing M or 
NSP5 proteins or the homologous virus. The expression of CD44 on IFN-γ+ CD4 
and CD8 T cells was assessed by flow cytometry as shown by representative dot 
plots. The mean % of unstimulated-corrected CD44high and CD44low IFN-γ+ T cells 
from duplicate cultures are presented for individual animals, and error bars show the 
SEM. The mean relative proportions of CD44 expression on IFN-γ+ T cells from all 
animals are additionally presented. Cells used in this experiment were previously 
cryopreserved and subsequently thawed for analysis. 
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Figure 4.10. Assessment of the expression of CD62L and IFN-γ on antigen-
specific T cells. PBMC were isolated from previously identified T cell responder 
pigs on day 30 post-infection and stimulated with either synthetic peptides 
representing M or NSP5 proteins or the homologous virus. The expression of CD62L 
on IFN-γ+ CD4 and CD8 T cells was assessed by flow cytometry as shown by 
representative dot plots. The mean % of unstimulated-corrected CD62Lhigh and 
CD62Llow IFN-γ+ T cells from duplicate cultures are presented for individual animals 
and error bars show the SEM. The mean relative proportions of CD62L expression 
on IFN-γ+ T cells from all animals are additionally presented. Cells used in this 
experiment were previously cryopreserved and subsequently thawed for analysis. 
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Figure 4.11. Assessment of the expression of CD27 and IFN-γ on antigen-
specific T cells. PBMC were isolated from previously identified T cell responder 
pigs on day 30 post-infection and stimulated with either synthetic peptides 
representing M or NSP5 proteins or the homologous virus. The expression of CD27 
on IFN-γ+ CD4 and CD8 T cells was assessed by flow cytometry as shown by 
representative dot plots. The mean % of unstimulated-corrected CD27high, CD27low 
and CD27- IFN-γ+ T cells from duplicate cultures are presented for individual 
animals and error bars show the SEM. The mean relative proportions of CD27 
expression on IFN-γ+ T cells from all animals are additionally presented. Cells used 
in this experiment were previously cryopreserved and subsequently thawed for 
analysis. 
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Figure 4.12. Assessment of the expression of CD25 and IFN-γ by antigen-
specific T cells. PBMC were isolated from previously identified T cell responder 
pigs on day 30 post-infection and stimulated with either synthetic peptides 
representing M or NSP5 proteins or the homologous virus. The expression of CD25 
and IFN-γ by CD4 and CD8 T cells was assessed by flow cytometry as shown by 
representative dot plots. The mean % of unstimulated-corrected CD25-IFN-γ+, 
CD25+IFN-γ+ and CD25+IFN-γ- T cells from duplicate cultures are presented for 
individual animals and error bars show the SEM. The mean relative proportions of 
CD25 and IFN-γ expressing T cells from all animals are additionally presented. Cells 
used in this experiment were previously cryopreserved and subsequently thawed for 
analysis. 
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Figure 4.13. Assessment of CD107a mobilisation on IFN-γ expressing antigen-
specific T cells. PBMC were isolated from previously identified T cell responder 
pigs on day 30 post-infection and stimulated with either synthetic peptides 
representing M or NSP5 proteins or the homologous virus. The surface expression of 
CD107a on IFN-γ+ CD4 and CD8 T cells was assessed by flow cytometry as shown 
by representative dot plots. The mean % of unstimulated-corrected CD107a+ and 
CD107a- IFN-γ+ T cells from duplicate cultures are presented for individual animals 
and error bars show the SEM. The mean relative proportion of surface CD107a on 
IFN-γ+ T cells from all animals is additionally presented. Cells used in this 
experiment were previously cryopreserved and subsequently thawed for analysis. 
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Figure 4.14. Assessment of co-expression of TNF-α and IFN-γ by antigen-
specific T cells. PBMC were isolated from previously identified T cell responder 
pigs on day 30 post-infection and stimulated with either synthetic peptides 
representing M or NSP5 proteins or the homologous virus. The expression of TNF-α 
and IFN-γ by CD4 and CD8 T cells was assessed by flow cytometry as shown by 
representative dot plots. The mean % of unstimulated-corrected TNF-α-IFN-γ+, TNF-
α+IFN-γ+ and TNF-α+IFN-γ- T cells from duplicate cultures are presented for 
individual animals and error bars show the SEM. The mean relative proportions of 
TNF-α and IFN-γ expressing T cells from all animals are additionally presented. 
Cells used in this experiment were previously cryopreserved and subsequently 
thawed for analysis. 
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4.2.5.4. Mapping of T cell antigenic peptides and epitopes on PRRSV-1 M and 
NSP5 proteins 
Identification of the antigenic peptide targets of M and NSP5 specific T cell 
responses was assessed using a two-way matrix pooling system to screen the 
individual 15mers. The matrices were designed horizontally vs. vertically so that 
each peptide was uniquely present in 2 defined pools. An illustration of how peptides 
were combined into matrix pools and how the CD8 T cell IFN-γ responses to these 
pools enabled the identification of putative antigenic peptides is shown in Table 4.1, 
using CD8 T cell responses of pig 86 to NSP5 peptides as an example. The results of 
the matrix pool screens are shown in Tables 4.2 and 4.3. PBMC from 21 or 30 dpi 
were stimulated with each matrix pool and IFN-γ responses were measured by flow 
cytometry. As observed before, the M matrix pools gave a diverse response profile 
and pools that induced a significant IFN-γ response and their corresponding putative 
antigenic peptides are summarised in Table 4.2. 
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Table 4.1 Example of the two-way matrix-pooling system used to identify T cell 
reactive peptides from pools representing PRRSV-1 M and NSP5 proteins. 
NSP5 Matrix Pools* 
A# B C D E F 
N
SP
5 
M
at
rix
 P
oo
ls
 G 1 2 3 4 5 6 
H 7 8 9 10 11 12 
I 13 14 15 16 17 18 
J 19 20 21 22 23 24 
K 25 26 27 28 29 30 
L 31 32 33 34 35 36 
M 37 38 39 40 
 
*The 40 overlapping 15mer peptides (#1-40) representing PRRSV NSP5 were 
pooled using a matrix system so that each peptide was uniquely represented in two 
matrix-pools (Pools A-M). 
#Matrix pools A, B and M stimulated significant CD8 T cell reactivity from pig 86 
and so overlapping peptides #37 and #38 were identified as putative antigenic 
peptides for further testing. 
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Table 4.2. Summary of the M matrix pools that induced a significant IFN-γ T 
cell response and the corresponding putative antigenic peptides. 
Pig  Positive matrix 
pool 
Corresponding antigenic peptides 
70  A B C H  7 8 9 
71  A B C H  7 8 9 
86 A B E F I J L 13 14 17 18 19 20 23 24 31 32 35 36 
87 A B E F I J L 13 14 17 18 19 20 23 24 31 32 35 36 
00 A B E F I J L 13 14 17 18 19 20 23 24 31 32 35 36 
72 A B C F H J 7 8 9 12 19 20 24 
73 A B E I J 13 14 17 19 20 23 
88 A B H 7 8 
89 E F I 17 18 
01 A B D F H I J 7 8 10 12 13 14 16 18 19 20 22 24 
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Table 4.3. Summary of the NSP5 matrix pools that induced a significant CD8 
IFN-γ T cell response and the corresponding putative antigenic peptides. 
Pig  Positive matrix 
pool 
Corresponding antigenic peptides 
70 C D E F G M 3 4 5 6 39 40 
71 C D E G M 3 4 5 39 40 
86 A B M 37 38 
87 A B M 37 38 
00 A B M 37 38 
72 C D G M 3 4 39 40 
73 C D M 39 40 
88 A C D G M 1 3 4 37 39 40 
89 - - 
01 C D M 39 40 
 
CD8 T cell responses to NSP5 were either to pools A, B and M (pigs 86, 87 
and 00) or pools C, D and M (pigs 70, 71, 72, 73, 88 and 01) which corresponded to 
putative over-lapping antigenic peptides 37 and 38 (pools A, B, M) or 39 and 40 
(pools C, D, M). In addition, pigs 70, 71 and 88 responded to pools E and G, adding 
the putative antigenic peptides 3, 4 and 5 to their profile (pig 70 also responded to 
pool F; peptide 6). As expected pig 89 did not mount a significant response to any 
NSP5 matrix pools.  
Putative antigenic peptides were then screened individually on PBMC from 
each pig to confirm their ability to induce a T cell IFN-γ response.  Responses to the 
M peptides was from both CD4 and CD8 T cells, with pigs 70, 71, 72 and 88 
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presenting a significant CD4 T cell response to peptide #8; M29-43 
(MIYALKVSRGRLLGL). Pig 71 also responded to peptide #9; M33-47 
(LKVSRGRLLGLLHIL). Pigs 86 and 87 gave a CD8 T cell response to peptide 13; 
M49-63 (FLNCSFTFGYMTYVR), (Figure 4.15). As expected, responses to NSP5 
were exclusively from CD8 T cells (Figure 4.16). Pigs 70, 71 and 88 showed a 
statistically significant response to peptide 4; NSP513-27 (FLLWRMMGHAWTPIV). 
In addition, these pigs, as well as pig 72, 73, and pig 01, showed a significant 
response to peptides 39 and 40; consensus sequence: NSP5156-167 
(DGSFSSAFFLRY). Pigs 86, 87 and 00 responded to peptides 37 and 38; consensus 
sequence: NSP5149-159 (LHNMLVGDGSF) (Figure 4.16). A summary of identified 
antigenic peptides with their amino acid position and sequences is shown in Table 
4.4.  
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Figure 4.15. Assessment of T cell reactivity against putative antigenic peptides 
from the M protein. PBMC were isolated from pigs on day 58 post infection and 
stimulated ex vivo with putative antigenic peptides identified from the matrix pool 
screen and IFN-γ expression by either CD4 (open bars) or CD8 (closed bars) T cells 
was assessed by flow cytometry. Data shown are the mean of duplicate cultures after 
correction with the unstimulated mean and error bars show the SEM. Values were 
compared to the unstimulated control using a one way ANOVA followed by a 
Bonferroni’s multiple comparisons test; **** p < 0.0001, ***p < 0.001, **p < 0.01, 
*p < 0.05. 
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Figure 4.16. Assessment of T cell reactivity against putative antigenic peptides 
from NSP5. PBMC were isolated from pigs on day 58 post infection and stimulated 
ex vivo with putative antigenic peptides identified from the matrix pool screen and 
IFN-γ expression by CD8 T cells was assessed by flow cytometry. Data shown are 
the mean of duplicate cultures after correction with the unstimulated mean and error 
bars show the SEM. Values were compared to the unstimulated control using a one 
way ANOVA followed by a Bonferroni’s multiple comparisons test; **** 
p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. 
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Table 4.4. Summary of antigenic peptides identified on M and NSP5, with the 
corresponding amino acid position and sequence.  
Protein Peptide # Peptide position on protein Amino acid sequence 
M 8 29-43 MIYALKVSRGRLLGL 
M 9 33-47 LKVSRGRLLGLLHIL 
M 13 49-63 FLNCSFTFGYMTYVR 
NSP5 4 13-27 FLLWRMMGHAWTPIV 
NSP5 37 145-159 KYRCLHNMLVGDGSF 
NSP5 38 149-163 LHNMLVGDGSFSSAF 
NSP5 39 153-167 LVGDGSFSSAFFLRY 
NSP5 40 156-170 DGSFSSAFFLRYFAE 
 
The minimal length peptides, which most likely represent the natural epitopes 
[Hiemstra et al, 1998], required to induce an IFN-γ response from immunodominant 
NSP5-specific CD8 T cells were investigated. The 11mer consensus sequences of the 
overlapping antigenic peptides from NSP5 (NSP5156-167 - DGSFSSAFFLRY and 
NSP5145-159 - LHNMLVGDGSF) and all of the possible derived 10mer, 9mer and 
8mer sequences were synthesised (Table 4.5) and titrations were used to stimulate 
PBMC from pig 71 and 86, as representative animals, based on their previous 
response profiles (Figure 4.17). Of the peptides representing the NSP5 39/40 
consensus sequence (NSP5156-167 - DGSFSSAFFLRY), the 8mer peptide GSFSSAFF 
induced the most sustained CD8 T cell IFN-γ response suggestive of it being the 
minimal length antigenic peptide (Figure 4.17). The shortest derivative of NSP5 
37/38 consensus peptide (NSP5145-159 – LHNMLVGDGSF) to induce the most 
sustained CD8 T cell response was the 10mer HNMLVGDGSF (Figure 4.17). Due 
to practical limitations this analysis was not attempted for the other antigenic regions 
on NSP5 or M protein. 
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Table 4.5 Minimal length peptides from NSP5 37/38 and NSP5 39/40 tested on 
PBMC from PRRSV-immune pigs. 
NSP5 37/38 
Amino acid position Amino acid sequence 
145-159 KYRCLHNMLVGDGSF 
149-163 LHNMLVGDGSFSSAF 
149-159 LHNMLVGDGSF  
150-159 HNMLVGDGSF  
149-158 LHNMLVGDGS  
149-157 LHNMLVGDG 
151-159 NMLVGDGSF  
150-158 HNMLVGDGS  
149-156 LHNMLVGD 
150-157 HNMLVGDG  
151-158 NMLVGDGS  
152-159 MLVGDGSF  
  
  
NSP5 39/40 
Amino acid position Amino acid sequence 
156-167 DGSFSSAFFLRY 
156-166 DGSFSSAFFLR 
157-167 GSFSSAFFLRY 
156-165 DGSFSSAFFL 
157-166 GSFSSAFFLR 
158-167 SFSSAFFLRY 
156-164 DGSFSSAFF 
157-165 GSFSSAFFL 
158-166 SFSSAFFLR 
159-167 FSSAFFLRY 
157-164 GSFSSAFF 
158-165 SFSSAFFL 
159-166 FSSAFFLR 
160-167 SSAFFLRY 
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 Figure 4.17. Identification of minimal length peptides that are recognised by 
NSP5 specific CD8 cells. PBMC from pigs 71 and 86 were stimulated ex vivo with 
selected antigenic NSP5 overlapping peptides and peptides representing the 
consensus 11mer sequence and their truncated derivatives in a log10 dilution series. 
IFN-γ expression by CD8 T cells was assessed by flow cytometry. The mean % of 
unstimulated-corrected IFN-γ+ T cells from duplicate cultures is presented and error 
bars show the SEM. For clarity, peptides that failed to evoke a significant response 
are not presented on the plots. 
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4.2.5.5. Assessment of sequence conservation of identified antigenic M and 
NSP5 regions amongst PRRSV strains and T cell recognition of variant peptide 
sequences 
The level of antigenic amino acid sequence conservation both within 
genotype 1 PRRSV strains and with the prototype genotype 2 virus was investigated, 
as in Chapter 3, to help further evaluate the identified antigens for potential vaccine 
application. M and NSP5 sequences used for comparison are shown in Table 4.4; 
identified variant sequences were then synthesised and tested for their ability to 
induce T cell responses in PBMC from representative pigs 86 and 71 as before 
(Figure 4.18). The CD4 T cell antigenic region of M was well conserved with only 1 
variant, a related substitution of a histidine for an arginine at position 37, which still 
induced CD4 T cell responses (although not deemed statistically significant) (Figure 
4.18). The NSP513-27 antigenic region had 4 potential amino acid substitutions, all but 
one of which still induced a statistically significant CD8 T cell IFN-γ response. The 
individual 15mers that made up NSP5145-159 were less well conserved however; all 
but one of their 6 variants induced a statistically significant IFN-γ response (although 
4 of these lay outside the consensus sequence of the two peptides and therefore 
probably had no effect on the antigenic region). Whilst there were only 2 amino acid 
substitutions in the NSP5153-170 region, these removed the peptides ability to induce 
an IFN-γ response (Figure 4.18). This is encouraging as clearly some variants 
retained their ability to induce an IFN-γ response, but also in some cases confirms 
that the antigenic region lies in the consensus sequence of two overlapping peptides. 
 
  
135 
 
 
Table 4.6. Assessment of the conservation of identified T cell antigenic regions among different PRRSV-1 isolates and the prototype 
PRRSV-2 strain. The overlapping antigenic peptides NSP5 37-40 (NSP5149-170) are shown as one antigenic region. 
PRRSV Strain Geno-type 
GenBank 
Acc. No. 
M29-43 
MIYALKVSRGRLLGL 
NSP513-27 
FLLWRMMGHAWTPIV 
NSP5149-170 
LHNMLVGDGSFSSAFFLRYFAE  
Olot-91 1.1 X92942 ............... ............... ......................  
Lelystad 1.1 AY588319 ............... ............... ......................  
H2 1.1 JN862511, KJ769655 ............... ............... ......................  
Porcilis 1.1 KF991509 ............... ............... ......................  
Cresa3266 1.1 JF276434 ............... ............... ......................  
195-06 1.1 KJ769659 ............... ............... ......................  
Cresa3249 1.1 JF276433 ............... ............... ......................  
Cresa3267 1.1 JF276435 ............... ............... ......................  
Cresa3256 1.1 JF276432 ............... ............... ......................  
Cresa3262 1.1 JF276431 ........H...... .............L. ......................  
Cresa2982 1.1 JF276430 ............... .............L. ......................  
07V063 1.1 GU737264 ............... ............... ......................  
Lena 1.3 JF802085 ............... ............... ......................  
SU1-Bel 1.3 KJ769664 ............... ............... ......................  
_BJEU06-1_China  GU047344 ............... ........Y...... ......................  
NMEU09-1_China  GU047345 ............... ..............I ...I.....C............  
HKEU16_HongKong  EU076704 ............... .............V. ......................  
VR2332 2 EF536003 ............... .............L. P.HI.....V..A.........  
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FLLWRMMGHAWTPIV 
 
********Y****** 
 
*************L* 
 
*************V* 
 
**************I 
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*H************* 
 
*H*****I*****C* 
 
*H*S*********** 
 
*******V*****V* 
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***I*****C***** 
 
***V*****V***** 
 
LVGDGSFSSAFFLRY 
 
*****C********* 
 
*****V********* 
 
DGSFSSAFFLRYFAE 
 
**C************ 
 
**V************ 
 
MIYALKVSRGRLLGL 
 
 
 
 
 
********H****** 
 
Figure 4.18. Effect of amino acid substitutions in the sequences of identified M and NSP5 antigenic peptides on T cell reactivity. Variant peptides were 
designed and synthesised based on the amino acid substitutions observed in different PRRSV isolates (Table 4.4). PBMC were isolated from pigs 71 and 86 and 
stimulated ex vivo with selected original and variant peptides. IFN-γ expression by CD4 T cells to M29-43 (pig 71) and CD8 T cells to NSP513-27 (pig 71), 
NSP5145-159 (pig 86) and NSP5153-170 (pig 71) peptides were assessed by flow cytometry. Data shown are the mean of duplicate cultures after correction with 
the unstimulated mean and error bars show the SEM. Values were compared to the unstimulated control using a one way ANOVA followed by a Bonferroni’s 
multiple comparisons test; **** p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. 
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4.2.5.6. Potential association of M and NSP5 specific T cell responses with 
defined MHC haplotypes.  
As in Chapter 3, animals were MHC typed in order to determine whether T 
cell responses to identified peptides could be attributed to specific MHC class I and 
II haplotypes (Tables 4.5 and 4.6). With regards to the MHC (SLA) class I, pigs 70, 
71, 72 and 88 were haploidentical heterozygotes, expressing haplotypes Lr-22.0 and 
Lr-35.0. Pig 86, 87 and 89 also shared the haplotype Lr-35.0 with the other animals, 
as well as haplotype Lr-38.0 between themselves. This could suggest that the 
antigenic region NSP5156-167 recognised by pigs 70, 71, 72, 73, 88 and 01 is restricted 
by the SLA-I haplotype Lr-22.0. It is not possible to suggest a specific haplotype 
restriction for the antigenic region NSP5145-159 as the responding pig 00 does not 
share either of its haplotypes with any of the other responding pigs. However, it 
could be speculated that this region is restricted by more than one haplotype, 
potentially Lr-38.0 (taking into account the non-responding pig 89) and Lr-35.0 (in 
the absence of Lr-22.0). The antigenic region NSP513-27 could potentially be 
recognised by multiple haplotypes. Only pigs 86 and 87 respond to the peptide M49-
63 and this could therefore be restricted by the Lr-38.0 (again taking into account the 
non-responding pig 89). The pigs that responded to the CD4 T cell antigenic peptide 
M29-43 (pigs 70, 71, 72 and 88) were haploidentical, sharing both SLA-II haplotypes 
Lr-0.01 and 0.15b, this combination appearing exclusively in these animals 
suggesting restriction by one of these two haplotypes.  
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Table 4.7.  Porcine MHC (SLA) class I low-resolution (Lr) haplotypes of PRRSV infected pigs and CD8 T cell reactivity against 
identified antigenic peptides. 
SLA Class I 
    
Pig SLA-1 SLA-3 SLA-2 Inferred  Haplotype Antigenic Peptide 
00 - - - -   NSP5149-159 
    
11XX 04XX/hb06 04XX 43.0     
01 04XX 04XX/hb06 04XX 04.0     NSP5156-167   
08XX 06XX/07XX 12XX 22.0     
70 08XX 06XX/07XX 12XX 22.0 NSP513-27 
  NSP5156-167 
  
12XX, 13XX 05XX 10XX 35.0     
71 08XX 06XX/07XX 12XX 22.0 NSP513-27 
  NSP5156-167 
  
12XX, 13XX 05XX 10XX 35.0     
72 08XX 06XX/07XX 12XX 22.0 
    
NSP5156-167 
  
12XX, 13XX 05XX 10XX 35.0       
73 08XX 06XX/07XX 12XX 22.0     NSP5156-167   
14XX hb06 06XX 62.0     
86 12XX, 13XX 05XX 10XX 35.0 
  
NSP5149-159 
  
M49-63 
15XX 04XX/hb06 12XX 38.0     
87 12XX, 13XX 05XX 10XX 35.0   NSP5149-159 
  M49-63 
15XX 04XX/hb06 12XX 38.0     
88 08XX 06XX/07XX 12XX 22.0 NSP513-27 
  
NSP5156-167 
  
12XX, 13XX 05XX 10XX 35.0     
89 12XX, 13XX 05XX 10XX 35.0 
        
15XX 04XX/hb06 12XX 38.0         
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Table 4.8.  Porcine MHC (SLA) class II low-resolution (Lr) haplotypes of 
PRRSV infected pigs and CD4 T cell reactivity against identified antigenic 
peptides. 
SLA Class II 
 Pig DRB1 DQB1 DQA Inferred Haplotype Antigenic Peptide 
00 04XX 02XX(0202) 02XX 0.15b   
09XX 04XX 03XX 0.11   
01 01XX 01XX 01XX 0.01 
  
02XX 02XX 02XX 0.02   
70 01XX 01XX 01XX 0.01 M29-43 
04XX 02XX(0202) 02XX 0.15b 
71 01XX 01XX 01XX 0.01 M29-43 
04XX 02XX(0202) 02XX 0.15b 
72 01XX 01XX 01XX 0.01 M29-43 04XX 02XX(0202) 02XX 0.15b 
73 
01XX 01XX 01XX 0.01   
09XX 04XX 03XX 0.11  
06XX 0202/0204 03XX ???   
86 09XX 04XX 03XX 0.11   
04XX 02XX(0202) 02XX 0.15b 
87 09XX 04XX 03XX 0.11 
  
04XX 02XX(0202) 02XX 0.15b   
88 01XX 01XX 01XX 0.01 M29-43 04XX 02XX(0202) 02XX 0.15b 
89 09XX 04XX 03XX 0.11   04XX 02XX(0202) 02XX 0.15b   
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4.3 Discussion 
IFN-γ secreting T cell responses appear important, if not essential for 
resolution of viraemia, in accordance with the published literature [Zuckermann et 
al, 2007]. This study showed, at least in the context of PRRSV SU1-Bel infection, 
that viraemia was cleared before induction of neutralising antibodies suggesting that 
T cell responses could be sufficient to resolve PRRSV infection in certain strains. 
This data supports the results of an earlier study that assessed the immune responses 
induced by infection with SU1-Bel [Morgan et al, 2013]. The ability of PRRSV 
infection to prime both CD4 and CD8 T cells was in accordance with the literature, 
also agreeing with the observed stronger CD4 T cell response following in vitro 
stimulation with PRRSV [Piras et al, 2005]. However, comparison with the 
frequencies of PRRSV peptide specific CD4 and CD8 T cells revealed that 
assessment of PRRSV-specific CD8 T cell responses by stimulation with live virus 
greatly underestimates the true response. It may be speculated that a low level of 
productive PRRSV infection occurs within PBMC and this limits the availability of 
NSPs and trafficking of PRRSV peptides into the ‘direct’ or cytosolic MHC class I 
processing and presentation pathway.  
Strong T cell responses were directed against the M and NSP5 proteins in 
pigs infected with both Olot/91 and SU1-Bel strains. These proteins have been 
identified previously in the literature [Wang et al, 2011, Bautista et al, 1999, 
Burgara-Estrella et al, 2013] but the phenotype of the responding T cells had not yet 
been defined. Indeed, the ability of NSP5 to induce IFN-γ has only been reported in 
one other study to date, and none of the identified antigenic peptides matched those 
identified here [Burgara-Estrella et al, 2013]. The antigenic region ‘M6’ identified as 
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a T cell epitope of a highly pathogenic PRRSV-2 strain by Wang and colleagues 
[2011] contains the peptide M29-43 identified here as a CD4 T cell epitope, which is 
an encouraging finding in the context of a potential pan- or at least broadly cross-
reactive PRRSV vaccine. 
The M protein was recognised by both memory CD4 (CD4+CD8αlow) and 
CD8 (CD4-CD8high) T cells [Gerner et al, 2009] whereas the NSP5 was the target of 
a strong CD8 T cell response. An antigen specific CD8 T cell response is important 
for the control of viral replication, especially in chronic or persistent viral infections, 
but the virus specific CD4 T cell response observed here (Figure 4.3) and in Chapter 
3 suggests that both may be important for the clearance of PRRSV-1. In addition, 
neither of these proteins induced significant amounts of the immunosuppressive 
cytokine IL-10 or the Th2 response driving cytokine IL-4.  
Despite the inter-animal variability, further in-depth phenotyping of the 
responding CD4 and CD8 T cells defined them as having the predominant phenotype 
CD44highCD62LlowCD27low/-CD25-/+ T cells that also displayed a marker of cytotoxic 
degranulation (CD107a) and produced TNF-α.  Based on studies in humans and 
mice the high expression of cell adhesion molecule CD44 and low expression of 
peripheral lymph node homing receptor, CD62L putatively identifies these 
responding T cells as effector or effector memory T cells [Wiesel et al, 2009]. Swine 
workshop cluster 2 (SWC2) has recently been identified as an orthologue of human 
CD27 [Reutner et al, 2012], costimulation of which is important for survival and 
proliferation of activated T cells [Mikkelsen, et al, 2011, Hendriks et al, 2003]. In 
porcine PBMC, both CD27- and CD27+ T cell populations have been distinguished 
suggesting that CD27 expression could define effector (TEM) and central memory 
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(TCM) T cell populations again as described for humans and mice. The IFN-γ+ T cells 
studied here showing low or no expression of CD27 would classify them as TEM 
cells rather than TCM cells based on the human system [Kobiyashi et al,  2006, 
Tomiyama et al,  2004]. Porcine effector memory cells as defined by lack of or low 
CD27 expression have recently been described in the context of classical swine fever 
vaccination [Franzoni et al, 2013]. However, it has also recently been reported that 
both CD27+ and CD27- CD4 T cells respond to recall stimulation with PRRSV or 
swine influenza virus [Reutner et al, 2013].  
CD25 is the IL-2 receptor molecule for the cytokine IL-2, which induces 
proliferation and differentiation of activated T cells and is expressed on the surface 
of activated lymphocytes but is then lost on memory cells [Saalmuller et al, 2002]. 
Co-expression of CD25 and IFN-γ was not observed, with the exception of virus-
specific CD4 T cells, which indicates that the majority of the cells present were IFN-
γ secreting memory T cells or a small proportion of CD25 expressing activated T 
helper cells. It may only be speculated that the increased proportion of virus specific 
CD4 IFN-γ+CD25+ cells could be cells that are becoming additionally reactivated 
due to the cytokine milieu triggered by the live virus infection.  
Dual functional T cells as defined by the simultaneous secretion of IFN-γ and 
TNF-α have been correlated with the quality and robustness of the T cell response 
[Seder et al, 2008] and the ability of the M and NSP5 proteins to stimulate these 
cells further supports the use of these two antigens in future vaccine development. 
CD107a or LAMP1 mobilisation is considered a marker for cytotoxic degranulation 
[Betts et al, 2003] and the majority of the M and NSP5 specific T cells were shown 
to express both IFN-γ and CD107a. PRRSV stimulated T cells also exhibited the 
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ability to mobilise CD107a in conjunction with IFN-γ but displayed a larger 
proportion of IFN-γ single positive cells. CD107a expression has been described on 
porcine CD8 T cells previously [Franzoni et al, 2013] but its expression on porcine 
CD4 T cells has rarely been reported although CD4 cytotoxic activity has been 
described in the context of African Swine fever infection (however, these cells also 
expressed CD8) [Denyer et al, 2006], as well as extensively in humans and mice 
[reviewed in Marshall and Swain, 2011]. Due to limitations on cell numbers and 
availability of anti-porcine antibodies it was not possible to conduct further 
characterisation of the responding T cell subsets, however in the future further 
analysis should be conducted. Areas of interest include additional memory markers 
such as CCR7 and isoforms of CD45, as well as secretion of the cytokine IL-2. 
Further elucidation of porcine T cell memory markers and phenotypes may be 
valuable tools in the quest to better dissect T cell responses, identify immunological 
correlates/surrogates of protection and aid vaccine development for PRRSV and 
other pathogens. 
The epitopes/antigenic peptides on each antigen that the individual pigs 
responded to appeared dependent on the MHC haplotypes of the pigs rather than the 
virus strain they were infected with and certain antigenic regions could potentially be 
attributed to a specific haplotype.  This could be an important finding if vaccination 
in combination with selective breeding for disease resistance was to be considered in 
the control of PRRS. Analysis of the sequence conservation of these antigenic 
peptides showed them to be highly conserved amongst PRRSV-1 strains and in some 
instances with the PRRSV-2 prototype strain. Pigs could still respond to antigenic 
peptides with certain amino acid substitutions identified in divergent strains (for 
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example in NSP5153-170), which is encouraging for vaccine applications when 
considering diverse PRRSV strains in the field [Reviewed in Meng, 2000].  
In conclusion this chapter has identified the M and NSP5 proteins as 
important targets of the T cell response to PRRSV and characterised the responding 
cells as well as identifying specific antigenic regions. Whilst the specific antigenic 
regions may differ from pig to pig, at the very least these two proteins as a whole 
should be evaluated further for their potential inclusion in next generation vaccines 
for the control of PRRSV 
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Chapter 5. Assessment of the immunogenicity and efficacy of an 
experimental particulate vaccine formulation of PRRSV or defined 
T cell antigens 
 
5.1. Rationale 
There is a requirement for the development of vaccines which induce strong 
cellular immune responses to enhance control of PRRSV and also other important 
viral pathogens. Various vaccine delivery systems are being developed and evaluated 
to induce T cell mediated immunity however one strategy which possesses a number 
of desirable features is the use of nanoparticles to deliver vaccine antigen directly to 
dendritic cells (DCs).  The previous Chapters have shown that resolution of PRRSV 
infection is associated with the induction of T cell responses. T cells target a range of 
viral antigens; however the M and NSP5 proteins have been identified as having 
particular vaccine potential since they bear multiple CD8 T cell epitopes, and in the 
case of M also bears CD4 T cell epitopes, as well as being well conserved amongst 
PRRSV isolates [Mokhtar et al, 2014]. This Chapter describes a study to assess the 
immunogenicity and efficacy of nanoparticulate delivery of PRRSV antigens.  
In collaboration with the UCL School of Pharmacy, London, adjuvanted 
vaccine formulations of inactivated PRRSV (as a crude and diverse mixture of 
antigens, which may be recognised by both B cells and T cells) or peptides 
representing the M and NSP5 proteins (T cell antigens) and a recombinant PRRSV 
GP5-M fusion protein (EM4) which does not induce neutralising antibodies in pigs 
(Dr Margarita Garcia-Duran, personal communication) were prepared. Hydrophobic 
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chitosan-based nanoparticles were selected for this study. Chitosan and its 
derivatives are abundantly expressed biological polysaccharides which may be 
formed into nanoparticles [Reviewed in Jayakumar et al, 2010]. Chitosan may offer 
an inherent adjuvant effect, through binding the innate immune sensor, TLR4, and 
has been shown to bind specifically to mannose receptors expressed on DCs [Villiers 
et al, 2009]. It has also been shown that targeting multiple TLRs results in enhanced 
vaccine immunogenicity and efficacy [Querec et al, 2006; Kasturi et al, 2011] and 
therefore a number of pathogen-associated molecular patterns (PAMPs) were 
screened to identify those that exerted potent and complimentary immunostimulatory 
effects on porcine DCs, for inclusion as a molecular adjuvant. Following in vitro 
characterisation of these formulations, groups of pigs were vaccinated and then 
challenged by inoculation of a field strain of PRRSV. Over the course of vaccination 
and subsequent challenge infection, the induction and kinetics of antigen-specific 
antibody and T cell responses were monitored in an attempt to associate immune 
responses with the degree of protection conferred.   
 
5.2. Results 
5.2.1. Summary 
Three particulate vaccine formulations were prepared using hydrophobic 
chitosan: (1) Encapsulation of β-propriolactone inactivated PRRSV and 
encapsulation and coating with the multi-TLR2 and TLR7 agonist Adilipoline 
(Virus-P); (2) Encapsulation of synthetic M and NSP5 peptides, coating with a 
recombinant M-GP5  fusion protein (EM4) (Peptide-P) and inclusion of Adilipoline 
as before (Peptide-P); and (3) negative control empty particles (Empty-P). 
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Characterisation of the formulations showed highly efficient antigen encapsulation 
into and absorption onto the surface of the particles, which were found to be in the 
low µm rather than nm size range and differed significantly in their surface charges 
dependant on their composition. The formulations were additionally screened on 
porcine leukocytes to assess the activation of DCs and monocytes, and the 
presentation of antigens to T cells. Both washed and unwashed particles bearing 
Adilipoline induced strong IL-12 and type I IFN responses from DCs and IL-8 
responses from both DCs and monocytes. All three particle formulations induced 
TNF-α responses from DC subsets and monocytes, suggesting responses induced by 
the chitosan polymer. Both the Virus-P and Peptide-P formulations resulted in the 
stimulation of CD4 and CD8 T cells from PRRSV-immune pigs, with the greatest 
responses being detected in the CD4 T cell population.  
Vaccination with these particulate formulations induced antigen-specific 
antibody responses, which were most pronounced following booster immunisation. 
M and NSP5-specific CD4, but not CD8, T cell IFN-γ reactivity was measurable 
following the booster immunisation in animals vaccinated with Peptide-P. Upon 
challenge, CD4 and CD8 T cell reactivity was detected in all groups, with the 
greatest responses being detected in the Peptide-P vaccinated group. Assessment of 
protection against PRRSV challenge infection revealed that only a minority of 
vaccinated pigs (2/8 from the Peptide-P group and 1/8 from the Virus-P group) 
showed some evidence of enhanced viral clearance.  Assessment of T cell responses 
in the lungs, at the point of resolution of the challenge infection, showed strong M 
and NSP5-specific T cell responses, which were almost exclusively from the CD8 T 
cell population. It can therefore be concluded that this study has provided further 
evidence for the role of M and NSP5-specific T cells, and CD8 T cells in particular, 
149 
 
in the immune response against PRRSV. However, further work is required to 
improve the immunogenicity of these nanoparticle formulations with a particular 
emphasis on enhancing the cross-presentation and activation of CD8 T cells. 
 
 
5.2.2 Design and quality control of particulate vaccines 
A panel of pathogen recognition receptor (PRR) agonists (synthetic multi-
TLR2 and -7 agonists CL513 and Adilipoline – both; TLR-9 agonists CpG ODNs 
21798 (class P), 2216 (class A) and 2007 (class B); TLR-7 agonist imiquimod, and 
TLR-3/RIG-I/MDA-5 agonist poly(I:C)) were tested for their ability to induce type 1 
T cell-driving cytokines, IL-12, TNF-α and IFN-α, by porcine plasmacytoid 
dendritic cells (pDCs) using flow cytometry (Figure 5.1). Both CpG ODN 2007 and 
poly(I:C) induced relatively poor cytokine responses. The other PAMPs induced 
significant cytokine responses, with many pDCs co-expressing all three cytokines. 
However, the multi-TLR ligand Adilipoline sustained statistically significant 
numbers of triple-cytokine expressing pDC down to a dilution of 1:100, and retained 
ability to induce statistically significant numbers of IL-12 producing pDCs at a 
dilution of 1:1000. Adilipoline was therefore selected for inclusion as a molecular 
adjuvant that would complement the TLR4 agonist properties of chitosan. 
  
150 
 
 
Figure 5.1. Screening of pathogen-associated molecular patterns for the 
capacity to stimulate type 1 T cell directing cytokine responses from porcine 
plasmacytoid DCs. Enriched blood DC cultures were stimulated with titrations of a 
panel of pathogen-associated molecular patterns (PAMPs): TLR-2/7 agonists CL531 
and Adilipoline; TLR-9 agonists CpG ODNs 21798 (class P), 2216 (class A) and 
2007 (class B); TLR-7 agonist imiquimod, and TLR-3/RIG-I/MDA-5 agonist 
poly(I:C). Expression of TNF-α, IL-12 and IFN-α by plasmacytoid dendritic cells 
(pDCs) was assessed by flow cytometry as described in Chapter 2.12.5-6. 
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Based on the data presented in Chapters 3 and 4, as well as the assessment of 
immunostimulatory properties of Adilipoline described above, chitosan-based 
particulate formulations were prepared as illustrated in Figure 5.2. The first 
formulation was made by encapsulating β-propriolactone inactivated PRRSV-1 
Olot/91 (Virus-P). The inactivated virus served as a crude and diverse mixture of 
antigens, which may be recognised by both B cells (antibody) and T cells. This 
formulation was adjuvanted by the inclusion of Adilipoline both within and coated to 
the surface of the particles. The second formulation was similarly adjuvanted but 
instead of virus the particles encapsulated synthetic peptides representing the M and 
NSP5 proteins, as T cell antigens (Peptide-P). The peptides were designed as 
overlapping 20mers offset by 10 amino acids spanning the M and the NSP5 protein 
sequences from PRRSV-1 Olot/91 (Appendix B). These particles were additionally 
coated with a recombinant M/GP5 fusion protein fragment (EM4) consisting of the 
main GP5 ectodomain followed by the C-terminal portion of M protein that was 
known to possess a non-neutralising antibody epitope. The third formulation, which 
served as the negative control, consisted of empty chitosan particles (Empty-P). 
Virus-P contained 100 µg total of Adilipoline and 106 TCID50 inactivated PRRSV-1 
Olot/91 per dose. Peptide-P also contained 100 µg total of Adilipoline, as well as 
100 µg of each peptide and 200 µg EM4 protein per dose. 
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 Virus-P                          Peptide-P          Empty-P 
 
 
Figure 5.2. Schematic representation of the three hydrophobic chitosan based 
particles that were formulated and evaluated for immunogenicity and efficacy 
in pigs. 
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5.2.2. Quality control and in vitro assessment of particulate vaccine 
formulations 
The vaccine particle preparations were examined by scanning electron 
microscopy (SEM) to assess whether each formulation of particles were in the 
nanometre size range (Figure 5.3A). Particles displayed a spherical morphology and 
were sized at typically less than 5µm in diameter, ranging up to about 20 µm, 
although the Virus-P tended to be larger. The Virus-P also appeared to collapse more 
easily, possibly due to the volume of antigen that was encapsulated (Figure 5.3A). 
Preparations were also assessed for charge and this analysis showed that the three 
particle formulations differed significantly in their surface charges, which most 
likely reflected their composition (Figure 5.3B). The Empty-P were positively 
charged, and the Peptide-P were even more so, whereas the Virus-P were negatively 
charged.  
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Figure 5.3. Assessment of the morphology, size and charge of particulate 
vaccine formulations. Representative SEM micrographs of chitosan particles (Batch 
2 – boost preparation). Scale bars indicate that the diameter of the majority of the 
particles were in the low micrometre range. The surface charge of the three particle 
formulations prepared for the prime (Batch 1) and booster (Batch 2) doses were 
assessed using the zeta potential using a Zetasizer Nano instrument. Results 
presented are the mean of two measurements of the same sample and error bars 
represent SEM. 
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ELISA analyses were conducted to determine the efficiency of virus or 
peptide encapsulation and coating with EM4 protein (Figure 5.4). This was assessed 
by quantifying antigen in particle-free supernatants. Inactivated PRRSV Olot/91 was 
evaluated using a novel antigen capture ELISA that was established and could detect 
less than 104 TCID50 PRRSV. Based on the starting concentration of 2.5x105 
PRRSV TCID50/ml  in the formulation and a residual concentration of approximately 
1x104 TCID50/ml in the supernatant, the encapsulation efficiency of virus into the 
nanoparticles was calculated to be around 96% efficient (Figure 5.4). The adsorption 
of EM4 protein onto the Peptide-P surface was similarly estimated by quantifying its 
presence in supernatants using a specific antigen-capture ELISA. Based on a starting 
concentration of 50µg/ml of EM4 in the formulation and a residual concentration of 
0.28 µg/ml in the supernatant, the adsorption efficiency was estimated to be over 
99% efficient (Figure 5.4). The coating of EM4 onto the surface of Peptide-P was 
additionally assessed by flow cytometry and showed that ~80% of Peptide-P had 
detectable levels of EM bound to their surface (Figure 5.5). Given the high 
efficiency of EM4-coating, a fluorometric-based biochemical assay was conducted to 
assess the encapsulation of M and NSP5 peptides. Based on the starting total peptide 
concentration of 825 µg/ml in the formulation and a maximal residual concentration 
of 30 µg/ml in the supernatant, the encapsulation of peptide was be estimated to be at 
least 98% efficient (Figure 5.4). Supernatant from Empty-P showed a comparable 
fluorescence to that of one of the Peptide-P batches, which could be due to free 
amine groups on the chitosan giving artifactual results. Assessment of Adilipoline 
incorporation was not possible by ELISA and the complex nature of the compound 
meant it was not readily amenable to assessment by other means e.g. HPLC.    
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Figure 5.4. Assessment of PRRSV, EM4 and peptide incorporation into particle 
formulations. The presence of inactivated PRRSV-1 Olot/91 (Virus) and EM4 
protein in particle-free supernatants were assessed by antigen-capture ELISAs. The 
presence of M and NSP5 peptides in particle-free supernatants was assessed by 
fluorometric OPA assay. Representative standard curves for each assay are 
presented, as are the mean triplicate values of titrations of particle supernatants, and 
error bars represent SEM. ‘Prime’ = vaccine batch 1; ‘Boost’ = vaccine batch 2.   
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Figure 5.5. Assessment of EM4 coating of chitosan particle formulations by flow 
cytometry. The absorption of EM4 protein onto the surface of chitosan particles was 
assessed by staining particles with a specific mAb and visualisation by staining with 
a fluorochrome labelled secondary antibody. Representative dot plots are shown of 
the forward and side scatter properties of each of the three formulations prepared for 
the booster immunisation and their staining following incubation with isotype 
control or EM4 specific mAbs (A). The percentage of cells falling into the positive 
staining gate is graphically presented in panel B. 
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The ability of the vaccine formulations to deliver antigens into MHC 
processing and presentation pathways was assessed in vitro by measuring the 
stimulation of T cell cytokine responses from PBMC isolated from PRRSV-immune 
pigs (pigs 71 and 86 from Animal Experiment 3, Chapter 4). Both the Virus-P and 
Peptide-P formulations resulted in the stimulation of CD4 and CD8 T cells, with the 
greatest IFN-γ and TNF-α responses being detected in the CD4 T cell population 
(Figure 5.6). The greatest proportion of IFN-γ+TNF-α+ CD4 T cells was induced by 
washed and unwashed Virus-P, however the greatest IFN-γ/TNF-α CD8 T cell 
response was induced by washed and unwashed Peptide-P in both pigs. Cytokine 
production induced by all Virus- and Peptide-P preparations from CD4 T cells were 
statistically significant, as was cytokine from CD8 T cells induced by washed 
Peptide-P in pig 71 and both washed and unwashed Peptide-P in pig 86. This data 
suggested that uptake of the antigen-loaded particles by antigen-presenting cells led 
to the processing and presentation of antigen by both MHC class I and II molecules. 
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Figure 5.6. In vitro stimulation of peripheral blood mononuclear cells with 
vaccine particle formulations stimulates CD4 and CD8 T cell responses. PBMC 
from two pigs immune to PRRSV Olot/91 (71 and 86) were stimulated with each of 
the three particulate vaccine formulations (Peptide-, Virus- or Empty-P), which for 
Peptide- and Virus-P were additionally tested with (Washed) and without 
(Unwashed) washing to potentially remove any unbound antigen. IFN-γ and TNF-α 
co-expression by CD4 and CD8 T cells was then assessed by flow cytometry. The 
mean data for triplicate cultures are presented and error bars represent SEM. 
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The vaccine particle formulations were additionally screened in vitro to 
assess the activation of blood DCs and monocytes and further characterise their 
immunostimulatory properties. Cultures of enriched blood DCs, which included both 
pDC and myeloid DC (mDC) subsets, and monocytes were cultured in the presence 
of titrations of particle formulations, which for Peptide- and Virus-P were 
additionally tested with (washed) and without (unwashed) pre-washing to potentially 
remove any unbound Adilipoline. No stimulation and addition of soluble Adilipoline 
were included as negative and positive controls, respectively. After incubation, the 
presence of IL-8, IL-10, IL12 and type I IFN in culture supernatants were assessed 
by cytokine ELISA (Figure 5.7). Statistically significant (p = 0.0001) IL-8 responses 
were induced by both the washed and unwashed adjuvanted particles at all particle 
doses tested. The highest concentration of Empty-P induced an IL-8 response from 
monocytes but this was not detectable in DC cultures. No IL-10 was detected in 
supernatants from DC cultures and only the higher concentrations of Virus-P 
induced a statistically significant (p = 0.0001) monocyte IL-10 response. Whilst not 
detected in monocyte cultures, high levels (statistically significant; p = 0.0001) of 
IL-12 and type I IFN were detected in DC cultures, induced by both Virus- and 
Peptide-P, irrespective of washing, suggesting that particle-associated Adilipoline 
was stimulating these responses.  
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Figure 5.7. Assessment of the cytokine response profiles from porcine DCs and 
monocytes pulsed with vaccine particle formulations. Cultures of enriched blood 
DCs and purified monocytes from naïve pigs were cultured for 18 hours in the 
presence of titrations of particle formulations: particle:cell ratios of 10:1 – blue bars; 
3:1 – orange bars; 1:1 – green bars; and 0.4:1 – red bars).  Both Peptide- and Virus-P 
were tested with (washed) and without (unwashed) washing to remove unbound 
Adilipoline. No stimulation and soluble Adilipoline were included as negative and 
positive controls, respectively. After incubation, the levels of IL-8, IL-10, IL-12 and 
type I IFN were quantified in cell-free culture supernatants by cytokine ELISA. The 
results presented are the mean unstimulated corrected values from triplicate cultures 
and error bars represent SEM.   
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Cytokine responses were further assessed by flow cytometric analysis of 
mixed cultures of enriched blood DCs and monocytes (Figure 5.8) Low percentages 
of monocytes produced IL-12 in response to all of the P preparations (only unwashed 
particles statistically significant; p = 0.01; compared to empty particles at the two 
highest doses) but up to 50% of monocytes produced TNF-α with the various 
preparations; the most being induced by washed Peptide-P (statistically significant; p 
= 0.05; until the lowest dose). High percentages (60-80%) of pDCs produced TNF-α 
in response to stimulation with the highest dose of particles (all preparations 
statistically significant; p = 0.05; at the highest dose), however lower percentages of 
pDCs produced IL-12 upon stimulation (washed particles only statistically 
significant; p = 0.0001; at the highest dose). The preparations that induced the 
greatest percentages of responding cells were the washed Peptide-P (around 80% at 
the highest input of NPs) and to a lesser extent, the Virus-P. CD1+ mDCs produced 
very little IL-12 upon stimulation but the preparations did stimulate the cells to 
produce TNF-α (all preparations statistically significant; p = 0.0001). Adjuvanted 
particles induced IL-12 expression by CD1- mDCs, albeit at low levels (statistically 
significant; p = 0.0001; at the highest dose for both virus-P and unwashed peptide-P; 
and at the second highest dose for washed peptide-P) and induced a more 
pronounced TNF-α response (statistically significant; p ≤ 0.05; for all preps until the 
second lowest dose). It appeared that the chitosan was inducing the TNF-α 
production in the monocytes and the pDCs as evidenced by the lack of statistical 
significance in between the different preparations. 
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Figure 5.8. Assessment of the induction of monocyte and DC subset cytokine responses following in vitro stimulation with vaccine 
particle formulations. Mixed cultures of enriched blood DCs and monocytes from a PRRSV-naïve pig were cultured for 18 hours in the 
presence of titrations of particle formulations, which for Peptide- and Virus-P were additionally tested with (Washed) and without 
(Unwashed) washing to potentially remove any unbound Adilipoline. Unstimulated and soluble Adilipoline were included as negative and 
positive controls, respectively. After, incubation the expression of TNF-α and IL-12 was assessed by flow cytometry. The mean unstimulated-
corrected data for triplicate cultures are presented and error bars represent SEM  
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5.2.3 Assessment of immune responses and protection following experimental 
vaccination in pigs 
Groups of pigs (n=6) were vaccinated twice with each of the vaccine particle 
formulations (Virus-P, Peptide-P and Empty-P) with a three week interval between 
prime and booster inoculations. After a further three weeks, all animals were 
challenged with a UK field strain of PRRSV-1 (215-06) and assessed for protection. 
Over the duration of the experiment, the induction of PRRSV-, M- and NSP5-
specific T cell and antibody responses were monitored and protection assessed by 
measuring viraemia by quantitative RT-PCR. 
  Each vaccine dose was delivered in a volume of 4ml, with 2ml inoculated 
subcutaneously behind each ear. After both prime and boost inoculations, mild local 
reactions were observed in the groups vaccinated with the Virus- and Peptide-P, 
suggesting that the presence of Adilipoline and/or antigens was inducing local 
inflammatory immune responses (Figure 5.9). 
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Figure 5.9. Illustrative photographs of the transient swelling and erythema of 
the skin at sites local to the injection of antigen-loaded, Adilipoline-adjuvanted 
chitosan particles. Photographs were taken 24-hours post-inoculation with either 
Virus-P (pig P14-7512) or Peptide-P (pig P14-7507) are shown. Swellings and mild 
and erythema as indicated by red arrows were observed after both prime and booster 
inoculations with both of the Adilipoline-adjuvanted particles and had diffused by 
48-72 hours post-inoculation. No swelling was observed in the animals inoculated 
with the empty particles. 
 
  
Virus-P Peptide-P 
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Over the course of vaccination and challenge, antigen-specific antibody (Ab) 
and T cell responses were assessed primarily by ELISA and flow cytometry, 
respectively. Assessment of PRRSV-specific Ab using a commercial nucleoprotein 
based ELISA showed that after the booster immunization, specific Ab was detected 
in the Virus-P group, albeit at low levels (not statistically significant compared to 
pre-immunization), which were rapidly boosted (statistically significant; p = 0.001; 
compared to pre-immunization on day 28 post-immunization and thereafter) 
following challenge infection (Figure 5.10). Comparable statistically significant (p = 
0.001)  PRRSV-specific Ab responses were detected in the Peptide- and Empty-P 
groups only from day 56 post-immunization (14 days post-challenge). Assessment of 
EM4-specific Ab showed low levels (not statistically significant compared to pre-
immunization) in the Peptide-P group, which were significantly boosted, becoming 
statistically significant (p = 0.001) following the second immunization (day 28 post-
immunization; Figure 5.10). As expected for this subdominant epitope there was 
little evidence of further boosting upon the challenge infection and levels remained 
low in the Virus- and Empty-P groups. Assessment of serum samples from the 
Virus-P group for their capacity to neutralize infection with PRRSV-1 Olot/91 was 
carried out using a MARC-145 cell based neutralization assay. The results showed 
that only 2 of the six animals had a detectable virus-neutralizing antibody titre 
calculated to be 1:4 (pig 12) and 1:11 (pig 15). 
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Figure 5.10. Assessment of PRRSV-specific antibody responses following 
vaccination and challenge. Longitudinal serum samples were analysed for PRRSV 
specific antibody using a commercial PRRSV N-protein based ELISA and assessed 
for EM4-specificity using an in-house ELISA. Data presented are the mean ELISA 
OD values for each group (n=6) and error bars represent SEM.  
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Following in vitro stimulation of PBMC samples with PRRSV-1 Olot/91 or 
M and NSP5 peptides, IFN-γ and TNF-α co-expression by CD4 and CD8 T cells was 
assessed by flow cytometry. Single cytokine producing cells were also assessed 
however there were very low levels of single IFN-γ+ cells and most IFN-γ+ cells 
were also positive for TNF-α and therefore only dual-positive cells were used for 
further analysis. M and NSP5-specific CD4, but not CD8, T cell reactivity was 
measurable but not statistically significant following the booster immunisation in 
animals vaccinated with the Peptide-P but not in the Virus- or Empty-P groups 
(Figure 5.11). Upon challenge, CD4 and CD8 T cell reactivity was detected in all 
groups; CD4 responses were statistically significant on day 56 after immunisation 
when stimulated with NSP5 (in the peptide-P group; p = 0.001) and stimulated with 
M and virus (in all groups; p ≤ 0.05). CD8 responses were statistically significant (p 
≤ 0.01) on day 56 post-immunization when stimulated with NSP5, M (virus-P and 
blank-P groups), and stimulated with virus (in all groups). The greatest magnitude of 
response was CD4 T cell responses detected in the Peptide-P group in response to 
stimulation with M. No statistically significant responses from CD4 T cells 
(compared to before vaccination) were observed until day 49 post-immunization (7 
days post-challenge (Peptide-P vaccinated group, all stimulations). Assessment of 
PRRSV, M and NSP5 specific IL-2, IL-4 and IL-10 responses was performed on 
days 35 (day 14 post-boost) and 56 (day 14 post-challenge) post-immunization. 
These cytokines were selected as markers to further assess type 1 responses (IL-2), 
potential type 2 responses (IL-4) and potential Treg responses (IL-10).  No IL-4 in 
response to virus or peptide or IL-2 and IL-10 in response to virus stimulation was 
detected (Data not shown). In contrast statistically significant IL-2 responses from 
PBMC from the Peptide-P vaccinated group was measured at both time-points (day 
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35, both NSP5 and M stimulated; p = 0.01; day 56 M stimulated; p = 0.05), and 
statistically significant IL-10 responses from the same group in both NSP5 and M 
stimulated on day 35, which were absent from both the Virus- and Empty-P groups; 
p = 0.05, (Figure 5.12). IL-2 is presented as OD rather than concentration due to 
technical difficulties in reading the standard curve. 
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Figure 5.11. Longitudinal T cell responses to ex vivo stimulation with M, NSP5 
or whole virus. Peripheral blood mononuclear cells (PBMC) collected over the 
course of vaccination and challenge were stimulated with peptides representing the 
PRRSV M and NSP5 proteins or PRRSV-1 Olot/91. IFN-γ and TNF-α co-expression 
by CD4 (open circles) and CD8 T cells (closed circles) was assessed using flow 
cytometry. Data represent the mean background corrected response for each group ± 
SEM. 
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Figure 5.12. Assessment of PRRSV M and NSP5 specific IL-2 and IL-10 
responses post-vaccination and challenge. On days 35 (day 14 post-boost) and 56 
(day 14 post-challenge) PBMC were stimulated with pools of synthetic peptides 
representing PRRSV M and NSP5 proteins and the secretion of IL-2 and IL-10 into 
culture supernatants were assessed after 24 hours by ELISA.  The mean 
unstimulated-corrected data for each group are presented and error bars represent 
SEM. Asterisks denote statistical significance when compared to empty-P as 
analyzed by a two-way analysis of variance (ANOVA) followed by a Dunnett’s 
multiple comparison test *p<0.05, **p<0.01 ***p<0.001.  
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Three weeks after the booster immunisation, all pigs were challenged 
intranasally with 105 TCID50 of a UK field stain PRRSV-1 215-06 [Morgan et al, 
2013]. Animals were scored for PRRS-related clinical signs post-challenge 
(Appendix A) and transient pyrexia and mild clinical signs were observed on day 4 
post-infection in a proportion of animals from each experimental group; Virus-P 
group: 3/6 animals, Peptide-P group: 4/6 animals and Empty-P group: 5/6 animals 
(Figure 5.13).  
 
 
 
Figure 5.13. Assessment of clinical signs following PRRSV challenge infection. 
Rectal temperatures and clinical signs were scored on a daily basis and the summed 
clinical scores for each experimental group are presented. 
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To assess whether these immune responses translated into a degree of protection 
against the challenge PRRSV infection, quantitative (q)RT-PCR was conducted on 
serum samples to assess the RNAemia (Figure 5.14). All animals regardless of 
vaccination group showed significant levels of PRRSV RNA in sera on day 7 post-
challenge. These levels were sustained on day 14 post-challenge for all animals 
except 2 Peptide-P and 1 Virus-P vaccinated animals that had reduced levels. By day 
19, all animals, bar two Virus-P vaccinees, had negligible amounts of viral RNA 
remaining.  
 
 
Figure 5.14. Assessment of PRRSV viraemia post-challenge by intranasal 
inoculation with the UK field PRRSV-1 isolate 215-06. Serum samples were 
collected post-challenge and PRRSV RNA assessed by quantitative RT-PCR. Data 
points represent the mean values for individual animals with lines representing the 
mean values for each group.  
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Upon termination of the experiment, day 21 post-challenge, post-mortem 
examinations were conducted on all animals. Gross lung pathology was only 
identified for a single animal from each of the Virus- and Empty-P groups. Lungs 
were lavaged, cellularity and composition determined, and T cell responses 
measured following stimulation with PRRSV or a pool of M/NSP5 peptides.  For 
technical reasons it was not possible to collect lavage fluid from all animals and 
since responses at this late-stage post-challenge did not differ significantly between 
the groups the compiled results from all animals are presented in Figure 5.15. The 
results showed that there was a significant T cell population in the lavage fluid with 
a greater number of CD8 compared to CD4 T cells. Assessment of antigen-specific 
responses showed a high number of PRRSV and M/NSP5 specific T cells in the 
lavage fluid, which were almost exclusively CD8 T cells. There was a statistically 
significant association between the numbers of PRRSV-specific CD8 T cells in the 
lungs and the virus load of the animals, as assessed by RNAemia, with greater 
numbers of cells being present in those animals that appear to still be actively 
clearing the infection. 
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Figure 5.15. Assessment of specific T cell IFN-γ responses in the lung following PRRSV challenge infection. On day 21 post-challenge, 
lungs were lavaged post-mortem and the numbers and phenotype of T cells calculated by volumetric flow cytometry (A). Isolated cells were 
stimulated with PRRSV or a pool of M and NSP5 peptides. IFN-γ and TNF-α expression by CD4 and CD8 T cells was assessed by flow 
cytometry and the results expressed as both relative proportions (B) and the estimated absolute cell numbers (C). The association between 
antigen-specific CD8 T cells and the virus load of the animals as assessed by RNAaemia is presented (D). Data points represent the mean 
background corrected response for individual animals, irrespective of vaccination group, with bars representing the mean and SEM. 
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5.3. Discussion 
The results presented in this Chapter have shown that hydrophobic chitosan 
may be used to generate particulate formulations using either whole PRRSV or 
defined PRRSV antigens. Co-formulation with the multi-PRR ligand Adilipoline 
further enhanced the immunostimulatory nature of these particles in vitro and 
potentially in vivo. However, despite this encouraging initial data, vaccination with 
these formulations failed to induce strong antigen-specific T cell responses, which 
are believed to be required for the effective control of PRRSV infection. It is worthy 
to note that the Peptide-P formulation appeared to prime CD4 as opposed to CD8 T 
cell responses. Review of the initial in vitro data showed that the formulations were 
capable of directing peptides into the MHC class I pathway but the resultant CD8 T 
cell responses were lower than expected based on earlier results presented in Chapter 
4. Tests also need to be performed to demonstrate that the vaccine formulations do 
not stimulate T cells from naïve animals. The data from the lung lavages following 
the resolution of the PRRSV infection was striking and would further suggest that it 
is a lack of CD8 T cell response that may underlie the poor vaccine efficacy 
observed. On-going analysis is being conducted on additional blood samples to 
further assess whether enhanced control of PRRSV was evident at least in a small 
proportion of vaccinated animals and whether they displayed distinct immunological 
responses. In addition lung biopsies were collected at day 21 post challenge and 
qRT-PCR will be conducted to assess PRRSV load at this time-point.  It was shown 
that in vitro the vaccine formulations did result in cross-presentation of antigen to 
CD8 T cell, albeit with a lower efficiency than to CD4 T cells.  Formulations also 
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induced significant IL-12 and IFN-α, which are both reported to drive cross-
presentation and induction of CD8 T cell responses. The majority of the IL-12 
response was produced by pDCs, with only a small response being detected by CD1- 
mDC.  Recent data has shown CD1- mDC to be orthologous to the CD8α-like mDC 
population defined in humans and mice (J. Edwards and S. Graham, unpublished 
data). CD8α-like mDC express IL-12 [Hochrein et al, 2001] and are highly efficient 
at cross-presenting exogenous antigen to CD8+ T cells [Heath et al, 2004]. Recent 
data from mice depleted of CD8α+ mDCs has shown that this population is essential 
for the induction of CD8+ T cell responses against RNA viruses and intracellular 
bacteria [Shortman and Heath , 2010]. Further work should therefore address how 
efficiently chitosan particles are taken up and processed by CD1- mDC, since 
enhancing the targeting and activation of this DC subset could be crucial to 
enhancing CD8 T cell induction in vivo.  
Interestingly, vaccination with peptide loaded particles induced an M – and 
NSP5-specific IL-10 response from PBMC. Whilst the cellular source of this 
cytokine was not discerned, due to a lack of monoclonal antibodies compatible with 
flow cytometry, it is tempting to speculate that immunisation had induced, in 
addition to CD4+ Th1 cells, a regulatory T cell response. IL-10 production from 
regulatory T cells can play an important role in defining the magnitude and quality of 
Th1 responses and has been shown in a mouse model to determine vaccine efficacy 
against leishmaniasis [Stober et al, 2005]. It therefore appears beneficial to 
investigate further whether the vaccine formulations are indeed inducing Treg 
responses and whether the adoption of alternative antigen delivery systems may alter 
the induction of IL-10 responses and their impact on protective Th1 responses 
[Darrah et al, 2010]. 
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Another factor which needs to be considered in the future is the route of 
inoculation. While the subcutaneous delivery ensured efficient delivery of the 
vaccine in vivo, recent studies have shown that intranasal delivery of an adjuvanted 
PLGA based nanoparticulate formulation of PRRSV antigens can protect against 
challenge infection [Binjawadagi et al, 2014a, 2014b]. The inherent mucoadhesive 
properties of hydrophobic chitosan [Lehr et al,  1992] makes this a viable proposal 
for investigating the induction of mucosal immunity which may be required for 
protection against PRRSV and intranasal immunisation should be considered in 
future work. In summary this experiment has shown promising initial data and has 
laid the groundwork for further optimisation of particulate vaccine formulations for 
the induction of T cell responses to PRRSV and other porcine pathogens.  
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Chapter 6. General Discussion 
6.1. Summary 
PRRSV causes an ever increasing financial burden to pork industries world-
wide and is a major threat to both animal welfare and food-security. Due to the 
replication cycle being prone to mutation and recombination events, PRRSV is a 
rapidly evolving virus. This is most dramatically illustrated by the emergence of 
highly pathogenic variants in South East Asia and Eastern Europe and is occurring 
despite the availability and use of a range of killed and modified live vaccines. 
Moreover, modified live vaccines have been responsible for the spread of PRRSV 
around the globe, with the introduction of vaccine-derived genotype 2 viruses into 
both European and Asian pig populations. Thus, safe and efficacious vaccines are 
urgently sought to improve PRRS control strategies. The development of such 
vaccines is however hindered by a lack of understanding of the immunological basis 
of immunity to PRRSV as well as the diversity of the pathogen. A large proportion 
of the research conducted to date has focussed on the antibody response to PRRSV, 
be it neutralising or non-neutralising, however this response has been deemed to be 
insufficient or potentially unnecessary for clearance of viraemia. It is now generally 
believed that T cell responses are crucial in providing immunity to PRRSV and 
therefore the research presented here addresses the hypothesis that identification of 
the targets of T cell responses within PRRSV would aid the design of more effective 
vaccines.  
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Chapters 3 and 4 describe the first use of a synthetic proteome-wide peptide library 
for identification of T cell antigens and epitopes of PRRSV-1. The library was 
screened on animals in three different experiments that were infected with three 
different strains of PRRSV-1, including the divergent subtype 3 strain SU1-Bel. 
Whilst in some cases different antigenic epitopes were identified, the M protein 
stood out as being the most consistently immunogenic protein recognised by the 
majority of animals. In addition NSP5 was found to be a strong inducer of T cell 
responses in two of the animal experiments. T cell responses to these two proteins 
were further defined in Chapter 4 and their efficacy in a vaccine formulation was 
tested in vivo in Chapter 5. The experimental vaccine induced T cell responses upon 
ex vivo restimulation; however these responses were mainly from CD4 T cells. Data 
from the earlier experiments and analysis of T cell responses in the lungs of 
vaccinated and control animals suggested that CD8 T cells are important in 
protection from infection. These observations may explain why the vaccine 
formulation failed to confer the expected protection against PRRSV challenge 
infection.  
6.2. Discussion 
Whilst the M and NSP5 proteins were identified as major targets of T cell 
responses in both Chapters 3 and 4, animals from the different experiments 
responded to a diverse set of proteins, as well as different epitopes within these 
proteins. This can be attributed to the different MHC haplotypes of the pigs involved 
and the highly polymorphic nature of the porcine MHC (SLA).  In addition, the pigs 
used were not of the same breed (Large White, Dutch Landrace or a cross-breed of 
the two) and therefore may have been another contributory factor to explain the 
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variation in the specificity of T cell responses. In spite of the different pig breeds and 
PRRSV-1 strains used, it is however encouraging that common T cell antigens were 
identified. Any potential vaccine would need to be applicable for a wide range of 
commercial pig breeds representing an array of MHC haplotypes, but it is reassuring 
to note that all animals vaccinated with M and NSP5 mounted specific CD4 T cell 
responses to both antigens and CD8 T cell responses were additionally detected post-
challenge. Determining T cell antigens and potentially epitopes recognised in the 
context of a wide variety of pig breeds/MHC haplotypes and a diverse range of 
PRRSV-1 and -2 strains would provide further rationale for a successful and 
commercially viable PRRSV vaccine.  The increasing threat of emerging highly 
pathogenic PRRSV-1 [Karniychuk et al, 2010; Weesendorp et al, 2013; Morgan et 
al, 2013] and -2 strains [Tian et al, 2007] as well as emergence of novel PRRSV-1 
strains [Chen et al, 2011] means that these strains should also be included in efforts 
to identify well conserved targets for both T cell and neutralising antibody responses.  
Identification of important T cell epitopes allows for the design of MHC-
tetramers; these are complexes of four MHC molecules loaded with peptide and 
fluorescently labelled, and are extremely useful tools in directly assessing antigen-
specific responses. These can be used to confirm and quantify the presence of MHC 
restricted antigen specific T cells [Meidenbauer et al, 2003], as well as to analyse the 
frequency of antigen specific T cell in circulation over the course of infection, an 
approach that has already been used in pigs in the context of foot and mouth disease 
virus [Patch et al,, 2010]. MHC tetramers can also be used in combination with 
functional assays, such as assessment of antigen specific T cell proliferation and 
phenotype. In addition, MHC tetramers have the potential to be used for adoptive T 
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cell transfer, allowing selection and expansion of peptide specific T cells [Knabel et 
al, 2002] for re-introduction into animals. Immunising a naïve animal by adoptive 
transfer of peptide specific T cells followed by challenge would confirm whether the 
cells mediate protection. This type of analysis has rarely been conducted in 
veterinary species; however McKeever et al, [1994] showed that naïve calves 
immunised with Theileria parva specific CD8 T cells were protected from challenge. 
Adoptive transfer in pigs is a realistic proposal due to the availability of several in-
bred MHC homozygous lines of pigs. 
As the lungs are the primary site of PRRSV infection and therefore the early 
immune response, further work comprising an in-depth analysis of the immune 
response in the lung over the course of infection should be conducted. In Chapter 5, 
it was striking to note the magnitude of PRRSV and M/NSP5 specific CD8 T cell 
responses at the point of resolution of challenge infection. The experimental design 
for such a study would be more challenging than longitudinally analysing T cell 
responses in peripheral blood. However, a time-course tissue-harvest design, perhaps 
using inbred MHC-matched lines of pigs, to improve inter-animal variability, could 
be adopted.  Whilst it would need to be considered from both an ethical and practical 
stand-point there would also be an alternative possibility of sequentially lavaging 
lungs from live pigs under anaesthesia.  
 The main marker of T cell responses utilised in this project was IFN-γ and in 
later experiments in tandem with TNF-α.  This stemmed from emerging data that 
enhanced viral control associated with multi-cytokine secreting, so called 
‘polyfunctional’ T cells [Koup and Douek 2011]. The three cytokines that are often 
considered in this context are IFN-γ, TNF-α and IL-2.  It would have therefore been 
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informative to test the IL-2 expression by antigen-specific T cells, especially as it has 
been shown to enhance PRRSV specific T cell responses [Romparto et al, 2006]. 
Unfortunately intracellular staining with anti-IL-2 mAbs proved technically 
problematic and future work should aim to perfect the application of this mAbs flow 
cytometry method to aid further understanding of the potential role of polyfuctional 
anti-viral T cell responses.  
Screening of vaccine induced T cell responses for induction of IL-4 and IL-
10 as markers of an undesirable immune response was conducted as a limited aspect 
of this study. It may be possible that particular viral proteins have an inherent 
propensity for inducing immunosuppressive or Th2 responses, as has been described 
for the induction of Treg responses by PRRSV-2 N protein [Wongyanin et al, 2012]. 
The nature of the vaccine formulation or adjuvant can play a major role in 
determining the cytokine bias of the T cell response, via its effect on DCs. In this 
study, chitosan particles were selected to encapsulate the protein or peptide. 
Encapsulated ovalbumin induced higher levels of both IgG1 and IgG2a in mice 
compared to soluble antigen [Uto et al, 2007] indicating the induction of a balanced 
Th1/Th2 response.  Furthermore, it has been reported that nanoparticle complexes 
(200-600nm) rather than micro particles (2-8µm) have been associated with bias 
towards a Th1 response [Gutierro et al, 2002].  The particulate formulations prepared 
in this study were larger than had been anticipated and were in the low µm rather 
than nm range. It is therefore possible that the larger particle size may have 
contributed to the relatively weak induction of type 1 T cell responses.   
Whilst far from optimal, the particulate vaccine formulation described in 
Chapter 5 demonstrated that it was possible to induce both Ab and CD4 T cell 
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immune responses using protein fragments and synthetic peptides representing M 
and NSP5. The approach of incorporating peptides into the particulate formulation 
was driven out of difficulties to express either the full-length M or NSP5 proteins in 
bacterial or insect cell systems, attributed to the multiple hydrophobic trans-
membrane domains present in both proteins. However, peptide vaccines have several 
advantages over protein; in addition to the relative ease, production can be well 
controlled and the product can be of a high purity. Both CD4 and CD8 T cell 
epitopes can be strung together, regions of the protein that may have an 
immunosuppressive activity can be excluded and the well conserved regions can be 
utilised. In addition, a study by Zhang and colleagues compared the processing of 
long peptides versus intact protein and found that whilst the protein was only 
processed via the endosome, the long peptides were processed via both the 
endosome and the cytosol, leading to better cross presentation [Zhang et al, 2009]. 
This enhancement of presentation by MHC-I molecules has also recently been 
corroborated by Rosalia et al, [2013].  
Chitosan was selected as the polymer core of the particulate vaccines due to 
its inherent immunostimulatory properties [Zhu et al, 2007, Zaharoff et al, 2007]. It 
was recently reported that formulation of an adenoviral vector with chitosan can 
actually have a negative effect on the induction of CD8 T cells which was attributed 
to an inhibition of APC activation [Lemke et al, 2011]. However, this may simply be 
due to the chitosan binding to the virus and interfering with the required expression 
of the vaccine antigen. Nevertheless, if chitosan may also impair the MHC class I 
presentation of antigen, delivered as protein or peptide, then another polymer, such 
as poly-(lactic-co-glycolic acid) (PLGA) could be a better choice for further 
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evaluation. PLGA is a synthetic biodegradable polymer which does not have any 
inherent immunostimulatory properties and is currently FDA approved as a drug 
delivery system [Danhier et al, 2012].  
Another strategy that may enhance vaccine potency and is amenable to 
particulate formulations is the addition of DC targeting moieties [Kreutz et al, 2013]. 
In order to improve the prospects of porcine DC specific targeting a better 
characterisation of porcine DC subsets is required. This could enable delivery of 
antigen into the appropriate cross presentation pathway by selectively targeting the 
CD8α-like DC population [Joffre et al, 2012]. Current knowledge of porcine blood 
DC subsets demonstrates the existence of two mDC populations alongside pDCs 
[Summerfield et al, 2003].  CD1- mDCs have recently been shown to be CD8α-like, 
secreting IL-12 and type I interferon in response to poly(I:C) and CpG ODN  and 
best able to cross present viral antigen to CD8+ T cells (J. Edwards and S. Graham, 
unpublished data). Thus the CD1- mDC represents a model cell population to assess 
targeting of antigen and the consequences on cross-presentation.  
The TLR2/7 ligand Adilipoline was selected as the molecular adjuvant for 
the vaccine formulation due to its ability to sustain a cytokine response from pDCs, 
however if the target cell population is CD1- mDCs, then further assessment of 
molecular adjuvants should be carried out with this in mind. Enhancement of cross-
presentation has been shown in CD8α+ DCs in mice by triggering TLR7, generating 
a strong cytotoxic T cell response [Crespo et al, 2014] but synergistic combinations 
of TLR ligands should be considered, as it has been shown that stimulation of TLRs3 
and 9 can also induce strong cytotoxic T cell responses [Schwarz et al, 2003; Datta et 
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al, 2003]. Targeting these TLRs has also been shown to improve the quality of the 
CD8 T cell response as evaluated by polyfunctional T cells [Kwissa et al, 2007]. 
The route of delivery is another variable that should be considered in the 
development of PRRSV vaccines and future studies should compare mucosal versus 
parenteral routes of inoculation. While intranasal delivery of vaccines is less invasive 
and thus is being promoted for human vaccines, there are concerns whether this 
practical benefit holds true for vaccinating livestock. What is perhaps more relevant 
to livestock is assessing whether intranasal delivery results in the induction of more 
protective mucosal immune responses. There is a growing body of data to suggest 
that targeting DCs at mucosal sites is crucial to programme mucosa-homing T cell 
responses as illustrated by Mikhak et al, [2013] and Sandoval et al, [2013].  
Alternatives to particulate delivery should also be considered for induction of 
CD8 T cell responses. The use of alternate prime/boost vaccination regimens 
employing recombinant replication-deficient adenovirus or MVA vectors are the 
subject intense investigation for the development of vaccines to induce CD8 T cell 
responses against a range of pathogens including HIV [Ratto-Kim et al,  2012], 
Plasmodium spp. [Reyes-Sandoval et al,  2011] and Mycobacterium tuberculosis 
[You et al,  2012.]. A recent study in a mouse model showed that the greatest CD8 
T-cell IFN-γ response in BALF was obtained following intranasal boosting after 
intramuscular priming, which translated into a degree of protection against 
heterotypic influenza virus challenge infection [Lambe et al, 2013]. Another viral 
vector vaccine delivery system that warrants consideration for induction of T cell 
immunity is the use of cytomegaloviruses (CMV). It has recently been shown in the 
primate/SIV model, that a Rhesus monkey CMV vector induced potent T effector 
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memory responses that resulted in an unprecedented degree of protection against 
viral challenge delivered at mucosal sites [Hansen et al, 2009;  Hansen et al,  2011]. 
Porcine CMV was originally identified in 1955 the causative agent of inclusion body 
rhinitis [Done 1955]. In addition to causing rhinitis and generalized infection in new-
born piglets, in utero infection with porcine CMV can cause foetal death. Like other 
CMV, porcine CMV infection may become latent and are rarely eliminated from the 
host; as such, porcine CMV infections have high prevalence in swine herds around 
the world. Despite this, most published research on porcine CMV has been in the 
context of xenotransplantation and the potential risk it may pose to humans 
[Gollackner et al, 2003] rather than from a veterinary perspective. The complete 
sequence of the porcine CMV genome has recently been published which shows it 
more closely related to members of the Roseolovirus genus than with other 
cytomegaloviruses [Gu et al, 2014]. Nevertheless, this data provides a basis to 
explore as to whether this virus can be engineered as a vaccine delivery vector 
[Ranasinghe and Walker 2013]. 
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6.3. CONCLUSION 
Overall, this study has provided data that has improved our understanding of 
the T cell responses induced by PRRSV-1 infection, which appear to play a key role 
in providing protection against reinfection. Using a synthetic peptide library 
spanning the PRRSV proteome, the NSP5 and M proteins were identified as the two 
well conserved antigens targeted by both CD4 helper and CD8 cytotoxic T cells. The 
vaccine potential of these antigens was assessed using a novel particulate 
formulation. Unfortunately, this vaccine induced CD4 but failed to prime a CD8 T 
cell response which likely was responsible for the lack of efficacy observed against 
PRRSV challenge infection. It is hoped that this data will aid development of the 
next generation of PRRS vaccines that are urgently required to improve control of 
this disease.  
 
 
 
 
 
 
 
 
 
190 
 
REFERENCES 
1. http://www.syfpeithi.de/. 
2. www.imtech.res.in/raghava/propred. 
3. www.cbs.dtu.dk/services/NetMHCpan/. 
4. http://www.iedb.org/. 
5. Ait-Ali T., Wilson A.D., Westcott D.G., Clapperton M., Waterfall M., 
Mellencamp M.A., Drew T.W., Bishop S.C., and Archibald A.L., Innate 
Immune Responses to Replication of Porcine Reproductive And Respiratory 
Syndrome Virus in Isolated Swine Alveolar Macrophages. Viral 
Immunology, 2007. 20(1): p. 105-118. 
6. Albina E., Carrat C., and Charley B., Interferon-alpha response to swine 
arterivirus (PoAV), the porcine reproductive and respiratory syndrome virus. 
J Interferon Cytokine Res, 1998. 18(7): p. 485-90. 
7. Aline F., Brand D., Pierre J., Roingeard P., Severine M., Verrier B., and 
Dimier-Poisson I., Dendritic cells loaded with HIV-1 p24 proteins adsorbed 
on surfactant-free anionic PLA nanoparticles induce enhanced cellular 
immune responses against HIV-1 after vaccination. Vaccine, 2009. 27(38): p. 
5284-91. 
8. Allende R., Kutish G.F., Laegreid W., Lu Z., Lewis T.L., Rock D.L., 
Friesen J., Galeota J.A., Doster A.R., and Osorio F.A., Mutations in the 
genome of porcine reproductive and respiratory syndrome virus responsible 
for the attenuation phenotype. Archives of Virology, 2000. 145(6): p. 1149-
1161. 
9. Allende R., Laegreid W.W., Kutish G.F., Galeota J.A., Wills R.W., and 
Osorio F.A., Porcine Reproductive and Respiratory Syndrome Virus: 
Description of Persistence in Individual Pigs upon Experimental Infection. 
Journal of Virology, 2000. 74(22): p. 10834-10837. 
10. Alonso C., Murtaugh M.P., Dee S.A., and Davies P.R., Epidemiological 
study of air filtration systems for preventing PRRSV infection in large sow 
herds. Preventive Veterinary Medicine, 2013. 112(1–2): p. 109-117. 
11. An T.Q., Tian Z.J., Zhou Y.J., Xiao Y., Peng J.M., Chen J., Jiang Y.F., 
Hao X.F., and Tong G.Z., Comparative genomic analysis of five pairs of 
virulent parental/attenuated vaccine strains of PRRSV. Vet Microbiol, 2011. 
191 
 
149(1-2): p. 104-12. 
12. Armengol E., Wiesmuller K.H., Wienhold D., Buttner M., Pfaff E., Jung 
G., and Saalmuller A., Identification of T-cell epitopes in the structural and 
non-structural proteins of classical swine fever virus. J Gen Virol, 2002. 
83(Pt 3): p. 551-60. 
13. Bao D., Wang R., Qiao S., wan B., Wang Y., Liu M., Shi X., Guo J., and 
Zhang G., Antibody-dependent enhancement of PRRSV infection down-
modulates TNF-α and IFN-β transcription in macrophages. Veterinary 
Immunology and Immunopathology, 2013. 156(1–2): p. 128-134. 
14. Barfoed A.M., Blixenkrone-Møller M., Jensen M.H., Bøtner A., and 
Kamstrup S., DNA vaccination of pigs with open reading frame 1–7 of 
PRRS virus. Vaccine, 2004. 22(27–28): p. 3628-3641. 
15. Bautista E.M., Faaberg K.S., Mickelson D., and McGruder E.D., 
Functional Properties of the Predicted Helicase of Porcine Reproductive and 
Respiratory Syndrome Virus. Virology, 2002. 298(2): p. 258-270. 
16. Bautista E.M. and Molitor T.W., Cell-Mediated Immunity to Porcine 
Reproductive and Respiratory Syndrome Virus in Swine. Viral Immunology, 
1997. 10(2): p. 83-94. 
17. Bautista E.M. and Molitor T.W., IFNγ inhibits porcine reproductive and 
respiratory syndrome virus replication in macrophages. Archives of Virology, 
1999. 144(6): p. 1191-1200. 
18. Bautista E.M., Suárez P., and Molitor T.W., T cell responses to the 
structural polypeptides of porcine reproductive and respiratory syndrome 
virus. Archives of Virology, 1999. 144(1): p. 117-134. 
19. Beerens N., Selisko B., Ricagno S., Imbert I., van der Zanden L., Snijder 
E.J., and Canard B., De novo initiation of RNA synthesis by the arterivirus 
RNA-dependent RNA polymerase. J Virol, 2007. 81(16): p. 8384-95. 
20. Benfield D.A., Nelson E., Collins J.E., Harris L., Goyal S.M., Robison D., 
Christianson W.T., Morrison R.B., Gorcyca D., and Chladek D., 
Characterization of swine infertility and respiratory syndrome (SIRS) virus 
(isolate ATCC VR-2332). J Vet Diagn Invest, 1992. 4(2): p. 127-33. 
21. Betts M.R., Brenchley J.M., Price D.A., De Rosa S.C., Douek D.C., 
Roederer M., and Koup R.A., Sensitive and viable identification of antigen-
192 
 
specific CD8+ T cells by a flow cytometric assay for degranulation. Journal 
of Immunological Methods, 2003. 281(1–2): p. 65-78. 
22. Beura L.K., Subramaniam S., Vu H.L., Kwon B., Pattnaik A.K., and 
Osorio F.A., Identification of amino acid residues important for anti-IFN 
activity of porcine reproductive and respiratory syndrome virus non-
structural protein 1. Virology, 2012. 433(2): p. 431-9. 
23. Bharali D.J., Pradhan V., Elkin G., Qi W., Hutson A., Mousa S.A., and 
Thanavala Y., Novel nanoparticles for the delivery of recombinant hepatitis 
B vaccine. Nanomedicine, 2008. 4(4): p. 311-7. 
24. Binjawadagi B., Dwivedi V., Manickam C., Ouyang K., Torrelles J.B., 
and Renukaradhya G.J., An innovative approach to induce cross-protective 
immunity against porcine reproductive and respiratory syndrome virus in the 
lungs of pigs through adjuvanted nanotechnology-based vaccination. Int J 
Nanomedicine, 2014. 9: p. 1519-35. 
25. Binjawadagi B., Dwivedi V., Manickam C., Ouyang K., Wu Y., Lee L.J., 
Torrelles J.B., and Renukaradhya G.J., Adjuvanted poly(lactic-co-
glycolic) acid nanoparticle-entrapped inactivated porcine reproductive and 
respiratory syndrome virus vaccine elicits cross-protective immune response 
in pigs. Int J Nanomedicine, 2014. 9: p. 679-94. 
26. Bivas-Benita M., Romeijn S., Junginger H.E., and Borchard G., PLGA-
PEI nanoparticles for gene delivery to pulmonary epithelium. Eur J Pharm 
Biopharm, 2004. 58(1): p. 1-6. 
27. Blaha T., The "colorful" epidemiology of PRRS. Vet Res, 2000. 31(1): p. 77-
83. 
28. Borghetti P., De Angelis E., Saleri R., Cavalli V., Cacchioli A., Corradi 
A., Mocchegiani E., and Martelli P., Peripheral T lymphocyte changes in 
neonatal piglets: Relationship with growth hormone (GH), prolactin (PRL) 
and cortisol changes. Vet Immunol Immunopathol, 2006. 110(1-2): p. 17-25. 
29. Brierley I., Digard P., and Inglis S.C., Characterization of an efficient 
coronavirus ribosomal frameshifting signal: Requirement for an RNA 
pseudoknot. Cell, 1989. 57(4): p. 537-547. 
30. Brockmeier S.L., Lager K.M., Grubman M.J., Brough D.E., Ettyreddy 
D., Sacco R.E., Gauger P.C., Loving C.L., Vorwald A.C., Kehrli M.E., 
193 
 
Jr., and Lehmkuhl H.D., Adenovirus-mediated expression of interferon-
alpha delays viral replication and reduces disease signs in swine challenged 
with porcine reproductive and respiratory syndrome virus. Viral Immunol, 
2009. 22(3): p. 173-80. 
31. Brown E., Lawson S., Welbon C., Gnanandarajah J., Li J., Murtaugh 
M.P., Nelson E.A., Molina R.M., Zimmerman J.J., Rowland R.R., and 
Fang Y., Antibody response to porcine reproductive and respiratory 
syndrome virus (PRRSV) nonstructural proteins and implications for 
diagnostic detection and differentiation of PRRSV types I and II. Clin 
Vaccine Immunol, 2009. 16(5): p. 628-35. 
32. Burgara-Estrella A., Diaz I., Rodriguez-Gomez I.M., Essler S.E., 
Hernandez J., and Mateu E., Predicted peptides from non-structural 
proteins of porcine reproductive and respiratory syndrome virus are able to 
induce IFN-gamma and IL-10. Viruses, 2013. 5(2): p. 663-77. 
33. Cafruny W.A., Duman R.G., Wong G.H., Said S., Ward-Demo P., 
Rowland R.R., and Nelson E.A., Porcine reproductive and respiratory 
syndrome virus (PRRSV) infection spreads by cell-to-cell transfer in cultured 
MARC-145 cells, is dependent on an intact cytoskeleton, and is suppressed 
by drug-targeting of cell permissiveness to virus infection. Virol J, 2006. 3: 
p. 90. 
34. Cai J., Ma Y., Li J., Yan C., Hu R., and Zhang J., Construction and 
characterization of a recombinant canine adenovirus expressing GP5 and M 
proteins of porcine reproductive and respiratory syndrome virus. Journal of 
Veterinary Medical Science, 2010. 72(8): p. 1035-1040. 
35. Calvert J.G., Slade D.E., Shields S.L., Jolie R., Mannan R.M., 
Ankenbauer R.G., and Welch S.-K.W., CD163 Expression Confers 
Susceptibility to Porcine Reproductive and Respiratory Syndrome Viruses. 
Journal of Virology, 2007. 81(14): p. 7371-7379. 
36. Cao J., Grauwet K., Vermeulen B., Devriendt B., Jiang P., Favoreel H., 
and Nauwynck H., Suppression of NK cell-mediated cytotoxicity against 
PRRSV-infected porcine alveolar macrophages in vitro. Veterinary 
Microbiology, 2013. 164(3–4): p. 261-269. 
37. Cao J., Wang X., Du Y., Li Y., Wang X., and Jiang P., CD40 ligand 
194 
 
expressed in adenovirus can improve the immunogenicity of the GP3 and 
GP5 of porcine reproductive and respiratory syndrome virus in swine. 
Vaccine, 2010. 28(47): p. 7514-22. 
38. Carrasco C.P., Rigden R.C., Schaffner R., Gerber H., Neuhaus V., 
Inumaru S., Takamatsu H., Bertoni G., McCullough K.C., and 
Summerfield A., Porcine dendritic cells generated in vitro: morphological, 
phenotypic and functional properties. Immunology, 2001. 104(2): p. 175-184. 
39. Cazenave C. and Uhlenbeck O.C., RNA template-directed RNA synthesis 
by T7 RNA polymerase. Proceedings of the National Academy of Sciences, 
1994. 91(15): p. 6972-6976. 
40. Chang H.-C., Peng Y.-T., Chang H.-l., Chaung H.-C., and Chung W.-B., 
Phenotypic and functional modulation of bone marrow-derived dendritic cells 
by porcine reproductive and respiratory syndrome virus. Veterinary 
Microbiology, 2008. 129(3–4): p. 281-293. 
41. Chang H.-W., Jeng C.-R., Liu J.J., Lin T.-L., Chang C.-C., Chia M.-Y., 
Tsai Y.-C., and Pang V.F., Reduction of porcine reproductive and 
respiratory syndrome virus (PRRSV) infection in swine alveolar 
macrophages by porcine circovirus 2 (PCV2)-induced interferon-alpha. 
Veterinary Microbiology, 2005. 108(3–4): p. 167-177. 
42. Charerntantanakul W., Platt R., Johnson W., Roof M., Vaughn E., and 
Roth J.A., Immune responses and protection by vaccine and various vaccine 
adjuvant candidates to virulent porcine reproductive and respiratory 
syndrome virus. Veterinary Immunology and Immunopathology, 2006. 
109(1–2): p. 99-115. 
43. Charerntantanakul W., Platt R., and Roth J.A., Effects of porcine 
reproductive and respiratory syndrome virus-infected antigen-presenting cells 
on T cell activation and antiviral cytokine production. Viral Immunology, 
2006. 19(4): p. 646-661. 
44. Chen C., Li J., Bi Y., Yang L., Meng S., Zhou Y., Jia X., Meng S., Sun L., 
and Liu W., Synthetic B- and T-cell epitope peptides of porcine reproductive 
and respiratory syndrome virus with Gp96 as adjuvant induced humoral and 
cell-mediated immunity. Vaccine, 2013. 31(14): p. 1838-47. 
45. Chen N., Cao Z., Yu X., Deng X., Zhao T., Wang L., Liu Q., Li X., and 
195 
 
Tian K., Emergence of novel European genotype porcine reproductive and 
respiratory syndrome virus in mainland China. Journal of General Virology, 
2011. 92(4): p. 880-892. 
46. Chen W., Shi M., Shi F., Mao Y., Tang Z., Zhang B., Zhang H., Chen L., 
Chen L., Xin S., and Wang F.S., HBcAg-pulsed dendritic cell vaccine 
induces Th1 polarization and production of hepatitis B virus-specific 
cytotoxic T lymphocytes. Hepatol Res, 2009. 39(4): p. 355-65. 
47. Chen Z., Lawson S., Sun Z., Zhou X., Guan X., Christopher-Hennings J., 
Nelson E.A., and Fang Y., Identification of two auto-cleavage products of 
nonstructural protein 1 (nsp1) in porcine reproductive and respiratory 
syndrome virus infected cells: nsp1 function as interferon antagonist. 
Virology, 2010. 398(1): p. 87-97. 
48. Chen Z., Li M., He Q., Du J., Zhou L., Ge X., Guo X., and Yang H., The 
amino acid at residue 155 in nonstructural protein 4 of porcine reproductive 
and respiratory syndrome virus contributes to its inhibitory effect for 
interferon-beta transcription in vitro. Virus Res, 2014. 189: p. 226-34. 
49. Chen Z., Zhou X., Lunney J.K., Lawson S., Sun Z., Brown E., 
Christopher-Hennings J., Knudsen D., Nelson E., and Fang Y., 
Immunodominant epitopes in nsp2 of porcine reproductive and respiratory 
syndrome virus are dispensable for replication, but play an important role in 
modulation of the host immune response. Journal of General Virology, 2010. 
91(4): p. 1047-1057. 
50. Chia M.Y., Hsiao S.H., Chan H.T., Do Y.Y., Huang P.L., Chang H.W., 
Tsai Y.C., Lin C.M., Pang V.F., and Jeng C.R., Immunogenicity of 
recombinant GP5 protein of porcine reproductive and respiratory syndrome 
virus expressed in tobacco plant. Vet Immunol Immunopathol, 2010. 135(3-
4): p. 234-42. 
51. Chiou M.-T., Jeng C.-R., Chueh L.-L., Cheng C.-H., and Pang V.F., 
Effects of porcine reproductive and respiratory syndrome virus (isolate tw91) 
on porcine alveolar macrophages in vitro. Veterinary Microbiology, 2000. 
71(1–2): p. 9-25. 
52. Choi Y.K., Goyal S.M., and Joo H.S., Retrospective analysis of etiologic 
agents associated with respiratory diseases in pigs. Canadian Veterinary 
196 
 
Journal, 2003. 44(9): p. 735-737. 
53. Chung H.K. and Chae C., Expression of Interleukin-10 and Interleukin-12 
in Piglets Experimentally Infected with Porcine Reproductive and 
Respiratory Syndrome Virus (PRRSV). Journal of Comparative Pathology, 
2003. 129(2–3): p. 205-212. 
54. Chung H.K., Lee J.H., Kim S.H., and Chae C., Expression of Interferon-α 
and Mx1 Protein in Pigs Acutely Infected with Porcine Reproductive and 
Respiratory Syndrome Virus (PRRSV). Journal of Comparative Pathology, 
2004. 130(4): p. 299-305. 
55. Ciernik I.F., Berzofsky J.A., and Carbone D.P., Induction of cytotoxic T 
lymphocytes and antitumor immunity with DNA vaccines expressing single 
T cell epitopes. The Journal of Immunology, 1996. 156(7): p. 2369-75. 
56. Cohen S.B., Crawley J.B., Kahan M.C., Feldmann M., and Foxwell 
B.M., Interleukin-10 rescues T cells from apoptotic cell death: association 
with an upregulation of Bcl-2. Immunology, 1997. 92(1): p. 1-5. 
57. Conzelmann K.K., Visser N., Van Woensel P., and Thiel H.J., Molecular 
characterization of porcine reproductive and respiratory syndrome virus, a 
member of the arterivirus group. Virology, 1993. 193(1): p. 329-39. 
58. Corrigan O.I. and Li X., Quantifying drug release from PLGA 
nanoparticulates. European Journal of Pharmaceutical Sciences, 2009. 37(3–
4): p. 477-485. 
59. Cousens L.P., Peterson R., Hsu S., Dorner A., Altman J.D., Ahmed R., 
and Biron C.A., Two roads diverged: interferon alpha/beta- and interleukin 
12-mediated pathways in promoting T cell interferon gamma responses 
during viral infection. J Exp Med, 1999. 189(8): p. 1315-28. 
60. Crespo M.I., Zacca E.R., Núñez N.G., Ranocchia R.P., Maccioni M., 
Maletto B.A., Pistoresi-Palencia M.C., and Morón G., TLR7 Triggering 
with Polyuridylic Acid Promotes Cross-Presentation in CD8α+ Conventional 
Dendritic Cells by Enhancing Antigen Preservation and MHC Class I 
Antigen Permanence on the Dendritic Cell Surface. The Journal of 
Immunology, 2013. 190(3): p. 948-960. 
61. Cutler T.D., Wang C., Hoff S.J., Kittawornrat A., and Zimmerman J.J., 
Median infectious dose (ID50) of porcine reproductive and respiratory 
197 
 
syndrome virus isolate MN-184 via aerosol exposure. Veterinary 
Microbiology, 2011. 151(3–4): p. 229-237. 
62. Dai B., Yang L., Yang H., Hu B., Baltimore D., and Wang P., HIV-1 Gag-
specific immunity induced by a lentivector-based vaccine directed to 
dendritic cells. Proceedings of the National Academy of Sciences, 2009. 
106(48): p. 20382-20387. 
63. Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., and Preat 
V., PLGA-based nanoparticles: an overview of biomedical applications. J 
Control Release, 2012. 161(2): p. 505-22. 
64. Darrah P.A., Hegde S.T., Patel D.T., Lindsay R.W., Chen L., Roederer 
M., and Seder R.A., IL-10 production differentially influences the 
magnitude, quality, and protective capacity of Th1 responses depending on 
the vaccine platform. J Exp Med, 2010. 207(7): p. 1421-33. 
65. Das P.B., Dinh P.X., Ansari I.H., de Lima M., Osorio F.A., and Pattnaik 
A.K., The Minor Envelope Glycoproteins GP2a and GP4 of Porcine 
Reproductive and Respiratory Syndrome Virus Interact with the Receptor 
CD163. Journal of Virology, 2010. 84(4): p. 1731-1740. 
66. Datta S.K., Redecke V., Prilliman K.R., Takabayashi K., Corr M., 
Tallant T., DiDonato J., Dziarski R., Akira S., Schoenberger S.P., and 
Raz E., A Subset of Toll-Like Receptor Ligands Induces Cross-presentation 
by Bone Marrow-Derived Dendritic Cells. The Journal of Immunology, 2003. 
170(8): p. 4102-4110. 
67. De Bruin M.G.M., Samsom J.N., Voermans J.J.M., van Rooij E.M.A., De 
Visser Y.E., and Bianchi A.T.J., Effects of a porcine reproductive and 
respiratory syndrome virus infection on the development of the immune 
response against pseudorabies virus. Veterinary Immunology and 
Immunopathology, 2000. 76(1–2): p. 125-135. 
68. Dea S., Gagnon C.A., Mardassi H., Pirzadeh B., and Rogan D., Current 
knowledge on the structural proteins of porcine reproductive and respiratory 
syndrome (PRRS) virus: comparison of the North American and European 
isolates. Archives of Virology, 2000. 145(4): p. 659-688. 
69. Dee S.A., Deen J., Jacobson L., Rossow K.D., Mahlum C., and Pijoan C., 
Laboratory model to evaluate the role of aerosols in the transport of porcine 
198 
 
reproductive and respiratory syndrome virus. Veterinary Record, 2005. 
156(16): p. 501-504. 
70. Delputte P.L., Vanderheijden N., Nauwynck H.J., and Pensaert M.B., 
Involvement of the matrix protein in attachment of porcine reproductive and 
respiratory syndrome virus to a heparinlike receptor on porcine alveolar 
macrophages. J Virol, 2002. 76(9): p. 4312-20. 
71. Den Boon J.A., Snijder E.J., Chirnside E.D., De Vries A.A.F., Horzinek 
M.C., and Spaan W.J.M., Equine arteritis virus is not a togavirus but 
belongs to the coronaviruslike superfamily. Journal of Virology, 1991. 65(6): 
p. 2910-2920. 
72. Denyer M.S., Wileman T.E., Stirling C.M., Zuber B., and Takamatsu 
H.H., Perforin expression can define CD8 positive lymphocyte subsets in 
pigs allowing phenotypic and functional analysis of natural killer, cytotoxic 
T, natural killer T and MHC un-restricted cytotoxic T-cells. Vet Immunol 
Immunopathol, 2006. 110(3-4): p. 279-92. 
73. Department for Environment F.a.R.A., Agriculture in the United 
Kingdom. 2013. 
74. Deres K., Schild H., Wiesmuller K.-H., Jung G., and Rammensee H.-G., 
In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic 
lipopeptide vaccine. Nature, 1989. 342(6249): p. 561-564. 
75. Desrosiers R., Transmission of swine pathogens: different means, different 
needs. Anim Health Res Rev, 2011. 12(1): p. 1-13. 
76. Diaz I., Darwich L., Pappaterra G., Pujols J., and Mateu E., Immune 
responses of pigs after experimental infection with a European strain of 
Porcine reproductive and respiratory syndrome virus. J Gen Virol, 2005. 
86(Pt 7): p. 1943-51. 
77. Díaz I., Darwich L., Pappaterra G., Pujols J., and Mateu E., Different 
European-type vaccines against porcine reproductive and respiratory 
syndrome virus have different immunological properties and confer different 
protection to pigs. Virology, 2006. 351(2): p. 249-259. 
78. Diaz I., Gimeno M., Darwich L., Navarro N., Kuzemtseva L., Lopez S., 
Galindo I., Segales J., Martin M., Pujols J., and Mateu E., 
Characterization of homologous and heterologous adaptive immune 
199 
 
responses in porcine reproductive and respiratory syndrome virus infection. 
Vet Res, 2012. 43: p. 30. 
79. Diaz I., Pujols J., Ganges L., Gimeno M., Darwich L., Domingo M., and 
Mateu E., In silico prediction and ex vivo evaluation of potential T-cell 
epitopes in glycoproteins 4 and 5 and nucleocapsid protein of genotype-I 
(European) of porcine reproductive and respiratory syndrome virus. Vaccine, 
2009. 27(41): p. 5603-11. 
80. Discher D.E. and Eisenberg A., Polymer vesicles. Science, 2002. 
297(5583): p. 967-73. 
81. Disis M.L., Gooley T.A., Rinn K., Davis D., Piepkorn M., Cheever M.A., 
Knutson K.L., and Schiffman K., Generation of T-cell immunity to the 
HER-2/neu protein after active immunization with HER-2/neu peptide-based 
vaccines. J Clin Oncol, 2002. 20(11): p. 2624-32. 
82. Dokland T., The structural biology of PRRSV. Virus Research, 2010. 
154(1–2): p. 86-97. 
83. Done J., An “inclusion body” rhinitis of pigs Vet. Record, 1955. 67: p. 525-
7. 
84. Done S.H., Paton D.J., and White M.E.C., Porcine reproductive and 
respiratory syndrome (PRRS): A review, with emphasis on pathological, 
virological and diagnostic aspects. British Veterinary Journal, 1996. 152(2): 
p. 153-174. 
85. Drew T.W., Classical Swine Fever (hog cholera). in OIE Manual of 
Diagnostic Tests and Vaccines for Terrestrial Animals (mammals, birds and 
bees). 2008. p. 1092–1106. 
86. Duan X., Nauwynck H.J., and Pensaert M.B., Effects of origin and state of 
differentiation and activation of monocytes/macrophages on their 
susceptibility to porcine reproductive and respiratory syndrome virus 
(PRRSV). Arch Virol, 1997. 142(12): p. 2483-97. 
87. Duan X., Nauwynck H.J., and Pensaert M.B., Virus quantification and 
identification of cellular targets in the lungs and lymphoid tissues of pigs at 
different time intervals after inoculation with porcine reproductive and 
respiratory syndrome virus (PRRSV). Vet Microbiol, 1997. 56(1-2): p. 9-19. 
88. Dwivedi V., Manickam C., Binjawadagi B., and Renukaradhya G.J., 
200 
 
PLGA nanoparticle entrapped killed porcine reproductive and respiratory 
syndrome virus vaccine helps in viral clearance in pigs. Veterinary 
Microbiology, 2013. 166(1–2): p. 47-58. 
89. Essler S.E., Ertl W., Deutsch J., Ruetgen B.C., Groiss S., Stadler M., 
Wysoudil B., Gerner W., Ho C.-S., and Saalmueller A., Molecular 
characterization of swine leukocyte antigen gene diversity in purebred 
Pietrain pigs. Animal Genetics, 2013. 44(2): p. 202-205. 
90. Evans C.M., Medley G.F., and Green L.E., Porcine reproductive and 
respiratory syndrome virus (PRRSV) in GB pig herds: farm characteristics 
associated with heterogeneity in seroprevalence. BMC Vet Res, 2008. 4: p. 
48. 
91. Fang Y. and Snijder E.J., The PRRSV replicase: Exploring the 
multifunctionality of an intriguing set of nonstructural proteins. Virus 
Research, 2010. 154(1–2): p. 61-76. 
92. Fang Y., Treffers E.E., Li Y., Tas A., Sun Z., van der Meer Y., de Ru 
A.H., van Veelen P.A., Atkins J.F., Snijder E.J., and Firth A.E., Efficient 
−2 frameshifting by mammalian ribosomes to synthesize an additional 
arterivirus protein. Proceedings of the National Academy of Sciences, 2012. 
109(43): p. E2920–E2928. 
93. Feng Y., Zhao T., Nguyen T., Inui K., Ma Y., Nguyen T.H., Nguyen V.C., 
Liu D., Bui Q.A., To L.T., Wang C., Tian K., and Gao G.F., Porcine 
respiratory and reproductive syndrome virus variants, Vietnam and China, 
2007. Emerg Infect Dis, 2008. 14(11): p. 1774-6. 
94. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram 
P.L., McKenzie I.F., and Plebanski M., Size-dependent immunogenicity: 
therapeutic and protective properties of nano-vaccines against tumors. J 
Immunol, 2004. 173(5): p. 3148-54. 
95. Firth A.E., Zevenhoven-Dobbe J.C., Wills N.M., Go Y.Y., Balasuriya 
U.B.R., Atkins J.F., Snijder E.J., and Posthuma C.C., Discovery of a 
small arterivirus gene that overlaps the GP5 coding sequence and is 
important for virus production. Journal of General Virology, 2011. 92(5): p. 
1097-1106. 
96. Flores-Mendoza L., Silva-Campa E., Reséndiz M., Osorio F.A., and 
201 
 
Hernández J., Porcine Reproductive and Respiratory Syndrome Virus 
Infects Mature Porcine Dendritic Cells and Up-Regulates Interleukin-10 
Production. Clinical and Vaccine Immunology, 2008. 15(4): p. 720-725. 
97. Franke E.D., Hoffman S.L., Sacci J.B., Jr., Wang R., Charoenvit Y., 
Appella E., Chesnut R., Alexander J., Del Guercio M.F., and Sette A., 
Pan DR binding sequence provides T-cell help for induction of protective 
antibodies against Plasmodium yoelii sporozoites. Vaccine, 1999. 17(9-10): 
p. 1201-5. 
98. Franzoni G., Kurkure N.V., Edgar D.S., Everett H.E., Gerner W., 
Bodman-Smith K.B., Crooke H.R., and Graham S.P., Assessment of the 
phenotype and functionality of porcine CD8 T cell responses following 
vaccination with live attenuated classical swine fever virus (CSFV) and 
virulent CSFV challenge. Clin Vaccine Immunol, 2013. 20(10): p. 1604-16. 
99. Fray M.D., Mann G.E., and Charleston B., Validation of an Mx/CAT 
reporter gene assay for the quantification of bovine type-I interferon. J 
Immunol Methods, 2001. 249(1-2): p. 235-44. 
100. Frossard J.-P., Hughes G.J., Westcott D.G., Naidu B., Williamson S., 
Woodger N.G.A., Steinbach F., and Drew T.W., Porcine reproductive and 
respiratory syndrome virus: Genetic diversity of recent British isolates. 
Veterinary Microbiology, 2013. 162(2–4): p. 507-518. 
101. Garcia F., Climent N., Assoumou L., Gil C., Gonzalez N., Alcami J., 
Leon A., Romeu J., Dalmau J., Martinez-Picado J., Lifson J., Autran B., 
Costagliola D., Clotet B., Gatell J.M., Plana M., and Gallart T., A 
therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis, 
2011. 203(4): p. 473-8. 
102. Gatza E. and Okada C.Y., Tumor cell lysate-pulsed dendritic cells are more 
effective than TCR Id protein vaccines for active immunotherapy of T cell 
lymphoma. J Immunol, 2002. 169(9): p. 5227-35. 
103. Geldhof M., Vanhee M., Van Breedam W., Van Doorsselaere J., 
Karniychuk U., and Nauwynck H., Comparison of the efficacy of 
autogenous inactivated Porcine Reproductive and Respiratory Syndrome 
Virus (PRRSV) vaccines with that of commercial vaccines against 
homologous and heterologous challenges. BMC Veterinary Research, 2012. 
202 
 
8(1): p. 182. 
104. Gerner W., Hammer S.E., Wiesmuller K.H., and Saalmuller A., 
Identification of major histocompatibility complex restriction and anchor 
residues of foot-and-mouth disease virus-derived bovine T-cell epitopes. J 
Virol, 2009. 83(9): p. 4039-50. 
105. Gerner W., Kaser T., and Saalmuller A., Porcine T lymphocytes and NK 
cells--an update. Dev Comp Immunol, 2009. 33(3): p. 310-20. 
106. Giger E.V., Puigmarti-Luis J., Schlatter R., Castagner B., Dittrich P.S., 
and Leroux J.C., Gene delivery with bisphosphonate-stabilized calcium 
phosphate nanoparticles. J Control Release, 2011. 150(1): p. 87-93. 
107. Gilboa E. and Vieweg J., Cancer immunotherapy with mRNA-transfected 
dendritic cells. Immunol Rev, 2004. 199: p. 251-63. 
108. Gimeno M., Darwich L., Diaz I., de la Torre E., Pujols J., Martin M., 
Inumaru S., Cano E., Domingo M., Montoya M., and Mateu E., Cytokine 
profiles and phenotype regulation of antigen presenting cells by genotype-I 
porcine reproductive and respiratory syndrome virus isolates. Vet Res, 2011. 
42: p. 9. 
109. Gollackner B., Mueller N.J., Houser S., Qawi I., Soizic D., Knosalla C., 
Buhler L., Dor F.J., Awwad M., Sachs D.H., Cooper D.K., Robson S.C., 
and Fishman J.A., Porcine cytomegalovirus and coagulopathy in pig-to-
primate xenotransplantation. Transplantation, 2003. 75(11): p. 1841-7. 
110. Gu W., Zeng N., Zhou L., Ge X., Guo X., and Yang H., Genomic 
organization and molecular characterization of porcine cytomegalovirus. 
Virology, 2014. 460-461: p. 165-72. 
111. Gudmundsdottir I. and Risatti G.R., Infection of porcine alveolar 
macrophages with recombinant chimeric porcine reproductive and respiratory 
syndrome virus: Effects on cellular gene transcription and virus growth. 
Virus Research, 2009. 145(1): p. 145-150. 
112. Gutierro I., Hernandez R.M., Igartua M., Gascon A.R., and Pedraz J.L., 
Size dependent immune response after subcutaneous, oral and intranasal 
administration of BSA loaded nanospheres. Vaccine, 2002. 21(1-2): p. 67-77. 
113. Guzylack-Piriou L., Balmelli C., McCullough K.C., and Summerfield A., 
Type-A CpG oligonucleotides activate exclusively porcine natural interferon-
203 
 
producing cells to secrete interferon-alpha, tumour necrosis factor-alpha and 
interleukin-12. Immunology, 2004. 112(1): p. 28-37. 
114. Han K., Seo H., Park C., and Chae C., Vaccination of sows against type 2 
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) before 
artificial insemination protects against type 2 PRRSV challenge but does not 
protect against type 1 PRRSV challenge in late gestation. Veterinary 
Research, 2014. 45(1): p. 12. 
115. Han M., Du Y., Song C., and Yoo D., Degradation of CREB-binding 
protein and modulation of type I interferon induction by the zinc finger motif 
of the porcine reproductive and respiratory syndrome virus nsp1α subunit. 
Virus Research, 2013. 172(1–2): p. 54-65. 
116. Hansen M.S., Pors S.E., Jensen H.E., Bille-Hansen V., Bisgaard M., 
Flachs E.M., and Nielsen O.L., An Investigation of the Pathology and 
Pathogens Associated with Porcine Respiratory Disease Complex in 
Denmark. Journal of Comparative Pathology, 2010. 143(2–3): p. 120-131. 
117. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-
Johnson L., Whizin N., Oswald K., Shoemaker R., Swanson T., Legasse 
A.W., Chiuchiolo M.J., Parks C.L., Axthelm M.K., Nelson J.A., Jarvis 
M.A., Piatak M., Lifson J.D., and Picker L.J., Profound early control of 
highly pathogenic SIV by an effector memory T-cell vaccine. Nature, 2011. 
473(7348): p. 523-527. 
118. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., 
Drummond D.D., Legasse A.W., Axthelm M.K., Oswald K., Trubey 
C.M., Piatak M., Jr., Lifson J.D., Nelson J.A., Jarvis M.A., and Picker 
L.J., Effector memory T cell responses are associated with protection of 
rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat 
Med, 2009. 15(3): p. 293-9. 
119. Heath W.R., Belz G.T., Behrens G.M., Smith C.M., Forehan S.P., Parish 
I.A., Davey G.M., Wilson N.S., Carbone F.R., and Villadangos J.A., 
Cross-presentation, dendritic cell subsets, and the generation of immunity to 
cellular antigens. Immunol Rev, 2004. 199: p. 9-26. 
120. Hendriks J., Xiao Y., and Borst J., CD27 Promotes Survival of Activated T 
Cells and Complements CD28 in Generation and Establishment of the 
204 
 
Effector T Cell Pool. The Journal of Experimental Medicine, 2003. 198(9): p. 
1369-1380. 
121. Hiemstra H.S., van Veelen P.A., Schloot N.C., Geluk A., van 
Meijgaarden K.E., Willemen S.J., Leunissen J.A., Benckhuijsen W.E., 
Amons R., de Vries R.R., Roep B.O., Ottenhoff T.H., and Drijfhout J.W., 
Definition of natural T cell antigens with mimicry epitopes obtained from 
dedicated synthetic peptide libraries. J Immunol, 1998. 161(8): p. 4078-82. 
122. Hirosue S., Kourtis I.C., van der Vlies A.J., Hubbell J.A., and Swartz 
M.A., Antigen delivery to dendritic cells by poly(propylene sulfide) 
nanoparticles with disulfide conjugated peptides: Cross-presentation and T 
cell activation. Vaccine, 2010. 28(50): p. 7897-7906. 
123. Ho C.S., Lunney J.K., Franzo-Romain M.H., Martens G.W., Lee Y.J., 
Lee J.H., Wysocki M., Rowland R.R.R., and Smith D.M., Molecular 
characterization of swine leucocyte antigen class I genes in outbred pig 
populations. Animal Genetics, 2009. 40(4): p. 468-478. 
124. Hochrein H., Shortman K., Vremec D., Scott B., Hertzog P., and 
O'Keeffe M., Differential production of IL-12, IFN-alpha, and IFN-gamma 
by mouse dendritic cell subsets. J Immunol, 2001. 166(9): p. 5448-55. 
125. Holtkamp D.J. K.J.B., Neumann E.J., J. J. Zimmerman, H.F. Rotto, 
T.K. Yoder, C. Wang, P.E. Yeske, C.L. Mowrer and C.A. Haley, 
Assessment of the economic impact of porcine reproductive and respiratory 
syndrome virus on United States pork producers. J Swine Health Prod, 2013. 
21(2): p. 72-84. 
126. Hoof I., Peters B., Sidney J., Pedersen L., Sette A., Lund O., Buus S., and 
Nielsen M., NetMHCpan, a method for MHC class I binding prediction 
beyond humans. Immunogenetics, 2009. 61(1): p. 1-13. 
127. Hou J., Wang L., He W., Zhang H., and Feng W.-h., Highly pathogenic 
porcine reproductive and respiratory syndrome virus impairs LPS- and 
poly(I:C)-stimulated tumor necrosis factor-alpha release by inhibiting ERK 
signaling pathway. Virus Research, 2012. 167(1): p. 106-111. 
128. Hou Y.H., Chen J., Tong G.Z., Tian Z.J., Zhou Y.J., Li G.X., Li X., Peng 
J.M., An T.Q., and Yang H.C., A recombinant plasmid co-expressing swine 
ubiquitin and the GP5 encoding-gene of porcine reproductive and respiratory 
205 
 
syndrome virus induces protective immunity in piglets. Vaccine, 2008. 
26(11): p. 1438-1449. 
129. Hou Y.-H., Chen J., Tong G.-Z., Tian Z.-J., Zhou Y.-J., Li G.-X., Li X., 
Peng J.-M., An T.-Q., and Yang H.-C., A recombinant plasmid co-
expressing swine ubiquitin and the GP5 encoding-gene of porcine 
reproductive and respiratory syndrome virus induces protective immunity in 
piglets. Vaccine, 2008. 26(11): p. 1438-1449. 
130. Jayakumar R., Menon D., Manzoor K., Nair S.V., and Tamura H., 
Biomedical applications of chitin and chitosan based nanomaterials—A short 
review. Carbohydrate Polymers, 2010. 82(2): p. 227-232. 
131. Jeong H.J., Song Y.J., Lee S.W., Lee J.B., Park S.Y., Song C.S., Ha 
G.W., Oh J.S., Oh Y.K., and Choi I.S., Comparative measurement of cell-
mediated immune responses of swine to the M and N proteins of porcine 
reproductive and respiratory syndrome virus. Clin Vaccine Immunol, 2010. 
17(4): p. 503-12. 
132. (a) Jiang W., Jiang P., Li Y., Tang J., Wang X., and Ma S., Recombinant 
adenovirus expressing GP5 and M fusion proteins of porcine reproductive 
and respiratory syndrome virus induce both humoral and cell-mediated 
immune responses in mice. Vet Immunol Immunopathol, 2006. 113(1-2): p. 
169-80. 
133. Jiang W., Jiang P., Li Y., Wang X., and Du Y., Analysis of 
immunogenicity of minor envelope protein GP3 of porcine reproductive and 
respiratory syndrome virus in mice. Virus Genes, 2007. 35(3): p. 695-704. 
134. Jiang W., Jiang P., Wang X., Li Y., Du Y., and Wang X., Enhanced 
immune responses of mice inoculated recombinant adenoviruses expressing 
GP5 by fusion with GP3 and/or GP4 of PRRS virus. Virus Res, 2008. 136(1-
2): p. 50-7. 
135. (b) Jiang Y., Xiao S., Fang L., Yu X., Song Y., Niu C., and Chen H., DNA 
vaccines co-expressing GP5 and M proteins of porcine reproductive and 
respiratory syndrome virus (PRRSV) display enhanced immunogenicity. 
Vaccine, 2006. 24(15): p. 2869-2879. 
136. Joffre O.P., Segura E., Savina A., and Amigorena S., Cross-presentation 
by dendritic cells. Nat Rev Immunol, 2012. 12(8): p. 557-69. 
206 
 
137. Johnson C.R., Griggs T.F., Gnanandarajah J., and Murtaugh M.P., 
Novel structural protein in porcine reproductive and respiratory syndrome 
virus encoded by an alternative ORF5 present in all arteriviruses. Journal of 
General Virology, 2011. 92(5): p. 1107-1116. 
138. Johnson W., Roof M., Vaughn E., Christopher-Hennings J., Johnson 
C.R., and Murtaugh M.P., Pathogenic and humoral immune responses to 
porcine reproductive and respiratory syndrome virus (PRRSV) are related to 
viral load in acute infection. Vet Immunol Immunopathol, 2004. 102(3): p. 
233-47. 
139. Jung H.S., Hwang I.W., Kim S.M., Kim C.J., Shin K.S., and Kim H.S., 
Expression of open reading frame 5 protein of porcine reproductive and 
respiratory syndrome virus using semliki forest virus expression system. 
Journal of veterinary science (Suwon-si, Korea), 2002. 3(1): p. 13-18. 
140. Jung S., Unutmaz D., Wong P., Sano G., De los Santos K., Sparwasser 
T., Wu S., Vuthoori S., Ko K., Zavala F., Pamer E.G., Littman D.R., and 
Lang R.A., In vivo depletion of CD11c+ dendritic cells abrogates priming of 
CD8+ T cells by exogenous cell-associated antigens. Immunity, 2002. 17(2): 
p. 211-20. 
141. Kadowaki N., Antonenko S., Lau J.Y., and Liu Y.J., Natural interferon 
alpha/beta-producing cells link innate and adaptive immunity. J Exp Med, 
2000. 192(2): p. 219-26. 
142. Karniychuk U., Geldhof M., Vanhee M., Van Doorsselaere J., Saveleva 
T., and Nauwynck H., Pathogenesis and antigenic characterization of a new 
East European subtype 3 porcine reproductive and respiratory syndrome 
virus isolate. BMC Veterinary Research, 2010. 6(1): p. 30. 
143. Karuppannan A.K., Qiang J., Chang C.C., and Kwang J., A novel 
baculovirus vector shows efficient gene delivery of modified porcine 
reproductive and respiratory syndrome virus antigens and elicits specific 
immune response. Vaccine, 2013. 31(46): p. 5471-5478. 
144. Kaser T., Gerner W., Hammer S.E., Patzl M., and Saalmuller A., 
Detection of Foxp3 protein expression in porcine T lymphocytes. Vet 
Immunol Immunopathol, 2008. 125(1-2): p. 92-101. 
145. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., 
207 
 
Nakaya H.I., Ravindran R., Stewart S., Alam M., Kwissa M., Villinger 
F., Murthy N., Steel J., Jacob J., Hogan R.J., Garcia-Sastre A., Compans 
R., and Pulendran B., Programming the magnitude and persistence of 
antibody responses with innate immunity. Nature, 2011. 470(7335): p. 543-
547. 
146. Kim D.Y., Kaiser T.J., Horlen K., Keith M.L., Taylor L.P., Jolie R., 
Calvert J.G., and Rowland R.R., Insertion and deletion in a non-essential 
region of the nonstructural protein 2 (nsp2) of porcine reproductive and 
respiratory syndrome (PRRS) virus: effects on virulence and 
immunogenicity. Virus Genes, 2009. 38(1): p. 118-28. 
147. Kim O., Sun Y., Lai F.W., Song C., and Yoo D., Modulation of type I 
interferon induction by porcine reproductive and respiratory syndrome virus 
and degradation of CREB-binding protein by non-structural protein 1 in 
MARC-145 and HeLa cells. Virology, 2010. 402(2): p. 315-326. 
148. Kim W.I., Lee D.S., Johnson W., Roof M., Cha S.H., and Yoon K.J., 
Effect of genotypic and biotypic differences among PRRS viruses on the 
serologic assessment of pigs for virus infection. Vet Microbiol, 2007. 123(1-
3): p. 1-14. 
149. Kimman T.G., Cornelissen L.A., Moormann R.J., Rebel J.M., and 
Stockhofe-Zurwieden N., Challenges for porcine reproductive and 
respiratory syndrome virus (PRRSV) vaccinology. Vaccine, 2009. 27(28): p. 
3704-18. 
150. Klechevsky E., Flamar A.L., Cao Y., Blanck J.P., Liu M., O'Bar A., 
Agouna-Deciat O., Klucar P., Thompson-Snipes L., Zurawski S., Reiter 
Y., Palucka A.K., Zurawski G., and Banchereau J., Cross-priming CD8+ 
T cells by targeting antigens to human dendritic cells through DCIR. Blood, 
2010. 116(10): p. 1685-97. 
151. Knabel M., Franz T.J., Schiemann M., Wulf A., Villmow B., Schmidt B., 
Bernhard H., Wagner H., and Busch D.H., Reversible MHC multimer 
staining for functional isolation of T-cell populations and effective adoptive 
transfer. Nat Med, 2002. 8(6): p. 631-637. 
152. Kobayashi N., Kondo T., Takata H., Yokota S., and Takiguchi M., 
Functional and phenotypic analysis of human memory CD8+ T cells 
208 
 
expressing CXCR3. Journal of Leukocyte Biology, 2006. 80(2): p. 320-329. 
153. Koup R.A. and Douek D.C., Vaccine Design for CD8 T Lymphocyte 
Responses. Cold Spring Harbor Perspectives in Medicine, 2011. 1(1). 
154. Kreutz M., Tacken P.J., and Figdor C.G., Targeting dendritic cells--why 
bother? Blood, 2013. 121(15): p. 2836-44. 
155. Kwang J., Zuckermann F., Ross G., Yang S., Osorio F., Liu W., and Low 
S., Antibody and cellular immune responses of swine following 
immunisation with plasmid DNA encoding the PRRS virus ORF's 4, 5, 6 and 
7. Res Vet Sci, 1999. 67(2): p. 199-201. 
156. Kwissa M., Amara R.R., Robinson H.L., Moss B., Alkan S., Jabbar A., 
Villinger F., and Pulendran B., Adjuvanting a DNA vaccine with a TLR9 
ligand plus Flt3 ligand results in enhanced cellular immunity against the 
simian immunodeficiency virus. The Journal of Experimental Medicine, 
2007. 204(11): p. 2733-2746. 
157. Labarque G., Reeth K.V., Nauwynck H., Drexler C., Van Gucht S., and 
Pensaert M., Impact of genetic diversity of European-type porcine 
reproductive and respiratory syndrome virus strains on vaccine efficacy. 
Vaccine, 2004. 22(31-32): p. 4183-90. 
158. Labarque G., Van Gucht S., Van Reeth K., Nauwynck H., and Pensaert 
M., Respiratory tract protection upon challenge of pigs vaccinated with 
attenuated porcine reproductive and respiratory syndrome virus vaccines. 
Veterinary Microbiology, 2003. 95(3): p. 187-197. 
159. Labarque G.G., Nauwynck H.J., Van Reeth K., and Pensaert M.B., 
Effect of cellular changes and onset of humoral immunity on the replication 
of porcine reproductive and respiratory syndrome virus in the lungs of pigs. J 
Gen Virol, 2000. 81(Pt 5): p. 1327-34. 
160. Lambe T., Carey J.B., Li Y., Spencer A.J., van Laarhoven A., Mullarkey 
C.E., Vrdoljak A., Moore A.C., and Gilbert S.C., Immunity against 
heterosubtypic influenza virus induced by adenovirus and MVA expressing 
nucleoprotein and matrix protein-1. Sci Rep, 2013. 3: p. 1443. 
161. Lamontagne L., Page C., Larochelle R., Longtin D., and Magar R., 
Polyclonal activation of B cells occurs in lymphoid organs from porcine 
reproductive and respiratory syndrome virus (PRRSV)-infected pigs. Vet 
209 
 
Immunol Immunopathol, 2001. 82(3-4): p. 165-82. 
162. Lanier L.L., NK cell recognition, in Annual Review of Immunology. 2005. 
p. 225-274. 
163. Lee C. and Yoo D., The small envelope protein of porcine reproductive and 
respiratory syndrome virus possesses ion channel protein-like properties. 
Virology, 2006. 355(1): p. 30-43. 
164. Lee S.M., Schommer S.K., and Kleiboeker S.B., Porcine reproductive and 
respiratory syndrome virus field isolates differ in in vitro interferon 
phenotypes. Vet Immunol Immunopathol, 2004. 102(3): p. 217-31. 
165. Lee S.-M. and Kleiboeker S.B., Porcine arterivirus activates the NF-κB 
pathway through IκB degradation. Virology, 2005. 342(1): p. 47-59. 
166. Lee Y.J., Park C.-K., Nam E., Kim S.-H., Lee O.S., Lee D.S., and Lee C., 
Generation of a porcine alveolar macrophage cell line for the growth of 
porcine reproductive and respiratory syndrome virus. Journal of Virological 
Methods, 2010. 163(2): p. 410-415. 
167. Lehr C.M., Bouwstra J.A., Schacht E.H., and Junginger H.E., In vitro 
evaluation of mucoadhesive properties of chitosan and some other natural 
polymers. International Journal of Pharmaceutics, 1992. 78(1-3): p. 43-48. 
168. Lemke C.D., Graham J.B., Geary S.M., Zamba G., Lubaroff D.M., and 
Salem A.K., Chitosan is a surprising negative modulator of cytotoxic CD8+ 
T cell responses elicited by adenovirus cancer vaccines. Mol Pharm, 2011. 
8(5): p. 1652-61. 
169. Li B., Fang L., Xu Z., Liu S., Gao J., Jiang Y., Chen H., and Xiao S., 
Recombination in vaccine and circulating strains of porcine reproductive and 
respiratory syndrome viruses. Emerg Infect Dis, 2009. 15(12): p. 2032-5. 
170. Li H. and Yang H., Infection of porcine reproductive and respiratory 
syndrome virus suppresses the antibody response to classical swine fever 
virus vaccination. Veterinary Microbiology, 2003. 95(4): p. 295-301. 
171. Li J., Guo D., Huang L., Yin M., Liu Q., Wang Y., Yang C., Liu Y., 
Zhang L., Tian Z., Cai X., Yu L., and Weng C., The interaction between 
host Annexin A2 and viral Nsp9 is beneficial for replication of porcine 
reproductive and respiratory syndrome virus. Virus Res, 2014. 189: p. 106-
13. 
210 
 
172. Li J., Jiang P., Li Y., Wang X., Cao J., Wang X., and Zeshan B., HSP70 
fused with GP3 and GP5 of porcine reproductive and respiratory syndrome 
virus enhanced the immune responses and protective efficacy against virulent 
PRRSV challenge in pigs. Vaccine, 2009. 27(6): p. 825-32. 
173. Li Y., Zhu L., Lawson S.R., and Fang Y., Targeted mutations in a highly 
conserved motif of the nsp1β protein impair the interferon antagonizing 
activity of porcine reproductive and respiratory syndrome virus. Journal of 
General Virology, 2013. 94(Pt 9): p. 1972-1983. 
174. Liu Y.-J., Kanzler H., Soumelis V., and Gilliet M., Dendritic cell lineage, 
plasticity and cross-regulation. Nat Immunol, 2001. 2(7): p. 585-589. 
175. Loemba H.D., Mounir S., Mardassi H., Archambault D., and Dea S., 
Kinetics of humoral immune response to the major structural proteins of the 
porcine reproductive and respiratory syndrome virus. Arch Virol, 1996. 
141(3-4): p. 751-61. 
176. López Fuertes L., Doménech N., Alvarez B., Ezquerra A., Domı́ nguez J., 
Castro J.M., and Alonso F., Analysis of cellular immune response in pigs 
recovered from porcine respiratory and reproductive syndrome infection. 
Virus Research, 1999. 64(1): p. 33-42. 
177. Lopez O.J. and Osorio F.A., Role of neutralizing antibodies in PRRSV 
protective immunity. Vet Immunol Immunopathol, 2004. 102(3): p. 155-63. 
178. Lopez-Fuertes L., Campos E., Domenech N., Ezquerra A., Castro J.M., 
Dominguez J., and Alonso F., Porcine reproductive and respiratory 
syndrome (PRRS) virus down-modulates TNF-alpha production in infected 
macrophages. Virus Res, 2000. 69(1): p. 41-6. 
179. Loving C.L., Brockmeier S.L., and Sacco R.E., Differential type I 
interferon activation and susceptibility of dendritic cell populations to 
porcine arterivirus. Immunology, 2007. 120(2): p. 217-229. 
180. Lowe J.F., Husmann R., Firkins L.D., Zuckermann F.A., and Goldberg 
T.L., Correlation of cell-mediated immunity against porcine reproductive and 
respiratory syndrome virus with protection against reproductive failure in 
sows during outbreaks of porcine reproductive and respiratory syndrome in 
commercial herds. Journal of the American Veterinary Medical Association, 
2005. 226(10): p. 1707-1711. 
211 
 
181. Lunney J.K., Ho C.S., Wysocki M., and Smith D.M., Molecular genetics 
of the swine major histocompatibility complex, the SLA complex. Dev Comp 
Immunol, 2009. 33(3): p. 362-74. 
182. Luo R., Xiao S., Jiang Y., Jin H., Wang D., Liu M., Chen H., and Fang 
L., Porcine reproductive and respiratory syndrome virus (PRRSV) suppresses 
interferon-β production by interfering with the RIG-I signaling pathway. 
Molecular Immunology, 2008. 45(10): p. 2839-2846. 
183. Marshall N.B. and Swain S.L., Cytotoxic CD4 T cells in antiviral 
immunity. J Biomed Biotechnol, 2011. 2011: p. 954602. 
184. Martinez-Lobo F.J., Diez-Fuertes F., Simarro I., Castro J.M., and Prieto 
C., Porcine Reproductive and Respiratory Syndrome Virus isolates differ in 
their susceptibility to neutralization. Vaccine, 2011. 29(40): p. 6928-40. 
185. Mateu E. and Diaz I., The challenge of PRRS immunology. The Veterinary 
Journal, 2008. 177(3): p. 345-351. 
186. Mayordomo J.I., Zorina T., Storkus W.J., Zitvogel L., Celluzzi C., Falo 
L.D., Melief C.J., Ildstad S.T., Kast W.M., Deleo A.B., and et al., Bone 
marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit 
protective and therapeutic antitumour immunity. Nat Med, 1995. 1(12): p. 
1297-302. 
187. McKeever D.J., Taracha E.L., Innes E.L., MacHugh N.D., Awino E., 
Goddeeris B.M., and Morrison W.I., Adoptive transfer of immunity to 
Theileria parva in the CD8+ fraction of responding efferent lymph. 
Proceedings of the National Academy of Sciences, 1994. 91(5): p. 1959-
1963. 
188. McShane H., Behboudi S., Goonetilleke N., Brookes R., and Hill A.V., 
Protective immunity against Mycobacterium tuberculosis induced by 
dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from 
antigen 85A. Infect Immun, 2002. 70(3): p. 1623-6. 
189. Meidenbauer N., Hoffmann T.K., and Donnenberg A.D., Direct 
visualization of antigen-specific T cells using peptide-MHC-class I tetrameric 
complexes. Methods, 2003. 31(2): p. 160-171. 
190. Meier W., Wheeler J., Husmann R., J., Osorio F., and Zuckermann F., 
A., Characteristics of the immune response of pigs to PRRS virus. Vet. Res., 
212 
 
2000. 31(1): p. 41. 
191. Meier W.A., Galeota J., Osorio F.A., Husmann R.J., Schnitzlein W.M., 
and Zuckermann F.A., Gradual development of the interferon-γ response of 
swine to porcine reproductive and respiratory syndrome virus infection or 
vaccination. Virology, 2003. 309(1): p. 18-31. 
192. Melief C.J., Cancer immunotherapy by dendritic cells. Immunity, 2008. 
29(3): p. 372-83. 
193. Meng X.J., Heterogeneity of porcine reproductive and respiratory syndrome 
virus: implications for current vaccine efficacy and future vaccine 
development. Veterinary Microbiology, 2000. 74(4): p. 309-329. 
194. Meng X.J., Paul P.S., Halbur P.G., and Morozov I., Sequence comparison 
of open reading frames 2 to 5 of low and high virulence United States 
isolates of porcine reproductive and respiratory syndrome virus. Journal of 
General Virology, 1995. 76(12): p. 3181-3188. 
195. Mengeling W.L., Lager K.M., and Vorwald A.C., Clinical effects of 
porcine reproductive and respiratory syndrome virus on pigs during the early 
postnatal interval. American Journal of Veterinary Research, 1998. 59(1): p. 
52-55. 
196. Metwally S., Mohamed F., Faaberg K., Burrage T., Prarat M., Moran 
K., Bracht A., Mayr G., Berninger M., Koster L., To T.L., Nguyen V.L., 
Reising M., Landgraf J., Cox L., Lubroth J., and Carrillo C., 
Pathogenicity and Molecular Characterization of Emerging Porcine 
Reproductive and Respiratory Syndrome Virus in Vietnam in 2007. 
Transboundary and Emerging Diseases, 2010. 57(5): p. 315-329. 
197. Meulenberg J.J., Hulst M.M., de Meijer E.J., Moonen P.L., den Besten 
A., de Kluyver E.P., Wensvoort G., and Moormann R.J., Lelystad virus, 
the causative agent of porcine epidemic abortion and respiratory syndrome 
(PEARS), is related to LDV and EAV. Virology, 1993. 192(1): p. 62-72. 
198. Meulenberg J.J., Petersen-den Besten A., De Kluyver E.P., Moormann 
R.J., Schaaper W.M., and Wensvoort G., Characterization of proteins 
encoded by ORFs 2 to 7 of Lelystad virus. Virology, 1995. 206(1): p. 155-63. 
199. Meulenberg J.J.M., Van Nieuwstadt A.P., Van Essen-Zandbergen A., 
and Langeveld J.P.M., Posttranslational processing and identification of a 
213 
 
neutralization domain of the GP4 protein encoded by ORF4 of Lelystad 
virus. Journal of Virology, 1997. 71(8): p. 6061-6067. 
200. Mikhak Z., Strassner J.P., and Luster A.D., Lung dendritic cells imprint T 
cell lung homing and promote lung immunity through the chemokine 
receptor CCR4. J Exp Med, 2013. 210(9): p. 1855-69. 
201. Mikkelsen M., Holst P.J., Bukh J., Thomsen A.R., and Christensen J.P., 
Enhanced and sustained CD8+ T cell responses with an adenoviral vector-
based hepatitis C virus vaccine encoding NS3 linked to the MHC class II 
chaperone protein invariant chain. J Immunol, 2011. 186(4): p. 2355-64. 
202. Mogensen T.H. and Paludan S.R., Molecular Pathways in Virus-Induced 
Cytokine Production. Microbiology and Molecular Biology Reviews, 2001. 
65(1): p. 131-150. 
203. Mokhtar H., Eck M., Morgan S.B., Essler S.E., Frossard J.-P., Ruggli N., 
and Graham S.P., Proteome-wide screening of the European porcine 
reproductive and respiratory syndrome virus reveals a broad range of T cell 
antigen reactivity. Vaccine, 2014(0). 
204. Moore K.W., O'Garra A., Malefyt R.W., Vieira P., and Mosmann T.R., 
Interleukin-10. Annual Review of Immunology, 1993. 11(1): p. 165-190. 
205. Morgan S.B., Graham S.P., Salguero F.J., Sánchez Cordón P.J., 
Mokhtar H., Rebel J.M.J., Weesendorp E., Bodman-Smith K.B., 
Steinbach F., and Frossard J.P., Increased pathogenicity of European 
porcine reproductive and respiratory syndrome virus is associated with 
enhanced adaptive responses and viral clearance. Veterinary Microbiology, 
2013. 163(1–2): p. 13-22. 
206. Murtaugh M., Yuan S., and Faaberg K., Appearance of Novel PRRSV 
Isolates by Recombination in the Natural Environment, in The Nidoviruses, 
E. Lavi, S. Weiss, and S. Hingley, Editors. 2001, Springer US. p. 31-36. 
207. Murtaugh M.P., Elam M.R., and Kakach L.T., Comparison of the 
structural protein coding sequences of the VR-2332 and Lelystad virus 
strains of the PRRS virus. Archives of Virology, 1995. 140(8): p. 1451-1460. 
208. Murtaugh M.P., Xiao Z., and Zuckermann F., Immunological responses 
of swine to porcine reproductive and respiratory syndrome virus infection. 
Viral Immunol, 2002. 15(4): p. 533-47. 
214 
 
209. Nchinda G., Amadu D., Trumpfheller C., Mizenina O., Uberla K., and 
Steinman R.M., Dendritic cell targeted HIV gag protein vaccine provides 
help to a DNA vaccine including mobilization of protective CD8+ T cells. 
Proc Natl Acad Sci U S A, 2010. 107(9): p. 4281-6. 
210. Nedialkova D.D., Gorbalenya A.E., and Snijder E.J., Arterivirus Nsp1 
modulates the accumulation of minus-strand templates to control the relative 
abundance of viral mRNAs. PLoS Pathog, 2010. 6(2): p. e1000772. 
211. Nelson E.A., Christopher-Hennings J., Drew T., Wensvoort G., Collins 
J.E., and Benfield D.A., Differentiation of U.S. and European isolates of 
porcine reproductive and respiratory syndrome virus by monoclonal 
antibodies. J Clin Microbiol, 1993. 31(12): p. 3184-9. 
212. Nembrini C., Stano A., Dane K.Y., Ballester M., van der Vlies A.J., 
Marsland B.J., Swartz M.A., and Hubbell J.A., Nanoparticle conjugation 
of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. 
Proc Natl Acad Sci U S A, 2011. 108(44): p. E989-97. 
213. Neumann E.J., Kliebenstein J.B., Johnson C.D., Mabry J.W., Bush E.J., 
Seitzinger A.H., Green A.L., and Zimmerman J.J., Assessment of the 
economic impact of porcine reproductive and respiratory syndrome on swine 
production in the United States. J Am Vet Med Assoc, 2005. 227(3): p. 385-
92. 
214. Nielsen J., Bøtner A., Tingstedt J.E., Aasted B., Johnsen C.K., Riber U., 
and Lind P., In utero infection with porcine reproductive and respiratory 
syndrome virus modulates leukocyte subpopulations in peripheral blood and 
bronchoalveolar fluid of surviving piglets. Veterinary Immunology and 
Immunopathology, 2003. 93(3–4): p. 135-151. 
215. Nobs L., Buchegger F., Gurny R., and Allemann E., Poly(lactic acid) 
nanoparticles labeled with biologically active Neutravidin for active 
targeting. Eur J Pharm Biopharm, 2004. 58(3): p. 483-90. 
216. OIE W.O.f.A.H., PRRS: the disease, its diagnosis, prevention and control. 
Report Of The OIE Ad Hoc Group On Porcine Reproductive Respiratory 
Syndrome, 2008. Appendices IV and V. 
217. Olin M.R., Batista L., Xiao Z., Dee S.A., Murtaugh M.P., Pijoan C.C., 
and Molitor T.W., γδ Lymphocyte Response to Porcine Reproductive and 
215 
 
Respiratory Syndrome Virus. Viral Immunology, 2005. 18(3): p. 490-499. 
218. Opriessnig T., Halbur P.G., Yoon K.J., Pogranichniy R.M., Harmon 
K.M., Evans R., Key K.F., Pallares F.J., Thomas P., and Meng X.J., 
Comparison of Molecular and Biological Characteristics of a Modified Live 
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Vaccine 
(Ingelvac PRRS MLV), the Parent Strain of the Vaccine (ATCC VR2332), 
ATCC VR2385, and Two Recent Field Isolates of PRRSV. Journal of 
Virology, 2002. 76(23): p. 11837-11844. 
219. Ostrowski M., Galeota J.A., Jar A.M., Platt K.B., Osorio F.A., and 
Lopez O.J., Identification of neutralizing and nonneutralizing epitopes in the 
porcine reproductive and respiratory syndrome virus GP5 ectodomain. J 
Virol, 2002. 76(9): p. 4241-50. 
220. Otake S., Dee S., Corzo C., Oliveira S., and Deen J., Long-distance 
airborne transport of infectious PRRSV and Mycoplasma hyopneumoniae 
from a swine population infected with multiple viral variants. Vet Microbiol, 
2010. 145(3-4): p. 198-208. 
221. Oussoren C. and Storm G., Liposomes to target the lymphatics by 
subcutaneous administration. Adv Drug Deliv Rev, 2001. 50(1-2): p. 143-56. 
222. Ozawa Y., Suda T., Nagata T., Hashimoto D., Nakamura Y., Enomoto 
N., Inui N., Koide Y., Nakamura H., and Chida K., Mucosal vaccine using 
CTL epitope-pulsed dendritic cell confers protection for intracellular 
pathogen. Am J Respir Cell Mol Biol, 2009. 41(4): p. 440-8. 
223. Parida R., Choi I.-S., Peterson D.A., Pattnaik A.K., Laegreid W., 
Zuckermann F.A., and Osorio F.A., Location of T-cell epitopes in 
nonstructural proteins 9 and 10 of type-II porcine reproductive and 
respiratory syndrome virus. Virus Research, 2012. 169(1): p. 13-21. 
224. Park C., Seo H.W., Han K., Kang I., and Chae C., Evaluation of the 
efficacy of a new modified live porcine reproductive and respiratory 
syndrome virus (PRRSV) vaccine (Fostera PRRS) against heterologous 
PRRSV challenge. Veterinary Microbiology, 2014. 172(3–4): p. 432-442. 
225. Park J.Y., Kim H.S., and Seo S.H., Characterization of interaction between 
porcine reproductive and respiratory syndrome virus and porcine dendritic 
cells. J Microbiol Biotechnol, 2008. 18(10): p. 1709-16. 
216 
 
226. Park K.S., Tae J., Choi B., Kim Y.S., Moon C., Kim S.H., Lee H.S., Kim 
J., Kim J., Park J., Lee J.H., Lee J.E., Joh J.W., and Kim S., 
Characterization, in vitro cytotoxicity assessment, and in vivo visualization 
of multimodal, RITC-labeled, silica-coated magnetic nanoparticles for 
labeling human cord blood-derived mesenchymal stem cells. Nanomedicine, 
2010. 6(2): p. 263-76. 
227. Pasternak A.O., Spaan W.J.M., and Snijder E.J., Nidovirus transcription: 
How to make sense...? Journal of General Virology, 2006. 87(6): p. 1403-
1421. 
228. Patch J.R., Pedersen L.E., Toka F.N., Moraes M., Grubman M.J., 
Nielsen M., Jungersen G., Buus S., and Golde W.T., Induction of Foot-
and-Mouth Disease Virus-Specific Cytotoxic T Cell Killing by Vaccination. 
Clinical and Vaccine Immunology, 2011. 18(2): p. 280-288. 
229. Patel D., Nan Y., Shen M., Ritthipichai K., Zhu X., and Zhang Y.J., 
Porcine reproductive and respiratory syndrome virus inhibits type I interferon 
signaling by blocking STAT1/STAT2 nuclear translocation. J Virol, 2010. 
84(21): p. 11045-55. 
230. Patton J.B., Rowland R.R., Yoo D., and Chang K.-O., Modulation of 
CD163 receptor expression and replication of porcine reproductive and 
respiratory syndrome virus in porcine macrophages. Virus Research, 2009. 
140(1–2): p. 161-171. 
231. Pejsak Z., Stadejek T., and Markowska-Daniel I., Clinical signs and 
economic losses caused by porcine reproductive and respiratory syndrome 
virus in a large breeding farm. Vet Microbiol, 1997. 55(1-4): p. 317-22. 
232. Peng Y.T., Chaung H.C., Chang H.L., Chang H.C., and Chung W.B., 
Modulations of phenotype and cytokine expression of porcine bone marrow-
derived dendritic cells by porcine reproductive and respiratory syndrome 
virus. Vet Microbiol, 2009. 136(3-4): p. 359-65. 
233. Petrini S., Ramadori G., Villa R., Borghetti P., de Angelis E., Cantoni A., 
Corradi A., Amici A., and Ferrari M., Evaluation of Different DNA 
Vaccines against Porcine Reproductive and Respiratory Syndrome (PRRS) in 
Pigs. Vaccines, 2013. 1(4): p. 463-480. 
234. Piqueras B., Connolly J., Freitas H., Palucka A.K., and Banchereau J., 
217 
 
Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 
waves of distinct chemokines to recruit immune effectors. Blood, 2006. 
107(7): p. 2613-8. 
235. Piras F., Bollard S., Laval F., Joisel F., Reynaud G., Charreyre C., 
Andreoni C., and Juillard V., Porcine reproductive and respiratory 
syndrome (PRRS) virus-specific interferon-gamma(+) T-cell responses after 
PRRS virus infection or vaccination with an inactivated PRRS vaccine. Viral 
immunology, 2005. 18(2): p. 381-389. 
236. Pirzadeh B. and Dea S., Immune response in pigs vaccinated with plasmid 
DNA encoding ORF5 of porcine reproductive and respiratory syndrome 
virus. Journal of General Virology, 1998. 79(5): p. 989-99. 
237. Plana J., Vayreda M., Vilarrasa J., Bastons M., Rosell R., Martinez M., 
San Gabriel A., Pujols J., Badiola J.L., Ramos J.A., and Domingo M., 
Porcine epidemic abortion and respiratory syndrome (mystery swine disease). 
Isolation in Spain of the causative agent and experimental reproduction of the 
disease. Veterinary Microbiology, 1992. 33(1–4): p. 203-211. 
238. Plana-Durán J., Bastons M., Urniza A., Vayreda M., Vilà X., and Mañé 
H., Efficacy of an inactivated vaccine for prevention of reproductive failure 
induced by porcine reproductive and respiratory syndrome virus. Veterinary 
Microbiology, 1997. 55(1–4): p. 361-370. 
239. Posthuma C.C., Pedersen K.W., Lu Z., Joosten R.G., Roos N., 
Zevenhoven-Dobbe J.C., and Snijder E.J., Formation of the arterivirus 
replication/transcription complex: a key role for nonstructural protein 3 in the 
remodeling of intracellular membranes. J Virol, 2008. 82(9): p. 4480-91. 
240. Prieto C., Alvarez E., Martinez-Lobo F.J., Simarro I., and Castro J.M., 
Similarity of European porcine reproductive and respiratory syndrome virus 
strains to vaccine strain is not necessarily predictive of the degree of 
protective immunity conferred. Vet J, 2008. 175(3): p. 356-63. 
241. Prieto C., Martínez-Lobo F.J., Díez-Fuertes F., Aguilar-Calvo P., 
Simarro I., and Castro J.M., Immunisation of pigs with a major envelope 
protein sub-unit vaccine against porcine reproductive and respiratory 
syndrome virus (PRRSV) results in enhanced clinical disease following 
experimental challenge. The Veterinary Journal, 2011. 189(3): p. 323-329. 
218 
 
242. Qiao S., Jiang Z., Tian X., Wang R., Xing G., Wan B., Bao D., Liu Y., 
Hao H., Guo J., and Zhang G., Porcine FcgammaRIIb mediates 
enhancement of porcine reproductive and respiratory syndrome virus 
(PRRSV) infection. PLoS One, 2011. 6(12): p. e28721. 
243. Qiu H.J., Tian Z.J., Tong G.Z., Zhou Y.J., Ni J.Q., Luo Y.Z., and Cai 
X.H., Protective immunity induced by a recombinant pseudorabies virus 
expressing the GP5 of porcine reproductive and respiratory syndrome virus 
in piglets. Veterinary Immunology and Immunopathology, 2005. 106(3-4): p. 
309-319. 
244. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., 
Akira S., Ahmed R., and Pulendran B., Yellow fever vaccine YF-17D 
activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate 
polyvalent immunity. J Exp Med, 2006. 203(2): p. 413-24. 
245. Ranasinghe S. and Walker B.D., Programming CMV for vaccine vector 
design. Nat Biotech, 2013. 31(9): p. 811-812. 
246. Rasmussen T.B., Reimann I., Uttenthal Å., Leifer I., Depner K., 
Schirrmeier H., and Beer M., Generation of recombinant pestiviruses using 
a full-genome amplification strategy. Veterinary Microbiology, 2010. 142(1–
2): p. 13-17. 
247. Ratto-Kim S., Currier J.R., Cox J.H., Excler J.-L., Valencia-Micolta A., 
Thelian D., Lo V., Sayeed E., Polonis V.R., Earl P.L., Moss B., Robb 
M.L., Michael N.L., Kim J.H., and Marovich M.A., Heterologous Prime-
Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular 
Immune Responses to HIV Proteins Than Homologous Regimens. PLoS 
ONE, 2012. 7(9): p. e45840. 
248. Reddy S.T., Swartz M.A., and Hubbell J.A., Targeting dendritic cells with 
biomaterials: developing the next generation of vaccines. Trends Immunol, 
2006. 27(12): p. 573-9. 
249. Reiner G., Fresen C., Bronnert S., and Willems H., Porcine Reproductive 
and Respiratory Syndrome Virus (PRRSV) infection in wild boars. Vet 
Microbiol, 2009. 136(3-4): p. 250-8. 
250. Renukaradhya G.J., Alekseev K., Jung K., Fang Y., and Saif L.J., 
Porcine reproductive and respiratory syndrome virus-induced 
219 
 
immunosuppression exacerbates the inflammatory response to porcine 
respiratory coronavirus in pigs. Viral Immunol, 2010. 23(5): p. 457-66. 
251. Reutner K., Leitner J., Essler S.E., Witter K., Patzl M., Steinberger P., 
Saalmuller A., and Gerner W., Porcine CD27: identification, expression 
and functional aspects in lymphocyte subsets in swine. Dev Comp Immunol, 
2012. 38(2): p. 321-31. 
252. Reutner K., Leitner J., Mullebner A., Ladinig A., Essler S.E., Duvigneau 
J.C., Ritzmann M., Steinberger P., Saalmuller A., and Gerner W., CD27 
expression discriminates porcine T helper cells with functionally distinct 
properties. Vet Res, 2013. 44: p. 18. 
253. Reyes-Sandoval A., Wyllie D.H., Bauza K., Milicic A., Forbes E.K., 
Rollier C.S., and Hill A.V., CD8+ T effector memory cells protect against 
liver-stage malaria. J Immunol, 2011. 187(3): p. 1347-57. 
254. Richardson J., The Cost of Endemic Disease in Pig Production. The Pig 
Journal, 2011. 65: p. 10-17. 
255. Robinson S.R., Figueiredo M.C., Abrahante J.E., and Murtaugh M.P., 
Immune response to ORF5a protein immunization is not protective against 
porcine reproductive and respiratory syndrome virus infection. Veterinary 
Microbiology, 2013. 164(3–4): p. 281-285. 
256. Rompato G., Ling E., Chen Z., Van Kruiningen H., and Garmendia 
A.E., Positive inductive effect of IL-2 on virus-specific cellular responses 
elicited by a PRRSV-ORF7 DNA vaccine in swine. Veterinary Immunology 
and Immunopathology, 2006. 109(1–2): p. 151-160. 
257. Ropp S.L., Wees C.E.M., Fang Y., Nelson E.A., Rossow K.D., Bien M., 
Arndt B., Preszler S., Steen P., Christopher-Hennings J., Collins J.E., 
Benfield D.A., and Faaberg K.S., Characterization of Emerging European-
Like Porcine Reproductive and Respiratory Syndrome Virus Isolates in the 
United States. Journal of Virology, 2004. 78(7): p. 3684-3703. 
258. Rosalia R.A., Quakkelaar E.D., Redeker A., Khan S., Camps M., 
Drijfhout J.W., Silva A.L., Jiskoot W., van Hall T., van Veelen P.A., 
Janssen G., Franken K., Cruz L.J., Tromp A., Oostendorp J., van der 
Burg S.H., Ossendorp F., and Melief C.J.M., Dendritic cells process 
synthetic long peptides better than whole protein, improving antigen 
220 
 
presentation and T-cell activation. European Journal of Immunology, 2013. 
43(10): p. 2554-2565. 
259. Rowland R.R., Robinson B., Stefanick J., Kim T.S., Guanghua L., 
Lawson S.R., and Benfield D.A., Inhibition of porcine reproductive and 
respiratory syndrome virus by interferon-gamma and recovery of virus 
replication with 2-aminopurine. Arch Virol, 2001. 146(3): p. 539-55. 
260. Saalmuller A., Werner T., and Fachinger V., T-helper cells from naive to 
committed. Vet Immunol Immunopathol, 2002. 87(3-4): p. 137-45. 
261. Sancho D., Mourao-Sa D., Joffre O.P., Schulz O., Rogers N.C., 
Pennington D.J., Carlyle J.R., and Reis e Sousa C., Tumor therapy in mice 
via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest, 
2008. 118(6): p. 2098-110. 
262. Sandoval F., Terme M., Nizard M., Badoual C., Bureau M.F., 
Freyburger L., Clement O., Marcheteau E., Gey A., Fraisse G., Bouguin 
C., Merillon N., Dransart E., Tran T., Quintin-Colonna F., Autret G., 
Thiebaud M., Suleman M., Riffault S., Wu T.C., Launay O., Danel C., 
Taieb J., Richardson J., Zitvogel L., Fridman W.H., Johannes L., and 
Tartour E., Mucosal imprinting of vaccine-induced CD8(+) T cells is crucial 
to inhibit the growth of mucosal tumors. Sci Transl Med, 2013. 5(172): p. 
172ra20. 
263. Savina A. and Amigorena S., Phagocytosis and antigen presentation in 
dendritic cells. Immunological Reviews, 2007. 219(1): p. 143-156. 
264. Sawicki S.G., Sawicki D.L., and Siddell S.G., A contemporary view of 
coronavirus transcription. Journal of Virology, 2007. 81(1): p. 20-29. 
265. Schuler-Thurner B., Schultz E.S., Berger T.G., Weinlich G., Ebner S., 
Woerl P., Bender A., Feuerstein B., Fritsch P.O., Romani N., and 
Schuler G., Rapid induction of tumor-specific type 1 T helper cells in 
metastatic melanoma patients by vaccination with mature, cryopreserved, 
peptide-loaded monocyte-derived dendritic cells. J Exp Med, 2002. 195(10): 
p. 1279-88. 
266. Schwartz R.H., T-lymphocyte recognition of antigen in association with 
gene products of the major histocompatibility complex. Annu Rev Immunol, 
1985. 3: p. 237-61. 
221 
 
267. Schwarz K., Storni T., Manolova V., Didierlaurent A., Sirard J.-C., 
Röthlisberger P., and Bachmann M.F., Role of Toll-like receptors in 
costimulating cytotoxic T cell responses. European Journal of Immunology, 
2003. 33(6): p. 1465-1470. 
268. Scortti M., Prieto C., Alvarez E., Simarro I., and Castro J.M., Failure of 
an inactivated vaccine against porcine reproductive and respiratory syndrome 
to protect gilts against a heterologous challenge with PRRSV. Vet Rec, 2007. 
161(24): p. 809-13. 
269. Scortti M., Prieto C., Martinez-Lobo F.J., Simarro I., and Castro J.M., 
Effects of two commercial European modified-live vaccines against porcine 
reproductive and respiratory syndrome viruses in pregnant gilts. Vet J, 2006. 
172(3): p. 506-14. 
270. Scortti M., Prieto C., Simarro I., and Castro J.M., Reproductive 
performance of gilts following vaccination and subsequent heterologous 
challenge with European strains of porcine reproductive and respiratory 
syndrome virus. Theriogenology, 2006. 66(8): p. 1884-93. 
271. Seder R.A., Darrah P.A., and Roederer M., T-cell quality in memory and 
protection: implications for vaccine design. Nat Rev Immunol, 2008. 8(4): p. 
247-258. 
272. Segales J., Martinez-Guino L., Cortey M., Navarro N., Huerta E., Sibila 
M., Pujols J., and Kekarainen T., Retrospective study on swine Torque 
teno virus genogroups 1 and 2 infection from 1985 to 2005 in Spain. Vet 
Microbiol, 2009. 134(3-4): p. 199-207. 
273. Seybert A., Posthuma C.C., van Dinten L.C., Snijder E.J., Gorbalenya 
A.E., and Ziebuhr J., A complex zinc finger controls the enzymatic 
activities of nidovirus helicases. J Virol, 2005. 79(2): p. 696-704. 
274. Shen H., Ackerman A.L., Cody V., Giodini A., Hinson E.R., Cresswell P., 
Edelson R.L., Saltzman W.M., and Hanlon D.J., Enhanced and prolonged 
cross-presentation following endosomal escape of exogenous antigens 
encapsulated in biodegradable nanoparticles. Immunology, 2006. 117(1): p. 
78-88. 
275. Sheng K.C., Kalkanidis M., Pouniotis D.S., Esparon S., Tang C.K., 
Apostolopoulos V., and Pietersz G.A., Delivery of antigen using a novel 
222 
 
mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. 
Eur J Immunol, 2008. 38(2): p. 424-36. 
276. Sheridan B.S. and Lefrancois L., Regional and mucosal memory T cells. 
Nat Immunol, 2011. 12(6): p. 485-491. 
277. Shi M., Holmes E.C., Brar M.S., and Leung F.C.-C., Recombination Is 
Associated with an Outbreak of Novel Highly Pathogenic Porcine 
Reproductive and Respiratory Syndrome Viruses in China. Journal of 
Virology, 2013. 87(19): p. 10904-10907. 
278. Shi X., Chen J., Xing G., Zhang X., Hu X., Zhi Y., Guo J., Wang L., Qiao 
S., Lu Q., and Zhang G., Amino acid at position 176 was essential for 
porcine reproductive and respiratory syndrome virus (PRRSV) non-structural 
protein 1alpha (nsp1alpha) as an inhibitor to the induction of IFN-beta. Cell 
Immunol, 2012. 280(2): p. 125-31. 
279. Shi X., Wang L., Li X., Zhang G., Guo J., Zhao D., Chai S., and Deng R., 
Endoribonuclease activities of porcine reproductive and respiratory syndrome 
virus nsp11 was essential for nsp11 to inhibit IFN-β induction. Molecular 
Immunology, 2011. 48(12–13): p. 1568-1572. 
280. Shi X., Wang L., Zhi Y., Xing G., Zhao D., Deng R., and Zhang G., 
Porcine reproductive and respiratory syndrome virus (PRRSV) could be 
sensed by professional beta interferon-producing system and had mechanisms 
to inhibit this action in MARC-145 cells. Virus Res, 2010. 153(1): p. 151-6. 
281. Shimizu K., Thomas E.K., Giedlin M., and Mule J.J., Enhancement of 
tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the 
addition of foreign helper protein. Cancer Res, 2001. 61(6): p. 2618-24. 
282. Shortman K. and Heath W.R., The CD8+ dendritic cell subset. Immunol 
Rev, 2010. 234(1): p. 18-31. 
283. Silva-Campa E., Cordoba L., Fraile L., Flores-Mendoza L., Montoya M., 
and Hernandez J., European genotype of porcine reproductive and 
respiratory syndrome (PRRSV) infects monocyte-derived dendritic cells but 
does not induce Treg cells. Virology, 2010. 396(2): p. 264-71. 
284. Silva-Campa E., Flores-Mendoza L., Resendiz M., Pinelli-Saavedra A., 
Mata-Haro V., Mwangi W., and Hernandez J., Induction of T helper 3 
regulatory cells by dendritic cells infected with porcine reproductive and 
223 
 
respiratory syndrome virus. Virology, 2009. 387(2): p. 373-9. 
285. Song C., Krell P., and Yoo D., Nonstructural protein 1α subunit-based 
inhibition of NF-κB activation and suppression of interferon-β production by 
porcine reproductive and respiratory syndrome virus. Virology, 2010. 407(2): 
p. 268-280. 
286. Song C.X., Labhasetwar V., Murphy H., Qu X., Humphrey W.R., 
Shebuski R.J., and Levy R.J., Formulation and characterization of 
biodegradable nanoparticles for intravascular local drug delivery. Journal of 
Controlled Release, 1997. 43(2–3): p. 197-212. 
287. Song S., Bi J., Wang D., Fang L., Zhang L., Li F., Chen H., and Xiao S., 
Porcine reproductive and respiratory syndrome virus infection activates IL-10 
production through NF-kappaB and p38 MAPK pathways in porcine alveolar 
macrophages. Dev Comp Immunol, 2013. 39(3): p. 265-72. 
288. Stober C.B., Lange U.G., Roberts M.T., Alcami A., and Blackwell J.M., 
IL-10 from regulatory T cells determines vaccine efficacy in murine 
Leishmania major infection. J Immunol, 2005. 175(4): p. 2517-24. 
289. Storgaard T., Oleksiewicz M., and Bøtner A., Examination of the selective 
pressures on a live PRRS vaccine virus. Archives of Virology, 1999. 144(12): 
p. 2389-2401. 
290. Subramaniam S., Kwon B., Beura L.K., Kuszynski C.A., Pattnaik A.K., 
and Osorio F.A., Porcine reproductive and respiratory syndrome virus non-
structural protein 1 suppresses tumor necrosis factor-alpha promoter 
activation by inhibiting NF-κB and Sp1. Virology, 2010. 406(2): p. 270-279. 
291. Summerfield A. and McCullough K.C., Porcine bone marrow myeloid 
cells: phenotype and adhesion molecule expression. J Leukoc Biol, 1997. 
62(2): p. 176-85. 
292. Sun L., Li Y., Liu R., Wang X., Gao F., Lin T., Huang T., Yao H., Tong 
G., Fan H., Wei Z., and Yuan S., Porcine reproductive and respiratory 
syndrome virus ORF5a protein is essential for virus viability. Virus 
Research, 2013. 171(1): p. 178-185. 
293. Sun Z., Chen Z., Lawson S.R., and Fang Y., The cysteine protease domain 
of porcine reproductive and respiratory syndrome virus nonstructural protein 
2 possesses deubiquitinating and interferon antagonism functions. J Virol, 
224 
 
2010. 84(15): p. 7832-46. 
294. Sun Z., Li Y., Ransburgh R., Snijder E.J., and Fang Y., Nonstructural 
protein 2 of porcine reproductive and respiratory syndrome virus inhibits the 
antiviral function of interferon-stimulated gene 15. J Virol, 2012. 86(7): p. 
3839-50. 
295. Suradhat S., Kesdangsakonwut S., Sada W., Buranapraditkun S., 
Wongsawang S., and Thanawongnuwech R., Negative impact of porcine 
reproductive and respiratory syndrome virus infection on the efficacy of 
classical swine fever vaccine. Vaccine, 2006. 24(14): p. 2634-42. 
296. Suradhat S. and Thanawongnuwech R., Upregulation of interleukin-10 
gene expression in the leukocytes of pigs infected with porcine reproductive 
and respiratory syndrome virus. Journal of General Virology, 2003. 84(10): 
p. 2755-2760. 
297. Suradhat S., Thanawongnuwech R., and Poovorawan Y., Upregulation of 
IL-10 gene expression in porcine peripheral blood mononuclear cells by 
porcine reproductive and respiratory syndrome virus. Journal of General 
Virology, 2003. 84(2): p. 453-459. 
298. Takamatsu H.H., Denyer M.S., Stirling C., Cox S., Aggarwal N., Dash P., 
Wileman T.E., and Barnett P.V., Porcine gammadelta T cells: possible 
roles on the innate and adaptive immune responses following virus infection. 
Vet Immunol Immunopathol, 2006. 112(1-2): p. 49-61. 
299. Tanaka Y., Sano S., Nieves E., De Libero G., Rosa D., Modlin R.L., 
Brenner M.B., Bloom B.R., and Morita C.T., Nonpeptide ligands for 
human gamma delta T cells. Proc Natl Acad Sci U S A, 1994. 91(17): p. 
8175-9. 
300. Terpstra C., Wensvoort G., and Pol J.M., Experimental reproduction of 
porcine epidemic abortion and respiratory syndrome (mystery swine disease) 
by infection with Lelystad virus: Koch's postulates fulfilled. Vet Q, 1991. 
13(3): p. 131-6. 
301. Thacker E.L., Immunology of the porcine respiratory disease complex. The 
Veterinary clinics of North America. Food animal practice, 2001. 17(3): p. 
551-565. 
302. Thanawongnuwech R., Brown G.B., Halbur P.G., Roth J.A., Royer R.L., 
225 
 
and Thacker B.J., Pathogenesis of porcine reproductive and respiratory 
syndrome virus-induced increase in susceptibility to Streptococcus suis 
infection. Vet Pathol, 2000. 37(2): p. 143-52. 
303. Thanawongnuwech R., Young T.F., Thacker B.J., and Thacker E.L., 
Differential production of proinflammatory cytokines: in vitro PRRSV and 
Mycoplasma hyopneumoniae co-infection model. Veterinary Immunology 
and Immunopathology, 2001. 79(1–2): p. 115-127. 
304. Thery C. and Amigorena S., The cell biology of antigen presentation in 
dendritic cells. Curr Opin Immunol, 2001. 13(1): p. 45-51. 
305. Tian K., Yu X., Zhao T., Feng Y., Cao Z., Wang C., Hu Y., Chen X., Hu 
D., Tian X., Liu D., Zhang S., Deng X., Ding Y., Yang L., Zhang Y., Xiao 
H., Qiao M., Wang B., Hou L., Wang X., Yang X., Kang L., Sun M., Jin 
P., Wang S., Kitamura Y., Yan J., and Gao G.F., Emergence of Fatal 
PRRSV Variants: Unparalleled Outbreaks of Atypical PRRS in China and 
Molecular Dissection of the Unique Hallmark. PLoS ONE, 2007. 2(6): p. 
e526. 
306. Tian X., Lu G., Gao F., Peng H., Feng Y., Ma G., Bartlam M., Tian K., 
Yan J., Hilgenfeld R., and Gao G.F., Structure and cleavage specificity of 
the chymotrypsin-like serine protease (3CLSP/nsp4) of Porcine Reproductive 
and Respiratory Syndrome Virus (PRRSV). J Mol Biol, 2009. 392(4): p. 977-
93. 
307. Tomiyama H., Takata H., Matsuda T., and Takiguchi M., Phenotypic 
classification of human CD8+ T cells reflecting their function: inverse 
correlation between quantitative expression of CD27 and cytotoxic effector 
function. European Journal of Immunology, 2004. 34(4): p. 999-1010. 
308. Torremorell M., Pijoan C., Janni K., Walker R., and Joo H.S., Airborne 
transmission of Actinobacillus pleuropneumoniae and porcine reproductive 
and respiratory syndrome virus in nursery pigs. American Journal of 
Veterinary Research, 1997. 58(8): p. 828-832. 
309. Trumpfheller C., Finke J.S., Lopez C.B., Moran T.M., Moltedo B., 
Soares H., Huang Y., Schlesinger S.J., Park C.G., Nussenzweig M.C., 
Granelli-Piperno A., and Steinman R.M., Intensified and protective CD4+ 
T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody 
226 
 
vaccine. J Exp Med, 2006. 203(3): p. 607-17. 
310. Trus I., Bonckaert C., van der Meulen K., and Nauwynck H.J., Efficacy 
of an attenuated European subtype 1 porcine reproductive and respiratory 
syndrome virus (PRRSV) vaccine in pigs upon challenge with the East 
European subtype 3 PRRSV strain Lena. Vaccine, 2014. 32(25): p. 2995-
3003. 
311. Ura T., Okuda K., and Shimada M., Developments in Viral Vector-Based 
Vaccines. Vaccines, 2014. 2(3): p. 624-641. 
312. van der Linden I.F.A., Voermans J.J.M., van der Linde-Bril E.M., 
Bianchi A.T.J., and Steverink P.J.G.M., Virological kinetics and 
immunological responses to a porcine reproductive and respiratory syndrome 
virus infection of pigs at different ages. Vaccine, 2003. 21(17–18): p. 1952-
1957. 
313. Van Gorp H., Van Breedam W., Delputte P.L., and Nauwynck H.J., 
Sialoadhesin and CD163 join forces during entry of the porcine reproductive 
and respiratory syndrome virus. J Gen Virol, 2008. 89(Pt 12): p. 2943-53. 
314. Van Reeth K., Labarque G., Nauwynck H., and Pensaert M., Differential 
production of proinflammatory cytokines in the pig lung during different 
respiratory virus infections: correlations with pathogenicity. Research in 
Veterinary Science, 1999. 67(1): p. 47-52. 
315. Vanderheijden N., Delputte P.L., Favoreel H.W., Vandekerckhove J., 
Van Damme J., van Woensel P.A., and Nauwynck H.J., Involvement of 
sialoadhesin in entry of porcine reproductive and respiratory syndrome virus 
into porcine alveolar macrophages. J Virol, 2003. 77(15): p. 8207-15. 
316. Vanhee M., Costers S., Van Breedam W., Geldhof M.F., Van 
Doorsselaere J., and Nauwynck H.J., A variable region in GP4 of 
European-type porcine reproductive and respiratory syndrome virus induces 
neutralizing antibodies against homologous but not heterologous virus 
strains. Viral Immunol, 2010. 23(4): p. 403-13. 
317. Vanhee M., Delputte P., L., Delrue I., Geldhof M., F., and Nauwynck H., 
J., Development of an experimental inactivated PRRSV vaccine that induces 
virus-neutralizing antibodies. Vet. Res., 2009. 40(6): p. 63. 
318. Vashisht K., Goldberg T.L., Husmann R.J., Schnitzlein W., and 
227 
 
Zuckermann F.A., Identification of immunodominant T-cell epitopes 
present in glycoprotein 5 of the North American genotype of porcine 
reproductive and respiratory syndrome virus. Vaccine, 2008. 26(36): p. 4747-
4753. 
319. Velasova M., Alarcon P., Williamson S., and Wieland B., Risk factors for 
porcine reproductive and respiratory syndrome virus infection and resulting 
challenges for effective disease surveillance. BMC Veterinary Research, 
2012. 8(1): p. 184. 
320. Villiers C., Chevallet M., Diemer H., Couderc R., Freitas H., Van 
Dorsselaer A., Marche P.N., and Rabilloud T., From secretome analysis to 
immunology: chitosan induces major alterations in the activation of dendritic 
cells via a TLR4-dependent mechanism. Mol Cell Proteomics, 2009. 8(6): p. 
1252-64. 
321. Vincent A.L., Thacker B.J., Halbur P.G., Rothschild M.F., and Thacker 
E.L., An investigation of susceptibility to porcine reproductive and 
respiratory syndrome virus between two genetically diverse commercial lines 
of pigs. J Anim Sci, 2006. 84(1): p. 49-57. 
322. (a) Wang R., Nan Y., Yu Y., Yang Z., and Zhang Y.J., Variable 
interference with interferon signal transduction by different strains of porcine 
reproductive and respiratory syndrome virus. Vet Microbiol, 2013. 166(3-4): 
p. 493-503. 
323. (b) Wang R., Nan Y., Yu Y., and Zhang Y.J., Porcine reproductive and 
respiratory syndrome virus Nsp1beta inhibits interferon-activated JAK/STAT 
signal transduction by inducing karyopherin-alpha1 degradation. J Virol, 
2013. 87(9): p. 5219-28. 
324. (a) Wang S., Fang L., Fan H., Jiang Y., Pan Y., Luo R., Zhao Q., Chen 
H., and Xiao S., Construction and immunogenicity of pseudotype 
baculovirus expressing GP5 and M protein of porcine reproductive and 
respiratory syndrome virus. Vaccine, 2007. 25(49): p. 8220-7. 
325. (b) Wang X., Eaton M., Mayer M., Li H., He D., Nelson E., and 
Christopher-Hennings J., Porcine reproductive and respiratory syndrome 
virus productively infects monocyte-derived dendritic cells and compromises 
their antigen-presenting ability. Archives of Virology, 2007. 152(2): p. 289-
228 
 
303. 
326. Wang X., Li J., Jiang P., Li Y., Zeshan B., Cao J., and Wang X., GM-
CSF fused with GP3 and GP5 of porcine reproductive and respiratory 
syndrome virus increased the immune responses and protective efficacy 
against virulent PRRSV challenge. Virus Res, 2009. 143(1): p. 24-32. 
327. (c) Wang Y., Zhao H., Ma Z., Wang Y., and Feng W.-h., CTLA4 
mediated targeting enhances immunogenicity against PRRSV in a DNA 
prime/killed virus boost strategy. Veterinary Immunology and 
Immunopathology, 2013. 154(3–4): p. 121-128. 
328. Wang Y.X., Zhou Y.J., Li G.X., Zhang S.R., Jiang Y.F., Xu A.T., Yu H., 
Wang M.M., Yan L.P., and Tong G.Z., Identification of immunodominant 
T-cell epitopes in membrane protein of highly pathogenic porcine 
reproductive and respiratory syndrome virus. Virus Res, 2011. 158(1-2): p. 
108-15. 
329. Wang Z.-h., Cao X.-h., Du X.-g., Feng H.-b., Di W., He S., and Zeng X.-
y., Mucosal and systemic immunity in mice after intranasal immunization 
with recombinant Lactococcus lactis expressing ORF6 of PRRSV. Cellular 
Immunology, 2014. 287(2): p. 69-73. 
330. Weesendorp E., Morgan S., Stockhofe-Zurwieden N., Graaf D.J.P.-D., 
Graham S.P., and Rebel J.M.J., Comparative analysis of immune 
responses following experimental infection of pigs with European porcine 
reproductive and respiratory syndrome virus strains of differing virulence. 
Veterinary Microbiology, 2013. 163(1–2): p. 1-12. 
331. Wei H., Wang S., Zhang D., Hou S., Qian W., Li B., Guo H., Kou G., He 
J., Wang H., and Guo Y., Targeted delivery of tumor antigens to activated 
dendritic cells via CD11c molecules induces potent antitumor immunity in 
mice. Clin Cancer Res, 2009. 15(14): p. 4612-21. 
332. Wensvoort G., Terpstra C., Pol J.M.A., ter Laak E.A., Bloemraad M., de 
Kluyver E.P., Kragten C., van Buiten L., den Besten A., Wagenaar F., 
Broekhuijsen J.M., Moonen P.L.J.M., Zetstra T., de Boer E.A., Tibben 
H.J., de Jong M.F., van ‘t Veld P., Greenland G.J.R., van Gennep J.A., 
Voets M.T., Verheijden J.H.M., and Braamskamp J., Mystery swine 
disease in the Netherlands: The isolation of Lelystad virus. Veterinary 
229 
 
Quarterly, 1991. 13(3): p. 121-130. 
333. Wiesel M., Walton S., Richter K., and Oxenius A., Virus-specific CD8 T 
cells: activation, differentiation and memory formation. APMIS, 2009. 117(5-
6): p. 356-381. 
334. Wissink E.H.J., Kroese M.V., Van Wijk H.A.R., Rijsewijk F.A.M., 
Meulenberg J.J.M., and Rottier P.J.M., Envelope protein requirements for 
the assembly of infectious virions of porcine reproductive and respiratory 
syndrome virus. Journal of Virology, 2005. 79(19): p. 12495-12506. 
335. Wongyanin P., Buranapraditkul S., Yoo D., Thanawongnuwech R., Roth 
J.A., and Suradhat S., Role of porcine reproductive and respiratory 
syndrome virus nucleocapsid protein in induction of interleukin-10 and 
regulatory T-lymphocytes (Treg). J Gen Virol, 2012. 93(Pt 6): p. 1236-46. 
336. Wongyanin P., Buranapraditkun S., Chokeshai-Usaha K., 
Thanawonguwech R., and Suradhat S., Induction of inducible 
CD4+CD25+Foxp3+ regulatory T lymphocytes by porcine reproductive and 
respiratory syndrome virus (PRRSV). Vet Immunol Immunopathol, 2010. 
133(2-4): p. 170-82. 
337. Xiao Z., Batista L., Dee S., Halbur P., and Murtaugh M.P., The level of 
virus-specific T-cell and macrophage recruitment in porcine reproductive and 
respiratory syndrome virus infection in pigs is independent of virus load. J 
Virol, 2004. 78(11): p. 5923-33. 
338. Xu Q., Crossley A., and Czernuszka J., Preparation and characterization of 
negatively charged poly(lactic-co-glycolic acid) microspheres. J Pharm Sci, 
2009. 98(7): p. 2377-89. 
339. Xu X.G., Wang Z.S., Zhang Q., Li Z.C., Ding L., Li W., Wu H.Y., Chang 
C.D., Lee L.H., Tong D.W., and Liu H.J., Baculovirus as a PRRSV and 
PCV2 bivalent vaccine vector: baculovirus virions displaying simultaneously 
GP5 glycoprotein of PRRSV and capsid protein of PCV2. J Virol Methods, 
2012. 179(2): p. 359-66. 
340. Xue Q., Zhao Y.-G., Zhou Y.-J., Qiu H.-J., Wang Y.-F., Wu D.-L., Tian 
Z.-J., and Tong G.-Z., Immune responses of swine following DNA 
immunization with plasmids encoding porcine reproductive and respiratory 
syndrome virus ORFs 5 and 7, and porcine IL-2 and IFNγ. Veterinary 
230 
 
Immunology and Immunopathology, 2004. 102(3): p. 291-298. 
341. Yang H. and Parkhouse R.M.E., Characterization of the porcine γδ T-cell 
receptor structure and cellular distribution by monoclonal antibody PPT27. 
Immunology, 2000. 99(4): p. 504-509. 
342. Yoo D., Song C., Sun Y., Du Y., Kim O., and Liu H.-C., Modulation of 
host cell responses and evasion strategies for porcine reproductive and 
respiratory syndrome virus. Virus Research, 2010. 154(1–2): p. 48-60. 
343. Yoon I.J., Joo H.S., Goyal S.M., and Molitor T.W., A modified serum 
neutralization test for the detection of antibody to porcine reproductive and 
respiratory syndrome virus in swine sera. J Vet Diagn Invest, 1994. 6(3): p. 
289-92. 
344. Yoon K.J., Wu L.L., Zimmerman J.J., Hill H.T., and Platt K.B., 
Antibody-dependent enhancement (ADE) of porcine reproductive and 
respiratory syndrome virus (PRRSV) infection in pigs. Viral Immunol, 1996. 
9(1): p. 51-63. 
345. Yoon K.J., Wu L.L., Zimmerman J.J., and Platt K.B., Field isolates of 
porcine reproductive and respiratory syndrome virus (PRRSV) vary in their 
susceptibility to antibody dependent enhancement (ADE) of infection. 
Veterinary Microbiology, 1997. 55(1-4): p. 277-287. 
346. You Q., Wu Y., Wu Y., Wei W., Wang C., Jiang D., Yu X., Zhang X., 
Wang Y., Tang Z., Jiang C., and Kong W., Immunogenicity and protective 
efficacy of heterologous prime-boost regimens with mycobacterial vaccines 
and recombinant adenovirus- and poxvirus-vectored vaccines against murine 
tuberculosis. Int J Infect Dis, 2012. 16(11): p. e816-25. 
347. Zaharoff D.A., Rogers C.J., Hance K.W., Schlom J., and Greiner J.W., 
Chitosan solution enhances both humoral and cell-mediated immune 
responses to subcutaneous vaccination. Vaccine, 2007. 25(11): p. 2085-2094. 
348. Zhang H., Hong H., Li D., Ma S., Di Y., Stoten A., Haig N., Di Gleria K., 
Yu Z., Xu X.-N., McMichael A., and Jiang S., Comparing Pooled Peptides 
with Intact Protein for Accessing Cross-presentation Pathways for Protective 
CD8+ and CD4+ T Cells. Journal of Biological Chemistry, 2009. 284(14): p. 
9184-9191. 
349. Zhang X., Li G., Gao L., Mu L., Zhang L., Cong Y., and Ding Z., Positive 
231 
 
inductive effect of IL-18 on virus-specific immune responses induced by 
PRRSV-GP5 DNA vaccine in swine. Research in Veterinary Science, 2013. 
94(2): p. 346-353. 
350. Zheng Q., Chen D., Li P., Bi Z., Cao R., Zhou B., and Chen P., Co-
expressing GP5 and M proteins under different promoters in recombinant 
modified vaccinia virus ankara (rMVA)-based vaccine vector enhanced the 
humoral and cellular immune responses of porcine reproductive and 
respiratory syndrome virus (PRRSV). Virus Genes, 2007. 35(3): p. 585-595. 
351. Zhu B., Qie Y., Wang J.l., Zhang Y., Wang Q., Xu Y., and Wang H., 
Chitosan microspheres enhance the immunogenicity of an Ag85B-based 
fusion protein containing multiple T-cell epitopes of Mycobacterium 
tuberculosis. European Journal of Pharmaceutics and Biopharmaceutics, 
2007. 66(3): p. 318-326. 
352. Zuckermann F.A., Garcia E.A., Luque I.D., Christopher-Hennings J., 
Doster A., Brito M., and Osorio F., Assessment of the efficacy of 
commercial porcine reproductive and respiratory syndrome virus (PRRSV) 
vaccines based on measurement of serologic response, frequency of gamma-
IFN-producing cells and virological parameters of protection upon challenge. 
Veterinary Microbiology, 2007. 123(1–3): p. 69-85. 
 
 
 
 
 
 
232 
 
 
APPENDICES 
Appendix A. PRRS clinical scoring system 
Parameter Criteria Score 
Behaviour 
Attentive (curious, stands up immediately) 0 
Slightly reduced (Stands up hesitantly but without help) 1 
Tired, gets up only when forced to, lies down again 2 
Dormant, will not stand up 3 
Breathing 
 (Judged before 
approaching pig) 
Frequency 10-15/min, barely visible chest movement 0 
Frequency >20/min distinct chest and abdominal movement 2 
Frequency >30/min, breathing through open mouth 3 
Body tension 
Relaxed, straight back 0 
Stiffness and bent back while standing up, afterwards normal 1 
Bent back and stiff walking remains 2 
Cramps 3 
Body shape 
Full stomach, "round" body 0 
Empty stomach, thinned body muscles 2 
Emaciated, backbone and ribs visible, head size too big compared to 
body size 3 
Nasal discharge 
Absent 0 
Present and clear 1 
Present and discouloured 2 
Sneezing 
None 0 
Mild (few incidences 1-5 observation duration) 1 
Severe (more frequent incidences, >5 observation duration) 2 
Coughing 
None 0 
Mild (few incidences as 1-5 observation duration) 1 
Severe (more frequent incidences >5 observation duration) 2 
Skin changes 
Evenly light pink, hair coat flat 0 
Reddening/purpling of skin 2 
Ear necrosis 3 
Eyes/conjunctiva 
Light pink 0 
Reddened, clear secretion 1 
Highly inflammated, turbid secretion 2 
Highly inflammated, turbid purulent secretion, accentuated blood vessels 3 
Defecation 
Soft faeces, normal amount 0 
Reduced amount of faeces, dry 1 
Only small amount of dry, fibrin-covered faeces, or diarrhoea 2 
No faeces, mucus in rectum or watery diarrhoea 3 
Appetite/leftovers at 
feeding 
Greedy, hungry, trough empty, clean 0 
Eats slowly when fed, trough almost empty, almost no left overs 1 
Does not eat when fed but tastes food, Food only partially eaten. 2 
Does not eat at all shows no interest for food, trough still full, nothing 
eaten 3 
Temperature 
37 C-39 C 0 
39 C-40 C 1 
40 C-41 C 2 
> 41 C 3 
Other Note any additional observations  
233 
 
 
Appendix B. M and NSP5 peptide sequences synthesised for vaccine 
formulation 
PRRSV-1 Olot/91 M Peptides 
MGSLDDFCNDSTAAQKLVLA 
STAAQKLVLAFSITYTPIMI 
FSITYTPIMIYALKVSRGRL 
YALKVSRGRLLGLLHILIFL 
LGLLHILIFLNCSFTFGYMT 
NCSFTFGYMTYVRFQSTNRV 
YVRFQSTNRVALTLGAVVAL 
ALTLGAVVALLWGVYSFTES 
LWGVYSFTESWKFVTSRCRL 
WKFVTSRCRLCCLGRRYILA 
CCLGRRYILAPAHHVESAAG 
PAHHVESAAGLHSIPASGNR 
LHSIPASGNRAYAVRKPGLT 
AYAVRKPGLTSVNGTLVPGL 
SVNGTLVPGLRSLVLGGKRA 
RSLVLGGKRAVKRGVVNLVK 
VLGGKRAVKRGVVNLVKYGR 
 
PRRSV-1 Olot/91 NSP5 Peptides 
GGLSTVQLLCVFFLLWRMMG 
VFFLLWRMMGHAWTPIVAVG 
HAWTPIVAVGFFLLNEILPA 
FFLLNEILPAVLVRAVFSFA 
VLVRAVFSFALFVLAWATPW 
LFVLAWATPWSAQVLMIRLL 
SAQVLMIRLLTASLNRNKLS 
TASLNRNKLSLAFYALGGVV 
LAFYALGGVVGLAAEIGTFA 
GLAAEIGTFAGRLSELSQAL 
GRLSELSQALSTYCFLPRVL 
STYCFLPRVLAMTSCVPTII 
AMTSCVPTIIIGGLHTLGVI 
IGGLHTLGVILWLFKYRCLH 
LWLFKYRCLHNMLVGDGSFS 
NMLVGDGSFSSAFFLRYFAE 
